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Abstract 
Abstract 
The drug Org 34167 is a novel antidepressant, which is currently undergoing clinical trials. The 
mechanism of action is unknown but in vitro testing revealed that the compound only displayed 
high affinity at the channel responsible for the generation of the hyperpolarisation-activated 
current (Ih). 
A possible way to address the mechanism of action is utilising antisense technology in rats to 
specifically and reversibly inhibit protein expression. Recently, four members of a gene family 
have been identified, which are believed to represent the molecular identity of Ih and termed 
Hyperpolarisation-activated, cyclic-nucleotide gated (HCN1 - 4). HCN2 was targeted with 
seven different phosphorothioate antisense sequences, one to a region encompassing the 
initiation-codon, and six designed to areas of the transcript predicted to be devoid of secondary 
structure. None of these sequences, when i. c. v. infused for 3- or 7-days, resulted in significant 
alteration of HCN2 mRNA expression. Similar findings were demonstrated following infusion 
of an end-modified oligonucleotide; employed to reduce toxicity. A HCN2 antibody was not 
validated at the time of study and [3H]-Org 34167 was demonstrated to be unsuitable for 
autoradiography thus preventing quantification of protein. Therefore, no successful antisense 
action was demonstrated following infusion of any sequence. 
Induction of immediate early genes (lEG) is commonly believed to reflect neuronal activity. 
The novel antidepressant, mirtazapine, was demonstrated to induce c-fos and Egr-1 mRNA in a 
number of regions common to known antidepressants; anterior insular cortex, septum and 
central amygdala. This provided proof of the concept that lEG expression can be used to 
classify psychoactive compounds. Org 34167 was also shown to induce IEG expression in 
these brain regions but also displayed a robust cortical induction, which is akin to 
psychostimulant compounds, and regions high in HCN1 and 2 expression. This agrees with 
behavioural tests, which demonstrated that Org 34167 was active in depression models and also 
induced tremors, headweaving and intracranial self-administration. 
Chronic antidepressant administration is required for clinical benefit due to adaptive changes. 
HCN 1-3 mRNA expression was significantly altered following Org 34167 (0.5 mg/kg, 28d), 
fluoxetine (5 mg/kg, 21d) or mirtazapine (2 mg/kg, 21d) administration. This provides further 
insight into Org 34167's mechanism of action and also a link between clinically used 
antidepressants and the channel. 
The observations made in this thesis contribute to the characterisation of the novel 
antidepressant Org 34167, and also provide a link between Ih (HCN) channels and depression, 
which was not previously apparent. 
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Chapter 1 General introduction 
1.1 Org 34167 -a novel antidepressant 
1.1.1 Preclinical and clinical observations 
Org 34167 is a novel antidepressant compound, which is about to enter into Phase II 
clinical trials. It has been shown to be very potent in a number of animal models of 
depression (Table 1.1). Despite this, in vitro testing revealed that the compound 
displayed very low affinity for over fifty G-protein coupled receptors (Ruigt, Personal 
communication). It also lacks affinity and efficacy at numerous traditional depression 
targets; such as monoamine receptors, transporters and monoamine oxidase; although 
weak affinity was shown for a213- and a2C-adrenoceptors (pK;; negative logarithm of the 
equilibrium dissociation constant, 5.4 & 5.7, respectively; Ruigt et al., Personal 
communication). Org 34167 only displayed high affinity for was the channel 
responsible for the hyperpolarisation-activated current (Ih channels); the compound was 
shown by electrophysiological recordings from CAI pyramidal cells to negatively 
modulate this current with a pIC5o; negative logarithm of molar concentration of agonist 
which produces 50 % of the maximum response, 8.0 (Ruigt et al., Personal 
communication). Additionally, weak affinity was been shown for Type I and Type 2 
binding sites on the sodium channel (pK; 5-7; Ruigt et al., Personal communication). 
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Table 1.1 Effect of Org 34167 in various animal models 
BEHAVIOURAL MODEL ACTIVE DOSE of Üuc 34167 
Rat sleeping stage test 0.3 mg/kg s. c; 10 mg/kg p. o. 
Rat `intracranial self- MED 0.5 mg/kg i. p. 
stimulation test' 
Mouse marble burying test ID50 0.4 mg/kg s. c.; 10.7 mg/kg p. o. 
DRL72 (rat) MED 0.75 mg/kg i. p.; > 10 mg/kg p. o. 
Porsolt test (mouse) MED 0.32 -1 mg/kg s. c.; > 10 mg/kg p. o. 
ACSO antidepressant profile Thr 0.32 mg/kg i. p. 
Rat penile erection ID5o 0.3 mg/kg s. c 
antagonism 
Rat lower lip retraction ID5o0.4mg/kg s. c 
antagonism 
Induction of forepaw ED50 0.46 mg/kg s. c 
treading 
Abb: ACSO, Automated sleep analysis system, DRL72, Differential Rates of Low reinforcement 72, 
ED50, effective dose at which 50 % change in baseline activity is observed, ID50, Dose causing 50 % 
inhibition of maximum response, i. p., intraperitoneal, MED, minimum effective dose, sc subcutaneous, 
Thr, Threshold. 
[3H]-Org 34167 was found to label a single, membrane-associated, binding site in rat 
CNS membrane preparations (Kd = 25 nM; Makkink, Personal communication). 
However, comparision of the estimated Ih channel density (8 - 40 fmol/mg protein), and 
the density of Org 34167 binding sites (1000 - 6000 fmol/mg protein) indicates a clear 
discrepancy, which would seem to suggest it binds to more than one site (Ruigt et al., 
Personal communication). Rat autoradiography experiments reveal that [3H]-Org 34167 
has a widespread distribution with high levels of binding in the substantia nigra, 
amygdala, globus pallidus, stria terminalis, geniculate nuclei, ventral tegmental area and 
the central grey of the cerebellum (Makkink, Personal communication). 
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In July 2001, Org 34167 completed Phase 1 clinical trials and was found to be well 
tolerated at low doses (< 2.5 mg) with a range of moderate adverse effects being 
reported by the patients at this and higher doses (15 and 40 mg; see Table 1.2). In 
healthy male volunteers, a significant prolongation of REM sleep latency was observed 
at 2.5 mg/kg, but not the higher doses (vanBerkel, Personal communication). This 
suggests that the drug may have antidepressant activity in humans and concurs with the 
potent effect in animal models of depression (vanBerkel, Personal communication). 
Table 1.2 Adverse effects of Org 34167 reported from Phase 1 clinical trials 
ADVERSE EFFECTS OF ORG 34167 REPORTED IN CLINICAL TRIALS 
Dizziness Daytime somnolence and fatigue 
Impaired concentration Headache 
Nausea and vomiting Palpitation 
Sleeping problems Agitation 
Vertigo Visual disturbances 
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1.2 Hyperpolarization-activated, cyclic-nucleotide-gated 
channels 
1.2.1 Introduction 
The description of a current, which activates upon hyperpolarization, to cause an 
inwards current that depolarises the cell, originated from studies using sino-atrial (SA) 
cells (Brown et al., 1979a; Brown et al., 1979b). It was shown to partially mediate the 
increase in cell firing evoked by adrenaline and termed If, for `funny' current (Brown et 
al., 1979a; Brown et al., 1979b). Within a few years, similar currents were reported in 
Purkinje fibres (DiFrancesco, 1981a; DiFrancesco, 1981b), photoreceptors (Attwell et 
al., 1980; Bader et al., 1984; Barnes et al., 1989), ventricular muscle (Yu et al., 1993), 
peripheral (Mayer et al., 1983) and central neurones (Halliwell et al., 1982). The 
additional terms Ih (for Hyperpolarization-activated current) in the CNS (Bader et al., 
1984; Mayer et al., 1983) or Iy (for `queer' current) and pacemaker channel 
(DiFrancesco et al., 1991; Gauss et al., 2000) were coined to describe them. 
Despite increasing knowledge regarding the properties of the current, it was not until 
the late 1990's before the cloned channel subunits, believed to be responsible for the 
generation of the current was identified. Three groups, almost simultaneously, 
published findings; two of which were based on the hypothesis that the channel would 
be related to voltage-gated potassium (K) and cyclic-nucleotide gated (CNG) channels, 
while the other serendipitously isolated the channel (Gauss et al., 1998; Ludwig et al., 
1998; Santoro et al., 1997). When the cDNAs identified by these groups are 
heterologously expressed in cell systems, the resultant channels properties are very 
similar to those of native Ih channels (as will be discussed in the following sections). 
However, despite the strong likelihood of these cloned channels, subsequently termed 
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Hyperpolarisation-activated, cyclic nucleotide-gated (HCN) channels, representing the 
molecular identity of the family of channels responsible for native Ih, this has yet to be 
fully confirmed. Therefore, throughout the remainder of this thesis, Ih or pacemaker 
channel will refer to native channels, and the term HCN to work performed on cloned 
channels. 
1.2.2. Molecular identification of HCN channels 
The first member of the gene family was identified using a yeast two-hybrid system, 
and the Src-homology 3 (SH3) domain of a neural specific form (N-Src) as bait. The 
authors isolated a novel murine cDNA, encoding a 132-kDa glycoprotein, which they 
termed brain cyclic nucleotide gated 1 (BCNG-1; Santoro et al., 1997). In the initial 
report the authors were unable to functionally express the cDNA but determined that it 
likely encoded for an ion channel based on sequence homology to voltage-gated K+ 
channels, CNG channels and plant inward rectifing K+ channels (Santoro et al., 1997). 
When successful heterologous expression was achieved, it demonstrated that the cDNA 
did indeed encode for a functional channel with properties akin to that of Ih in the brain 
(Santoro et al., 1998). Reverse-transcription polymerise chain reaction experiments 
performed on murine BCNG-1 identified an additional two homologous murine gene 
fragments (subsequently termed murine BCNG-2 and murine BCNG-3; Santoro et al., 
1998). Furthermore, a Basic Local Alignment Search Tool (BLAST) search in mouse 
and human Expressed Sequence Tag (EST) database homology search using the protein 
sequence of murine BCNG-1 revealed a further mouse gene (murine BCNG-4) and two 
human genes (hBCNG-1 and -2) that shared homology with murine BCNG-1 sequence 
(Santoro et al., 1998). Each of the mouse genes was shown to display a different 
distribution pattern using Northern blot analysis, with members found in the brain, 
heart, liver, kidney, skeletal muscle and lung (Santoro et al., 1998). Murine BCNG-1 
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was found to be mainly located in the brain, murine BCNG-2 in both brain and heart 
tissue, murine BCNG-3 in brain, heart, lung and skeletal muscle, and murine BCNG-4 
mainly in liver, but also in brain, lung and kidney (Santoro et al., 1998). 
An EST BLAST database using the conserved cyclic nucleotide binding domain 
(CNBD) of CNG channels performed by Ludwig et al., (1998), identified a sequence 
fragment of a new class of channel. The authors termed this Hyperpolarisation- 
activated channel (HAC)-1. Full-length cloning of this murine fragment identified a 
further two related sequences, HAC2 and HAC3, which shared an overall homology of 
60 %. The amino acid sequence of the newly identified family was shown to share 
significant homology with cyclic-nucleotide-gated (CNG) channel a-subunits (28%) 
and ether-ä-gogo K+ channels (27%); with a pore region similar to K+ channels and a 
cyclic-nucleotide-binding domain (Ludwig et al., 1998). 
Another group designed primers based on the CNG channels to clone cDNA from a sea 
urchin Strongylocentrotus purpuratus (Sp) testis library. Functional expression of this 
cDNA demonstrated that it encoded a weakly K+ selective, hyperpolarisation-activated 
channel, which the authors termed SPIH (Gauss et al., 1998). After these initial 
findings further clones were identified in rat, rabbit and human, and were named based 
around the initial three group's classification (see Table 1.3 for list of known HCN 
channel isoforms). Due to the confusing nomenclature Hyperpolarisation-Activated, 
Cyclic Nucleotide-Gated (HCN) channel was proposed to be an appropriate name based 
on two of the main properties of the channel (Clapham, 1998). Cloning of these 
channels enabled the testing of Org 34167, which had demonstrated affinity for Ih 
channels, in cell lines expressing these new identified channels. As expected, Org 
34167 displayed high affinity for HCN channels (Ruigt et al., Personal communication) 
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and provides a further link suggestive that these channels represent the molecular 
identity of Ih. 
1.2.3 Functional properties of Ih and HCN channels 
Native and recombinant channels display a 3: 1 - 4: 1 ratio for K+ : sodium (Na+) ions, 
which sets the reversal potential for the channels at -35 mV (Gauss et al., 1998; Ho et 
al., 1994; Ludwig et al., 1998; McCormick et al., 1990b; Pape, 1996; Santoro et al., 
1998; Wollmuth et al., 1992). Therefore, there is an inward current, mainly carried by 
Na+ ions, at the hyperpolarised potentials (< -50 mV) at which the channel is open. 
These properties cause pacemaker channels to generate a rebound depolarisation 
following an action potential or inhibitory postsynaptic potential (IPSP), which 
increases the membrane potential thereby contributing to rhythmic activity of cells and 
contributes to the resting membrane potential (Pape, 1996). 
7 
Chapter 1 General Introduction 
Table 1.3 Details of known HCN channel gene members (with both original and updated 
nomenclature). 
NEW ORIGINAL NAME SPECIES REFERENCES 
NOMENCLATURE 
mBCNG-1 / HAC2 Mouse 1,2 
hBCNG-1 Human 4 
HCN 1 
HCN 1 Rat AF247453 
HCN 1 Rabbit 7 
mBCNG-2 / HACI Mouse 2,4 
hBCNG2 / hHCN2 Human 4,5,6 
HCN2 
HCN2 Rat 7, AF247451 
HCN2 Rabbit 7 
mBCNG-4 / HAC3 Mouse 2,4 
HCN3 HCN3 Rat AF247452 
HCN3 Rabbit 7 
mBCNG-3 Mouse 4 
hHCN4 Human 5,8 
HCN4 
HCN4 Rat AF247450 
HCN4 Rabbit 7,9 
SpHCN SPIH Sea urchin 3 
HvHCN HvCNG Silkmoth AJ012664 
DmHCN DMIH Fruitfly AF124300 
Adapted from Kaupp et al., (2001). References: 1. (Santoro et al., 1997); 2. (Ludwig et al., 1998); 3. 
(Gauss et al., 1998); 4. (Santoro et al., 1998); 5. (Ludwig et al., 1999); 6. (Vaccari et al., 1999); 7. (Shi et 
al., 1999); 8. (Seifert et al., 1999); 9. (Ishii et al., 1999). AF24750-AF24753, AJO12664 and AF124300 
refer to National Centre for Biotechnology Information accession numbers (NCBI). 
Pacemaker channels have been well studied in the heart where there are four main 
channels, which are believed to contribute to the action potential (L- and T-type calcium 
(Ca2+) channels, a K+ channel and pacemaker channels). Ih generates an inward current 
during the falling phase of the action potential, which causes a resultant increase in 
membrane potential thereby facilitating the firing of another action potential. Addition 
of (3-adrenoceptor agonists (Brown et al., 1979a), or cAMP (DiFrancesco et al., 1991), 
shifts the half-maximal activation (V112) of Ih to more positive membrane potentials, 
causing a resultant increase in heart rate. This is one of the reasons why sympathetic 
stimulation by adrenaline increases the heart rate and conversely why parasympathetic 
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innervation by acetylcholine (ACh) slows the heart rate (Brown et al., 1979a; Brown et 
al., 1979b; see Figure 1.1). 












I 2 time (s) 
Adapted from Biel et al., (1999). 1h current shows the slow depolarisation caused by activation of this 
current. lea refers to both T- and L-type Ca 2+ channels, which are the main channels responsible for the 
depolarising phase of the action potential. IK is the K+ currents that underlie the repolarisation phase. 
The black trace shows action potentials under normal conditions and the red trace demonstrates the 
acceleration of their rate following addition of (i-adrenoceptor agonists. 
Many different V1/2 values, which provide information as to the operational voltage 
range of the channels, have been reported for recombinant HCN channels. Initial 
studies placed the values at < -105 mV (Ludwig et al., 1998; Ludwig et al., 1999; 
Santoro et al., 1998) and there was debate regarding the functional significance of the 
channel. However, Seifert et al., (1999) demonstrated that V J/2 critically depended on 
the length of the hyperpolarising pulse and that the actual values lie between -70 to -80 
mV, which is similar to the V1/2 of native pacemaker channels (Bader et al., 1984; 
Mayer et al., 1983; McCormick et al., 1990a; Pape, 1996). Following this, Santoro et 
al., (2000) re-evaluated HCNI and HCN2 properties and found similar values in the 
physiological range (see Table 1.4 for list of V172 values of native and HCN channels). 
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Additionally, each of the HCN channel isoforms display distinct tau (ti)-activation 
properties (see Table 1.4 for values). Throughout the brain, native Ih activation 
properties have been demonstrated to vary significantly, which may be due to the 
presence of different isoforms (see Table 1.4). These different activation properties 
may have important physiological implications, such as the contribution to thalamic 
spindle wave activity (McCormick et al., 1997), in addition to the role already 
mentioned in the heart. 
The channel is sensitive to modulation via binding of cAMP to the CNBD, which 
results in increased current, alteration of the activation kinetics and a shift in Vuu2 (see 
Table 1.4). It has been demonstrated that the modulation of Ih occurs via direct binding 
of cAMP to the channel, independently of protein phosphorylation (DiFrancesco et al., 
1991; Gauss et al., 1998; Ludwig et al., 1998). There is also a degree of voltage 
modulation by protein kinase A (PKA) dependent phosphorylation (Vargas et al., 2002; 
Yu et al., 1993). Additionally, a number of HCN isoforms contain PKA-consensus 
phosphorylation sites, which indicate why cAMP modulation is more apparent than 
PKA-modulation (Santoro et al., 1998). 
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Table 1.4 Functional properties of native and recombinant HCN channels 
V1/2 
VV1/2 
ISOFORVI MODULATION BY PNJPk 'Z-ACTIVATION 
(MV) 
CAMP (mV) 
100 -300 ms HCN 1 -71.6k + 2a 0.25a (at -130 to -100mv)a'g 
200 - 500 ms HCN2 -78.3k +12-14 
b,, 0 24b" 
(at -140 to -100mV)b'` 
HCN3 n. d n. d. n. d n. d 
400 ms (at -140mV) to HCN4 -75.2' +11-23 c, 
d, f 
23s (at -110mV)c 
SpHCN -26e -24e 0.23e n. d 
Ih -74 
to - +2- 13 
0.2- 
300ms to 8.3sh, 1, m 
85h, 1, m 0.4`'i. m 
References: a) Santoro et al., (1998) b) Ludwig et al., (1998) c) Ludwig et al., (1999) d) Ishii et al., 
(1999) e) Gauss et al., (1998) f) Seifert et al., (1999) g) Santoro et al., 2000) h) McCormick et al., 1990b) 
i) Wollmuth et al., (1992) j) Kaupp et al., (2001) k) Santoro et al., (1999)1) Luthi et al., (1998) m) Pape, 
(1996). 
Recombinant HCN channels have high affinity for cAMP; HCN2 has been 
demonstrated to have a K112 of 0.5 pM, and that of SpHCN is 0.7 µM, but cGMP has 
10-fold less affinity at HCN2 channels and 1000-fold at SpHCN (Gauss et al., 1998; 
Ludwig et al., 1998). Truncation mutants of HCN1 and HCN2 channels lacking a 
CNBD have been used to further investigate the role cAMP exerts on the channel 
(Wainger et al., 2001). These studies suggest that the CNBD inhibits gating of HCN 
channels by blocking the pore and that binding of cAMP, or deletion of this domain 
removes this inhibition (Wainger et at., 2001; Wang et al., 2001). Deletion of the 
HCN 1 channel CNBD does not produce as dramatic an alteration in the channel 
properties as the corresponding HCN2 mutant, which is suggestive that the differences 
in cAMP modulation between HCN1 and HCN2 may be due to differences in the 
inhibitory CNBD (Wainger et al., 2001). 
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Extracellular caesium (Cs+) ions block Ih currents in hippocampal slices, at millimolar 
concentrations (Halliwell et al., 1982), while it is relatively insensitive to barium (Ba+) 
ions (Ludwig et al., 1998; Pape, 1996; Santoro et al., 1998). Similar findings have been 
demonstrated for recombinant HCN channels (Ludwig et al., 1998; Santoro et al., 
1998). Aside from these cations, there are only a few compounds that display affinity 
for the HCN channel. One such compound is the bradycardiac agent, ZD 7288, which 
is an antagonist at micromolar concentrations (BoSmith et al., 1993; Gasparini et al., 
1997; Ghamari-Langroudi et al., 2000; Harris et al., 1995; Khakh et al., 1998). Studies 
performed on recombinant mHCN1 channels demonstrate that ZD 7288 reversibly 
blocks the current in a concentration-dependent fashion. This block took -4s when 
applied to inside-out patches but a few minutes when applied to the extracellular surface 
(Shin et al., 2001). Moreover, this block was highly voltage-dependent, at more 
depolarised potentials where the channel is not fully open, ZD 7288 produced an 
effective block, which was diminished at more hyperpolarised potentials (BoSmith et 
al., 1993; Shin et al., 2001). Ivabradine has also recently been shown to be an open- 
channel blocker, similar to ZD 7288 in rabbit SA-node cells (Bucchi et al., 2002). 
Zatebradine, a bradycardic agent with a similar structure to verapamil (L-type Ca2+ 
channel blocker), has been demonstrated to be a use-dependent blocker of Ih channels 
but also to inhibit voltage-gated outwards K+ currents (IK) and L-type Ca 2+ channels 
(Goethals et al., 1993; Satoh et al., 2002). 
The common physical properties of native and recombinant HCN channels are 
summarised in Table 1.5. Auxiliary proteins, formation of heteromeric channels and/or 
ß-subunits may be able to explain the subtle differences between native and 
recombinant channels. However, the available evidence is highly suggestive of HCN 
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channels representing the molecular identity of pacemaker channels. Although, until 
dominant-negative mutants are available there remains a question mark over this. 
Table 1.5 Common physical properties of native and recombinant HCN channels 
PHYSICAL PROPERTIES OF NATIVE AND RECOMBINAN'T' HCN CHANNELS 
Slow activation (although kinetics vary between both brain regions and 
cloned isoforms) and do not inactivate 
Conduction of both K+ and Na' ions, with a ratio of 3: 1 - 4: 1. 
Direct enhancement of channel current and shift in V112 by binding of cAMP 
Extracellular Cs+ blocks the current 
Removal of external K+ blocks the inward current (Frace et al., 1992; 
Wollmuth et al., 1992) 
External C1 ions modulate the channel (Frace et al., 1992; Santoro et al., 
1998; Zong et al., 2001) 
1.2.4 Structural properties of HCN channels 
There is a good deal now known about the structural features of HCN channels due to 
homology screening and mutagenesis studies performed on the different channel 
isoforms. Hydropathicity plots of the initial sequences were predictive of a channel 
with six transmembrane segments, with intracellular hydrophilic N- and C- termini and 
a putative CNBD in the C-termini (Gauss et al., 1998; Santoro et al., 1997; Santoro et 
al., 1998). 
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Figure 1.2 Structural representation of an HCN channel isoform 
Adapted from Kaupp et al., (2001). 
The four different HCN isoforms display an overall sequence homology of - 60 %, 
although this is increased to 80 - 90 % around the core region (the SI transmembrane 
segment to the CNBD). Primary structure analysis of the core region reveals that HCN 
channels are most closely related to voltage-gated K+ channels, including Shaker (14 % 
homology), ether-ä-gogo (27 %), HERG (22 %), and CNG channel a-subunits (28 %; 
Ludwig et al., 1998). It has been postulated that the fusion of an ancestral K+ channel 
and CNG occurred before the evolutionary separation of plants and animals (Warmke et 
al., 1994) and that the newly identified HCN channel represents the closest link known 
to this ancestral channel (Santoro et al., 1997). 
HCN channels are predicted to comprise of four subunits due to the resemblance to both 
Shaker and CNG channels (Santoro et al., 1998). It is unclear whether, homomeric or 
heteromeric channels, are formed, or a combination of both. Recombinant studies have 
demonstrated that homomeric channels are functional (Ishii et al., 1999; Ludwig et al., 
1998; Ludwig et al., 1999; Santoro et al., 1998; Vaccari et al., 1999). The expression 
profile of the different subunits does little to resolve this question, as it reveals areas 
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that are predominantly one isoform but other regions where the four subunits are 
equally distributed (Moosmang et al., (1999); see Section 1.2.5 for full details of HCN 
channel expression). Studies on native channels reveal Ih channels with differing 
properties throughout the CNS (see Table 1.4), which may be due to the presence of 
alternative splicing, homomeric or heteromeric channels, or the presence of auxiliary 
subunits (Santoro et al., 1999). However, differences in the protocols used between 
groups render it difficult to draw any firm conclusions about these electrophysiological 
differences, although it seems likely that the different kinetics of the subunits 
contribute. Ulens et at., (2001a) reported functional HCN1 / HCN2 heteromers based 
upon co-expression studies of HCN1 and HCN2 channels in oocytes. The heteromers 
displayed properties lying between the fast kinetics and low cAMP modulation of 
HCN1, and slow gating HCN2 isoform; similar to native Ih in CAl pyramidal neurones 
(Ulens et at., 2001a). Additionally, chimeric cDNA constructs of HCN1 and HCN2, 
covalently linked at the C-terminus of HCN1 and N-terminus of HCN2 subunits 
(concatenated), gave rise to a functional channel with properties similar to that in co- 
expressing cells (Ulens et al., 2001a). 
In another mutagenesis study, using Chinese hamster ovary cells, HCN2 channels 
lacking an amino terminus did not locate to the cell surface, as determined using 
immunofluorescence, and unsurprisingly therefore, did not produce functional channels 
(Proenza et al., 2002). In the same report, using yeast-two hybrid assays, it was 
demonstrated that the N-termini of HCN1 and HCN2 interacted, both homomerically 
and heteromerically (Proenza et al., 2002). Deletion of the B-helix of the CNBD also 
produced homomeric channels which were not functional. Immunofluorescence 
demonstrated that these mutants were located intracellularly, whereas the wildtype was 
located at the cell surface (Proenza et al., 2002). This may be due to alterations in the 
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tertiary structure of the proteins, or a second reason provided by the authors, based on 
work by Ma et al., (2001) in COST cells. This showed that motifs present in inwardly 
rectifying K+ (Kir) channels were responsible for localisation to the plasma membrane, 
and similar motifs may be present in the B-helix of HCN channels. 
1.2.5 Expression profile of HCN channel subunits 
The successful cloning of HCN1 -4 cDNAs enabled examination of the expression 
pattern of the different isoforms throughout the brain and periphery. Initial distribution 
studies were performed by the groups who isolated the cDNA for the HCN subunits, 
and since then there have been a number of more extensive studies examining the 
distribution of the four subunits in mouse and rat brain. Northern blots performed by 
Santoro et al., (1998) to establish the distribution of the mouse isoforms, revealed that 
they all display different profiles, for example mBCNG-1 (HCN1) was solely found in 
the brain. However, expression of other HCN members was seen in brain, heart, liver, 
kidney, skeletal muscle and lung. 
An extensive in situ hybridisation study on the distribution of HCN1-4 isoform mRNAs 
in mouse brain was performed by Moosmang et al., (1999). This group demonstrated 
that the HCN1 transcript was highly expressed in cortical structures, such as the 
neocortex, hippocampus and cerebellum; although there were also high levels in the 
superior colliculus. The most ubiquitous and abundant isoform was found to be HCN2, 
which was present in the majority of brain structures analysed, but particularly high 
expression was observed in the thalamus, the olfactory bulb, hippocampus and 
cerebellum. HCN3 subunit mRNA expression was found at low levels throughout the 
brain, except from the olfactory bulb, and a similar pattern was observed for HCN4 
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mRNA, with the habenula and thalamus also demonstrating high expression levels 
(Moosmang et al., 1999). 
The distribution of the four HCN isoforms in rat was demonstrated to be similar to that 
found in mouse by Moosmang et al., (1999), with HCN2 displaying the most ubiquitous 
and widespread profile (Monteggia et al., 2000; Figure 1.3). Bender et al., (2001), 
using in situ hybridisation, observed that the expression profiles of HCN1,2 and 4 
mRNA throughout the hippocampus differ significantly between adult and juvenile rats. 
Immunohistochemical reports on HCN1 protein expression reveal a similar distribution 
to that shown by in situ hybridisation. These studies show protein expression on apical 
dendrites as well as axonal terminals of the hippocampus, less prominent in the CA3 
region as compared with the CAl (Santoro et al., 2000). HCN1 immunoreactivity in 
apical dendrite membranes in rat hippocampus displays a 60-fold increase from somatic 
to distal apical dendrite membranes (Lorincz et al., 2002). Additionally, the density of 
HCN1 immunoreactivity was found to be significantly higher in dendritic shafts than in 
spines, at similar distances from the soma (Lorincz et al., 2002). 
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Figure 1.3 Representative transverse autoradiograms of HCNI-4 mRNA distribution in rat brain 
iC st cý 
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Adapted from B. Henry, (Personal communication). Abb: AD, anterodorsal thalamic nucleus, AV, 
anteroventral thalamic nucleus, CA, CA fields of the hippocampus, Cb, cerebellum, Ct, cortex, DG, 
dentate gyrus, Hb, habenula, IC, inferior colliculus, OP Sc, optic nerve layer of the superior colliculus, Rt, 
reticular thalamic nucleus, SG Sc, superfical grey layer of the superior colliculus, St, striatum, Thal, 
thalamus. 
1.2.6 Physiological functions 
There have been three main physiological functions attributed to Ih channels in the 
brain: 
1. Control of the rate of rhythmic activity in neurones and neuronal networks. 
2. Contribution to the resting neuronal membrane potential. 
3. Contributing to the neuronal response after hyperpolarising currents. 
There are numerous examples of the generation of rhythmic activity within neuronal 
networks (in addition to that of the heart rate mentioned previously); one such is spindle 
waves (McCormick et al., 1997; Santoro et al., 1999). These oscillations have a 
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frequency of 7- 14 Hz, wax and wane within 1-3s, display periodicity of 3- 20 s and 
are common throughout early stages of sleep. Spindle waves are gradually replaced by 
lower frequency, 0.5 -4 Hz firing patterns and neurones can switch between the two 
with only small alterations in membrane potential (see McCormick et al., (1997) for a 
review on thalamocortical oscillations). Ih channels are believed to contribute to both 
characteristic wave patterns. The refractory time period between spindle waves is 
believed to be determined by the time course of Ih channel deactivation (McCormick et 
al., 1997). Interaction between the T-type Cat+- and Ih channels is thought to generate 
the low frequency 0.5 -4 Hz rhythm to the thalamic relay neurones (for review see 
McCormick et al., (1997)). 
The fact that Ih and HCN channels are positively modulated by cyclic nucleotides and 
PKA enables G-protein coupled receptors to alter the properties of the channels via 
regulation of CAMP- and PKA-levels. Al adenosine (Pape, 1992; Strecker et al., 2000) 
and µ-opioid receptors (Ingram et al., 1994; Svoboda et al., 1998; Ulens et al., 2001b) 
have been demonstrated to modulate pacemaker channels through this mechanism. In a 
recent study utilising different 5-hydroxytryptamine (5-HT) receptor agonists, 
Bickmeyer et al., (2002) demonstrated that 5-HT4- and 5-HT7-receptor activation 
increased the Ih current and shifted V112 by +5 mV, whereas 5-HT1A-receptor activation 
shifted V1/2 to more hyperpolarised potentials by 5 mV in murine hippocampus. 
Moreover, Ulens et al., (2001b) demonstrated in Xenopus oocytes that GS-coupled 5- 
HT4-receptor activation modulated HCN2 via CAMP but had no effect on HCN1 
channels, which was also the case for G; /Go-coupled µ-opioid receptors. This concurs 
with the knowledge that CAMP dramatically alters HCN2 channel properties but has 
very little effect on HCN1 (see Table 1.4). Therefore, HCN channels are extremely 
important as both primary and secondary drug targets. Unsurprisingly, due to their 
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involvement in rhythmic oscillations, Ih channels have been implicated in epilepsy and 
sleep disorders, as well as neuropsychiatric disorders, such as depression, given the 
altered sleep patterns observed in patients (Monteggia et al., 2000; Moosmang et al., 
1999). 
1.2.7 HCN channels and depression 
Sleep disturbance is a key aspect of depression, with an estimated 75 % of patients 
suffering some form of sleep dysfunction (Thase, 1999). The knowledge that HCN 
channels contribute to the generation of spindle waves and their refractory period 
suggests that modulation of these channels would lead to alterations in the sleep 
architecture. The findings from Phase 1 clinical trials of Org 34167 have provided 
evidence for this hypothesis, with increased REM sleep demonstrated in healthy male 
volunteers (vanBerkel, Personal communication). To date, this finding, and those from 
preclinical animal models of depression, are the only confirmed data supporting a link 
between HCN channels and depression. 
A recent study in crayfish muscle cells proposed another property of HCN channels; 
namely presynaptic facilitation of neurotransmitter release (Beaumont et al., 2000). The 
report suggests that the mechanism through which the channels achieve this is via direct 
coupling to the vesicular release machinery, as it occurs independent of an increase in 
intracellular Ca2+ (Beaumont et al., 2000). This has potential implications for a number 
of diseases, including depression, as all current antidepressant mechanisms of action 
involve, either directly or indirectly, elevating central monoamine transmitter 
concentrations. 
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1.3 Depression 
1.3.1 Introduction 
Over 340 million people worldwide are affected by major depression, with females 
comprising roughly two thirds of that number. The average age of onset is now in the 
20's compared with the late 40's before World War II (Weissman et al., 1996). The 
World Health Organisation estimate that by 2020, unipolar major depression, will 
become the second largest cause of global disease burden in the world, behind 
ischaemic heart disease (Murray et al., 2001). Within the female population in the 
developing countries, unipolar depression is predicted to become the largest cause of 
disease burden (Murray et al., 2001). Therefore, depression represents a major medical 
and social problem. Despite the last 40 years witnessing the introduction of agreed 
criteria e. g. Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition 
(DSM-1V; see Table 1.6), newer, faster onset treatments and an increased understanding 
of the neurobiology of depression, studies indicate that roughly 30% of patients do not 
receive any benefit from present drugs (Doris et al., 1999). 
The original modem drugs used for the treatment of depression were the monoamine 
oxidase inhibitor (MAOI) iproniazid, and the tricyclic antidepressant (TCA) imipramine 
(mainly blocks noradrenaline (NA) reuptake). Both compounds were discovered 
fortuitously, with iproniazid being developed as a treatment for tuberculosis and 
imipramine as an antihistamine but tested for the treatment of schizophrenia due to the 
success of chlorpromazine. The discovery of these compounds' mechanisms of actions 
led to the catecholamine hypothesis of depression being developed in the mid-1960s. 
This theory stated "that some, if not all, depressions are associated with an absolute or 
relative deficiency of catecholamines, particularly noradrenaline (NA), at functionally 
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important adrenoceptor sites in the brain. Elation conversely may be associated with an 
excess of such amines" (Schildkraut, 1965). 
Table 1.6 DSM-IV criteria for major depressive disorder 
DSM-IV CRITERIA FOR MAJOR DEPRESSIVE DISORDER 
A. Five (or more) of the following symptoms have been present during the same 2-week period 
and represent a change from previous functioning; at least one of the symptoms is either (1) 
depressed mood or (2) loss of interest or pleasure. 
(1) Depressed mood most of the day, as indicated by either subjective report (e. g. feels sad or 
empty) or observation made by others (e. g. appears tearful). Note: In children and adolescents 
can be irritable mood. 
(2) Markedly diminished interest or pleasure in all, or almost all, activities most of the day, 
nearly everyday (as indicated by either subjective account or observation made by others). 
(3) Significant weight loss when not dieting or weight gain (e. g. a change in more than 5% of 
body weight in a month), or decrease or increase in appetite nearly everyday. Note: In children, 
consider failure to make expected weight gains. 
(4) Insomnia or hypersomnia nearly every day. 
(5) Psychomotor agitation or retardation nearly everyday (observable by others, not merely 
subjective feelings of restlessness or being slowed down). 
(6) Fatigue or loss of energy nearly everyday 
(7) Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) 
nearly everyday (not merely self-reproach or guilt about being sick). 
(8) Diminished ability to think or concentrate, or indecisiveness, nearly everyday (either by 
subjective account or as observed by others). 
(9) Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a 
specific plan, or a suicide attempt or a specific plan for committing suicide. 
B. The symptoms do not meet the criteria for a mixed episode. 
C. The symptoms cause clinically significant distress or impairment in social, occupational, or 
other important areas of functioning. 
D. The symptoms are not due to the direct physiological effects of a substance (e. g. a drug of 
abuse, a medication) or a general medical condition (e. g. hypothyroidism). 
E. The symptoms are not better accounted for by bereavement, i. e., after the loss of a loved one, 
the symptoms persist for longer than 2 months or are characterised by marked functional 
impairment, morbid preoccupation with worthlessness, suicidal ideation, psychotic symptoms or 
psychomotor retardation. 
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There is still a lack of understanding of the pathology of depression, which has hindered 
the development of novel therapies, and all present antidepressant therapies have a 
delayed onset of action with their primary action to increase the levels of monoamines 
in the brain. These therapies have proved very successful and remain the most widely 
prescribed drugs (for example, TCAs, MAOIs and uptake inhibitors). Currently, a 
number of novel drug targets are being examined as new antidepressants, with the hope 
of a more rapid onset of action and more universal effectiveness. 
1.3.2 Monoamine theories of depression 
The first catecholamine theory of depression was proposed by Schildkraut (1965), based 
mainly on the actions of reserpine (depletes catecholamine stores and to a lesser extent 
5-HT), iproniazid and imipramine. It stated that a deficiency of catecholamines, 
particularly NA, led to some forms of depression. Evidence for this came from 
reserpine, a drug used in the treatment of hypertension due to its ability to decrease 
sympathetic activity, which was noted to cause sedation and in many instances evoke 
severe depression in patients. Tetrabenazine, a similar agent to reserpine, was also 
shown to induce depression in many patients (Lingjaerde, 1963). 
In contrast, iproniazid was fortuitously noted to elevate mood in depressed patients in 
the early 1950s, and thereafter was shown to increase extracellular NA and 5-HT 
concentrations. Initially, imipramine cast doubt on the catecholamine theory because it 
was shown not to inhibit MAO. However, Hertting et al., (1961) demonstrated that it 
inhibited cellular uptake of NA in peripheral tissues. This enabled imipramine to fit 
into the hypothesis as it, like iproniazid, elevated both mood and NA (see Figure 1.4). 
Moreover, both antidepressant agents were demonstrated to attenuate reserpine-induced 
sedation (Carlsson, 1961; Chessin et al., 1957; Sulser et al., 1964). Similarly, 
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administration of dihydrophenylalanine (DOPA; a precursor of dopamine (DA) and 
NA) to laboratory animals was shown to reverse reserpine-induced sedation (Carlsson et 
al., 1957); a finding reproduced in humans (Schildkraut et al., 1965). Amphetamine, 
which releases NA from vesicles and prevents re-uptake was also used in the treatment 
of depression at the time with varying success and so added further support to the 
catecholamine theory of depression (Schildkraut et al., 1965). 
Shortly after Schildkraut's catecholamine hypothesis was published, Coppen (1967) 
proposed that 5-HT, rather than NA, was the more important neurotransmitter in 
depression. This was based on similar evidence to that of the NA theory as reserpine, 
imipramine and iproniazid all affect the 5-HT system, in addition to the noradrenergic 
system (Coppen, 1967). It was also supported by work demonstrating that if 
catecholamine levels were depleted by up to 20 % but 5-HT neurotransmission 
remained unaltered, there was no sedation in animals (Brodie et al., 1966). Alongside 
this, the main observation promoting the 5-HT theory was that administration of a 
MAOI in conjunction with tryptophan (precursor of 5-HT) elevated mood in control 
patients and potentiated the antidepressant effect of MAOI (Coppen et al., 1963). Set 
against this, combination of a MAOI with DOPA did not produce further therapeutic 
benefit (Klerman et al., 1963). Additionally, the therapeutic effect of MAOI and TCA 
drugs was later shown to be blocked by administration of 5-HT synthesis inhibitors 
(Shopsin et al., 1976; Shopsin et al., 1975). 
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Figure 1.4 Mechanism of NA reuptake inhibitors and u2-adrenoceptor antagonists 
The 5-HT hypothesis gained significant weight with the introduction of the selective 
serotonin reuptake inhibitors (SSRI) in the mid-1980s, which soon became the main 
prescribed antidepressant medication. Indeed the success of SSRI's led to the role of 5- 
HT in depression and antidepressant therapies dominating thinking in scientific and 
drug company research throughout the 1980's. However, these monoamine hypotheses 
do not address the fact that alterations of neurotransmitters occur after acute 
administration of the pharmacologic agents, whereas the onset of therapeutic action 
requires 2-4 weeks (Doris et al., 1999). Indeed, although tolerance develops to the side- 
effects of SSRIs, the opposite appears to be the case with their therapeutic effects 
continuing to grow over time (Stahl, 1998). Additionally, the fact that antidepressants 
do not elevate mood in healthy individuals does not fit with the original hypothesis. 
The time lag in current SSRI antidepressant medications is believed, at least in part, to 
be due to desensitisation of 5-HTIA autoreceptors, which occurs over a three to four 
week period (Bel et al., 1993; Rutter et al., 1994). The increase in 5-HT levels in 
response to reuptake block is partially offset by activation of these autoreceptors 
initially, which decreases cell firing (Gardier et al., 1996). In view of this a number of 
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5-HT1A-receptor antagonist drugs have been used in attempts to augment and accelerate 
antidepressant drug actions. Despite animal studies demonstrating the clear efficacy of 
pindolol (a 5-HT1A-receptor partial agonist and (3-adrenoceptor antagonist) in achieving 
this (Arborelius et al., 1995; Arborelius et al., 1996), clinical studies have been 
ambiguous (see Artigas et al., (2001) for review). There are a number of possible 
reasons for this, such as sample population, and the fact that pindolol is a partial 
agonist. Additionally, it is believed that the therapeutic effects of increasing 5-HT 
levels are due to action on 5-HT1A post-synaptic receptors, as buspirone (a 5-HT1A 
agonist) displays some antidepressant properties (Rickels et al., 1990; Stahl et al., 
1998). Therefore, the post-synaptic actions of pindolol may offset the pre-synaptic 
ones. A more specific compound, which only blocked somatodendritic 5-HT1A- 
autoreceptors may be more successful in accelerating the clinical onset of current 
medications. 
The decreased levels of NA proposed by Schildkraut, suggested that there would be a 
compensatory upregulation of 3-adrenoceptors. Despite inconsistent findings 
supporting this, more consistent evidence demonstrates that chronic treatment with 
antidepressants and electroconvulsive therapy (ECT) decrease 3-adrenoceptor density in 
the rat forebrain (Banerjee et al., 1977; Banerjee et al., 1978). This lead to the theory 
that P-adrenoceptor downregulation was required for clinical antidepressant efficacy 
(Sulser et al., 1978). However, some of the newly developed antidepressants do not 
alter, or even increase (3-adrenoceptor density (Vetulani et al., 2000). 
Another adrenoceptor implicated in depression is the presynaptic a2-adrenoceptor 
(Leonard, 1997). Chronic desipramine (strongly inhibits NA reuptake and to a lesser 
extent 5-HT) treatment in rats decreased the sensitivity of a2-adrenoceptors, a finding 
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supported by the fact that clonidine (a2-adrenoceptor agonist) administration caused a 
significant increase in growth hormone (an indirect measure of (12-adrenoceptor activity) 
although platelet studies proved inconsistent (Cheetham et al., 1991). Heal et at., 
(1991) demonstrated that chronic administration of the antidepressants, amitriptyline 
(inhibits catecholamine reuptake; 10 mg/kg), desipramine (10 mg/kg) or 
tranylcypromine (MAGI; 10 mg/kg) attenuated clonidine-induced hypoactivity and 
mydriasis. Moreover, post-mortem studies, performed in brains of suicide victims, 
demonstrate an upregulation of a2-adrenoceptor binding sites in the prefrontal cortex 
(Garcia-Sevilla et al., 1999), hippocampus and striatum (Callado et al., 1998). These 
data imply a supersensitivity of a2-adrenoceptors in depression, which has been 
postulated to decrease locus coeruleus (the main projection site of NA in the CNS) 
firing and therefore decrease NA release (Charney et al., 1981; Spyraki et al., 1980). 
The NA theory received a major boost with the arrival of new antidepressants in the 
1990s, including mirtazapine (mainly an (12-adrenoceptor antagonist with 5-HT2 and 5- 
HT3 receptor antagonist properties), venlafaxine (inhibitor of 5-HT and NA reuptake) 
and in particular reboxetine (the most specific inhibitor of NA reuptake approved for 
treating depression). Indeed, reboxetine has been shown in clinical trials to be at least 
as effective as citalopram, the most specific inhibitor of 5-HT re-uptake currently 
available. This finding suggests that individual modulation of either NA or 5-HT 
neurotransmission is beneficial in treating depression. However, there is substantial 
interplay between the two systems, as for example, in addition to enhancing NA release, 
a2-adrenoceptor antagonism also increases serotonergic neurotransmission due to 
blockade of a2-adrenoceptor present on 5-HT nerve terminals (Bengtsson et al., 2000). 
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1.3.2.1 Evidence from clinical studies: - 
Post-mortem studies remain equivocal about the levels of neurotransmitters in 
depression and their receptors and transporters. There are numerous reports showing 
elevated, no alteration, or decreases in monoamine metabolite levels, monoamine 
receptors and uptake sites, in the studies examining them (see Cheetham et al., (1991) 
for review). One of the more consistent findings from post-mortem brains (in addition 
to the a2-adrenoceptor increase already discussed) are elevated 5-HT2 receptor levels in 
the frontal cortex of suicide victims (Gross-Isseroff et al., 1989; Mann et al., 1986; 
Stanley et al., 1983); a group which contains a significant proportion of depressed 
patients (Barraclough et al., 1974). Additionally, the antidepressants mirtazapine, 
mianserin (non-selective 5-HT2 receptor antagonist), trazodone (inhibits 5-HT reuptake) 
and nefazodone (5-HT2 receptor antagonist and weak 5-HT reuptake inhibitor) all have 
5-HT2 receptor antagonistic properties, which decrease serotonergic side-effects 
associated with antidepressant treatment (de Boer, 1996; DeVane et al., 2002; Fuller et 
al., 1984; Nutt, 1997). 
In order to investigate the relative mechanisms of antidepressants depletion studies have 
been performed over the course of the last 20 years in a further attempt to elucidate the 
role of NA and 5-HT and their receptors in depression. In the 1970s administration of 
parachlorophenylalanine (an inhibitor of tryptophan hydroxylase) produced a relapse in 
depressive symptoms of treated patients (Shopsin et al., 1976), but it is considered too 
toxic for use today. Therefore, tryptophan depletion paradigms have been used to 
reduce 5-HT levels in the brain, and are performed by giving a drink loaded with amino 
acids, except tryptophan. In animals, such depletion is known to increase pain 
sensitivity, motor activity, aggression and decrease REM sleep, all behaviours which 
indicate a deficit in 5-HT function (Bel et al., 1996; Kawai et al., 1994; Young et al., 
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1989). Control patients subjected to tryptophan depletion, do not demonstrate a 
lowering of mood (Benkelfat et al., 1994; Carpenter et al., 1998; Knott et al., 1999). 
Similarly, untreated depressives subjected to this paradigm do not demonstrate any 
worsening of symptoms, which was a surprise as it was hypothesised that there would 
be a further decline in mood in response to lowering of 5-HT levels (Delgado et al., 
1994; Price et al., 1997; Price et al., 1998). This could be due to the fact that the 5-HT 
system is already diminished and that a further decline has no effect, or that downstream 
responses to 5-HT function are the main component of depression. However, in an 
SSRI treated group, tryptophan depletion causes a relapse in depressive symptoms and 
especially in those whose symptoms had remitted for under 2 weeks while having little 
effect on patients treated with mainly NA drugs (Bremner et al., 1997; Delgado et al., 
1991; Nutt et al., 1999). The opposite holds true for catecholamine depletion studies 
using a-methyl-p-tyrosine (an inhibitor of tyrosine hydroxylase). This is suggestive that 
there are subsets of patients where either 5-HT or NA is the more important 
neurotransmitter in depression. Additionally, patients treated with noradrenergic drugs 
relapse more frequently than those treated with serotonergic antidepressants (Miller et 
al., 1996). 
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Figure 1.5 Mechanism of action of 5-HT reuptake inhibitors and pindolol 
1.3.2.2 Dopamine 
With discrepancies emerging regarding the NA and 5-HT theories of depression, the 
1970s saw DA postulated to play a critical role in depression and antidepressant action. 
It had been known that drugs such as amphetamine and cocaine elevated mood as well 
as DA release, but not in depressed patients (Schildkraut, 1965). This knowledge, 
coupled with the knowledge that reserpine depletes DA, in addition to NA and 5-HT, to 
produce sedation and severe depression in some patients provided evidence for DA 
playing a significant role in depression. Additionally, Serra et al., (1979) examined the 
role of antidepressants on dopaminergic neurotransmission, demonstrating that chronic 
imipramine, amitriptypline and mianserin treatment prevented or reversed the sedative 
effect of low doses of apomorphine (Di- and D_, -receptor agonist). This finding has 
since been replicated with other antidepressants, ECT treatment and REM-sleep 
deprivation (Collu et al., 1997; D'Aquila et al., 1997; D'Aquila et al., 2000). These 
effects are believed to reflect an increased sensitivity of postsynaptic DA receptors 
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induced by chronic antidepressant treatment, as opposed to the initial belief that these 
findings reflected a subsensitivity of Dl-autoreceptors (D'Aquila et al., 2000). 
Early autoradiographical studies utilising dopamine agonists provided inconsistent 
findings, but the advent of selective DA antagonists provided findings consistent with 
DA postsynaptic receptor upregulation by antidepressants. These antagonists revealed 
an increased D2/D3-receptor number following chronic antidepressant treatment, 
particularly in the nucleus accumbens, but also in the striatum (Ainsworth et at., 1998b; 
Maj et al., 1998; Maj et al., 1996; Papp et al., 1994), as well as increased D2 mRNA 
expression (Dziedzicka-Wasylewska, 1997; Dziedzicka-Wasylewska et al., 1997a). 
This may relate, in part to, the therapeutic profile of the antidepressants, given the role 
of the nucleus accumbens, which is impaired in depressed patients (Di Chiara, 2002; 
Drevets, 2000). A recent animal study by Lammers et al., (2000) reported that a 
common effect of chronic antidepressant treatment was a selective increase in D3 
receptor gene expression in the shell of the nucleus accumbens. Desipramine, 
imipramine, amitriptyline and tranylcypromine all elevated D3 mRNA in this region 
after 21-day treatment. Interestingly, fluoxetine following 42-day administration, 
despite significantly decreasing D3 mRNA levels, prevented the down-regulation of D3- 
receptors caused by handling stress, as did imipramine. ECT produced the largest 
increase of the treatments, both mRNA and D3 receptor number, which is an accordance 
with clinical efficacy (Lammers et al., 2000). This finding may have implications for 
depression and may provide a novel target for new antidepressants but requires further 
verification. 
Lending weight to the DA theory of depression are a number of dopaminergic 
compounds, which have been successful in treating depression; bupropion (weak 
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inhibitor of DA, NA and 5-HT uptake; Rudorfer et al., 1984), nomifensine (inhibitor of 
DA and NA-uptake; Feighner et al., 1984; Goldstein et al., 1984)) and amineptine 
(inhibitor of DA reuptake; Garattini, 1997). Pramipexole (D3-receptor agonist) has been 
approved for use in Parkinson's disease but has also been shown in two animal models, 
the forced swim test and exposure to chronic stress, to be antidepressant-like (Maj et al., 
1997; Willner et al., 1994). Although no large scale clinical trials have been performed, 
a small-scale trial by Ostow with 22 patients, demonstrated not only that pramipexole 
augmented previously ineffectual antidepressant treatments, but that it significantly 
improved mood alone with relatively few side-effects (Ostow, 2002). However, it is 
clear that a larger trial will have to be performed to validate these findings. 
Another line of evidence supporting a role of DA in depression comes from Keck et al., 
(2002), who successfully demonstrated that repetitive transcranial magnetic stimulation 
(rTMS) elevates DA in the hippocampus, nucleus accumbens and striatum. A previous 
study by Keck et al., (2000) revealed an increase in DA but not in 5-HT and NA in the 
hippocampus, providing evidence that DA may play a role in the use of rTMS in 
depression. These findings have also been supported by a clinical study showing that 
rTMS decreased ["C]raclopride (D2, D3 and D4 receptor antagonist) binding (Strafella 
et al., 2001). This evidence is suggestive of alterations in the dopaminergic system in 
depression, which, at least partially, are redressed by antidepressant treatments. 
However, it is unknown whether this is secondary to changes in other monoaminergic 
systems given the interaction between DA and these. 
Taken as a whole, the body of literature dealing with monoamine deficits in depression 
does not satisfactorily provide clear evidence for one neurotransmitter being central to 
the aetiology. Both serotonergic and noradrenergic compounds are equally useful in 
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treating patients, and there are also a number of dopaminergic drugs that are successful 
in treating depression. This may also reflect different underlying heterogeneity of 
depressive disorders. It is clear that these drugs, which raise monoamine levels in the 
synapse, have been very successful in the treatment of depression. What still remains 
unclear is whether disruption of these systems initiates depressive symptoms. 
Figure 1.6 Summary of monoamine drug treatment evolution 
Enzyme Uptake Receptor 









1990s RIMAs ýr SNRIs 
NARIs Mirtazapine 
Abb: NARIs = NA selective reuptake blocker; RIMAs = Reversible inhibitor of MAO; SNRIs = 5-HT 
and NA selective reuptake inhibitor. 
TCAs 
rý Subtype- NA 5-HT selective Mianserin selective MAO1s selective I 
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1.3.3 Novel approaches to research the proposed role of Ih channels in 
depression 
The lack of selective ligands for Ih/HCN channels has hindered further insight into the 
potential role of this channel in depression, and other behaviours it may contribute to, 
such as epilepsy (see Chen et al., (2002) for review). There are a number of genetic 
approaches, which are presently being taken by Organon Laboratories to address this 
issue, including the generation of HCN1 and HCN2 isoform knockout mice. Indeed, 
Ludwig et al., (2003) have published on HCN2 knockout mice, which demonstrate 
lower locomotor activity, spontaneous absence seizures and sinus dysrhythmia. 
However, such techniques are time-consuming (the knockout mice lines are predicted to 
be ready in August/September 2003) and expensive to produce. Additionally, there are 
a number of developmental adaptive changes, which can take place, and given the 
knowledge that in the hippocampus (Bender et al., 2001) and in the heart (Shi et al., 
1999) there are developmental alterations in HCN channel isoform mRNA expression, 
make interpretation of data obtained from knockout mice more complicated. 
An alternative approach is the use of antisense technology, which utilises the 
administration of a short synthetic oligonucleotide (< 25 bases), complementary to the 
target gene's mRNA sequence, to specifically and reversibly inhibit gene expression 
(See Section 1.4). In this manner a specific HCN isoform can be targeted, and if 
successful down-regulation of the gene is observed in vivo, rats can be introduced to a 
variety of behavioural paradigms and biochemical assays to ascertain the effect of 
down-regulation of HCN protein. 
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1.4 Antisense oligonucleotide technology 
1.4.1 Introduction to antisense 
Antisense technology was first utilised by Zamenik and Stephenson (1978), who 
injected a complementary phosphodiester oligonucleotide to the Rous sarcoma virus, in 
chicken embryo fibroblasts tissue cultures, and inhibited virus production. Since then, 
antisense technology has expanded and become a commonly used laboratory technique 
to reversibly inhibit mRNA translation. With increasing knowledge of this technique, 
modifications to the phosphodiester structure have been implemented to improve the 
antisense sequence stability and lower toxicity. In theory, any mRNA sequence which 
is known, can be targeted to downregulate the corresponding protein expression, 
thereby providing a powerful tool for the study of specific gene products, both in vitro 
and in vivo. 
1.4.2 Mechanism of antisense-mediated action 
Antisense oligonucleotides are believed to exert their biological action, down-regulation 
of a target protein, via numerous mechanisms due to the complexity of mRNA. There 
are a number of theoretical mechanisms by which antisense oligonucleotides may act 
and while experimental evidence for some of these has been demonstrated the precise 
manner by which antisense oligonucleotides achieve their goal remains to be fully 
established. There are two main mechanisms, which have been demonstrated to be 
responsible for knockdown of the target protein; steric hindrance and RNase H- 
mediated degradation of the mRNA. 
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1.4.2.1 Steric hindrance 
The majority of antisense sequences designed by early antisense workers were 
complementary to the initiation-encoding region of an mRNA as disruption of this vital 
region was believed to lead to the greatest down-regulation. The mechanism of action 
responsible for sequences targeted here is believed to be steric hindrance of the 
ribosome; a mechanism which could be employed anywhere along the entire length of 
the mRNA. 




The antisense sequence targeted to the initiation-encoding region of the mRNA prevents the ribosome 
from binding to and scanning the message. A similar effect can occur wherever the antisense is targeted 
along the entire length of the mRNA. Abb: 5' UTR, 5' untranslated region 
Another possible outcome of antisense binding may be to alter the overall RNA spatial 
structure, which in turn could prevent the binding and interaction of a number of factors 
such as the ribosome, or indeed even destabilise the RNA molecule (Crooke, 1999). 
1.4.2.2 RNase H activated degradation 
An alternative mechanism of action of antisense oligonucleotides, which has been 
demonstrated in vitro, is cleavage of the mRNA via activation of a ubiquitous enzyme, 
ribonuclease H (RNase H). This enzyme selectively cleaves the RNA strand of a 
RNA/DNA duplex (Zamaratski et al., 2002). The cleaved RNA products then undergo 
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further degradation by 5' and 3' exonucleases while the antisense sequence is freed to 
bind to another complementary target, effectively making the process catalytic (Figure 
1.8). It is this mechanism of antisense-mediated protein inhibition that makes it 
beneficial for oligonucleotides to comprise of DNA-like regions, such as phosphodiester 
or phosphorothioate linkages (see Section 1.4.4). This increases their likelihood of 
successful antisense activity via this mechanism. 
Activation of RNase H has been demonstrated in numerous studies; Toulme et al., 
(1992) demonstrated that oligonucleotides targeted at the coding region were 
unsuccessful unless RNase H-mediated cleavage of mRNA occurred. However, the 
most persuasive evidence to date is from an in vitro study where exogenous RNase H 
application was required for successful antisense activity (Brussaard, 1997) as well as 
the success of RNase H design (See Section 1.4.3.3). Additionally, a number of the 
modified oligonucleotides, including all 2'-modifications, do not activate RNase H as 
the cleavage reaction occurs at the 2'-OH of the RNA strand (Zamaratski et al., 2001) 
and are less active. The only backbone modifications, which form duplexes that have 
been shown to activate RNase H are phosphodiester, phosphorothioates (Stein et al., 
1993) and boranophosphates (Rait et al., 1999a; Rait et al., 1999b). In fact, it has 
recently been implied that RNase H may play a critical role in the unravelling process of 
RNA enabling the oligonucleotide to bind (Zamaratski et al., 2001). The extent to 
which RNase H activation is necessary for successful antisense application may depend 
on the oligonucleotide and the system used as it has been shown that RNase H activity 
is quite low in the cytoplasm of neurones compared to that of the nucleus (Crum et al., 
1988). 
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Figure 1.8 Example of RNase H-mediated antisense action. 
W* I 
3'ATGCATACCGTTAGGACTC5' 
5' translated region UACGUAUGGCAAUCCUGAGC 
................. 3' 
3'ATGCATACCGTTAGGACTC5' 




The formation of a RNA/DNA duplex activates RNase H (black) which selectively cleaves the RNA 
strand (red), leaving the antisense oligonucleotide free to bind to another complementary target. The 
resulting RNA cleavage products are further degraded by 5' and 3' exonucleases, and the growing 
polypeptide chain (green) is also degraded. 
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1.4.3 Design of antisense oligonucleotide sequences 
One of the main obstructions of antisense therapeutics has been the design of 
oligonucleotides, which has proved more difficult than first predicted. There are a 
number of reasons why this is the case, but there is a mounting body of evidence 
establishing that the folding of an mRNA molecule (and indeed of some antisense 
oligonucleotides) is the main determinant of unsuccessful antisense design (Crooke, 
1999; Milner et al., 1997). The shortest sequence that should convey specificity is a 13- 
mer, as each base can be altered, giving the probability of a matching sequence to be of 
the order 413. Therefore, to ensure specificity, antisense sequences should be 14 bases 
or longer, and despite this being statistically significant for a single region of mRNA 
then each antisense oligonucleotide's specificity must be confirmed using a database, 
such as the National Centre for Biotechnology Information (NCBI). 
Originally, researchers targeted the initiation-encoding region of mRNA molecules, 
believing that this vital region would convey the largest down-regulation of the protein. 
However, coupled with the fact that not all sequences complementary to the initiation 
site display antisense activity, it is now known that certain motifs are biologically active 
in a manner independent to that of antisense activity and may be unavoidable. 
Additionally, the initiation-encoding region is highly conserved, which may result in a 
loss of specificity of the sequence (Cooper et al., 1999). It has been demonstrated that 
numerous accessible sites for antisense molecules can exist along the entire length of an 
mRNA, from the 5'-untranslated region to the 3'-polyadenylated tail (Agrawal et al., 
2000), and it is considered advantageous to test oligonucleotides over a wide region of 
the mRNA. 
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1.4.3.1 Random design 
This method involves designing a large number of sequences (up to 100) that are 
complementary to regions along the length of the target mRNA, and then individually 
assessing each one. Unsurprisingly, this approach does not yield a high proportion of 
successful sequences, only 2-5% (Sohail et al., 2000) and is labour intensive, time- 
consuming and expensive. However, it avoids oligonucleotides that are complementary 
to other mRNAs and also immuno-active motifs (see Section 1.4.4.2) that may not be 
possible when targeting the initiation-encoding region. 
1.4.3.2 Secondary structure prediction design 
Researchers have employed computational packages that predict the secondary structure 
of mRNA in an attempt to provide a more scientific approach to the design of 
oligonucleotides. The majority of computer models, such as mfold 
(http: //bioinfo. math. rpi. edu/-mfold/rna/), calculate the global minimum free energy 
structure of the mRNA, and returns an optimal fold and a number of suboptimal folds 
(Figures 1.9). 
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Figure 1.9 Example of a predicted mRNA secondary structure using the computer package mfold. 
The chain like structures are areas where the mRNA folds back upon itself, while the circular patterns are 
predicted to be single-stranded and therefore areas were antisense oligonucleotides would be targeted. 
Oligonucleotides can then be designed to target the regions, which are predicted to be 
predominantly single-stranded and then examined for antisense activity. There are a 
number of inherent weaknesses involved in computational prediction. These 
predominantly stems from the lack of understanding of RNA secondary and tertiary 
structure at present (Schail et al., 2001). A histogram can be generated based on all the 
predicted structures by plotting the single-stranded frequency of each base (see Figure 
1.10) in an attempt to isolate areas, which are predicted to be predominantly single- 
stranded. Computer packages do not account for any tertiary folding which may occur, 
or interactions with cytoplasmic proteins, and instead treat the mRNA as an isolated 
entity, which further detract from the accuracy of the predicted folds (Stein, 1999). 
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The x-axis represents the base number and the y-axis the single-stranded frequency. By analysing the 
entire mRNA in this way areas which are predicted to be predominantly single-stranded can utilised to 
design antisense oligonucleotides. 
Conflicting findings on the success of oligonucleotide sequences subjected to this 
method have been reported (Amarzguioui et al., 2000; Wrzesinski et al., 2000). 
Although this method may represent an improvement over random design of 
oligonucleotides, until the computer methods employed to predict the structure of 
mRNA molecules are more accurate, the usefulness of this method is limited. 
1.4.3.3 Ribonuclease H mapping design 
The knowledge that certain oligonucleotides activate RNase H (See Section 1.4.2.2) has 
been incorporated into the design of antisense oligonucleotides and has shown 
promising results to date. A number of researchers have demonstrated that the sites 
identified by RNase H digestion of in vitro transcribed mRNA correlate to antisense 
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sequences, which are active in vitro (Matsuda et al., 1998) and in vivo (Matveeva et al., 
1997). However, attempts to correlate sequences identified by RNase H mapping with 
the secondary structure of RNA have been unable to reveal any significant relationship 
(Amarzguioui et al., 2000; Slew Peng et al., 1998; Wrzesinski et al., 2000). 
1.4.3.4 Antisense oligonucleotide scanning array design 
A method enabling the measurement of oligonucleotide binding affinity to mRNA in 
vitro has recently been developed and shown promising results (Milner et al., 1997; 
Sohail et al., 2001). Interestingly, the latter study demonstrated that the starting 
position of an antisense sequence appears to be more vital than the length in conferring 
binding affinity. Sohail et al., (2001) attempted to correlate the sequences identified 
using a scanning array with mfold analysis of the secondary structure of mRNA in order 
to describe the specific hybridisation pattern found but could show no relationship. 
Alternatively, good correlation has been demonstrated between sequences predicted by 
RNase H digestion and those by scanning arrays and also with antisense activity in vitro 
(Milner et al., 1997). Not all sites identified by hybridisation affinity translate to active 
antisense sequences, although there does appear to be a high level of success using this 
method, and this, along with RNase H mapping promise to improve oligonucleotide 
design. 
1.4.4 Experimental controls 
1.4.4.1 Introduction 
Experimental controls are vital when using antisense oligonucleotides. They are 
required to ensure that the measured biological effect results from knockdown of the 
target protein and not from non-specific toxicity. Positive controls are antisense 
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sequences designed to be complementary to another region along the mRNA molecule. 
This type of control is recommended if there exists no method for directly measuring 
the protein level of a target gene and should alter the target mRNA levels, or 
demonstrate the same behavioural phenotype (Brysch, 1999). However, due to the lack 
of accessible sites and the number of different possible antisense mechanisms it is often 
difficult to design a positive control, which satisfies all the design criteria. There are a 
variety of negative controls, which can be designed to validate that the measured 
parameter of an antisense infusion is due to target gene downregulation and these must 
be designed to fulfil a number of criteria (see Table 1.7). To date, no one control can 
rule out all the other possible oligonucleotide administration factors, and therefore 
suitable controls for each individual experiment must be designed. 
There are four main negative controls used in antisense experiments (See Table 1.8) and 
of these mismatch controls are the most commonly utilised. Mismatches incorporate 
base switches from the antisense control, and those introduced in the centre of a 
sequence have more effect than peripheral swaps as there are less consecutive 
complementary bases (Brysch, 1999). Furthermore, the bases which are swapped play a 
crucial role in ensuring that a mismatch sequence does not retain hybridisation affinity 
for the target mRNA. The general rule for base changes from greatest effect to least is 
G--ºA/T>C->A>G/C-ºC/G>A/T->G>A- C>A/T-+T/A(A, adenine, C, 
cytosine, G, guanine, T, thymine; Brysch, 1999). 
Table 1.7 Design criteria for antisense oligonucleotide controls 
DESIGN CRITERIA FOR NEGATIVE ANTISENSE CONTROLS 
The same length and modifications as the antisense oligonucleotide 
Retain similar base composition as the antisense oligonucleotide 
No ability (or decreased) to bind to the target mRNA or any other cellular mRNA 
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1.4.4.2. Biologically active sequence motifs 
It has become apparent that not all sequences reported to successfully inhibit expression 
have achieved this `success' via knockdown of the target protein. A reason for this is 
the presence of motifs within an antisense sequence, which cause biological effects, 
such as immune stimulation, unrelated target gene knockdown. These include, CG 
bases with a phosphorothioate linkage (CpG), which is immunostimulatory (Yu et al., 
2002) and GGGG, which can form tetrads and bind to a variety of proteins (Anselmet et 
al., 2002). 
1.4.5 Backbone Modifications 
When Zamecnik and Stephenson (1978) first developed the idea of administering 
antisense to down-regulate the expression of a target protein `natural' phosphodiester 
oligonucleotides were used. There have been numerous backbone modifications 
employed in a bid to optimise the stability and lower the toxicity of antisense 
administration, both in vivo and in vitro. No ideal backbone modification has been 
developed for use in antisense therapeutics, but a number of important properties have 
been identified (Table 1.9). 
Table 1.9 Optimal antisense oligonucleotide properties for use in vivo. 
DESIRED PROPERTIES OF ANTISENSE OLIGONUCLEOTIDES 
Maximal cellular uptake 
Protection against degradation by nucleases 
High affinity for rnRNA 
Ability to bind specifically to target mRNA 
Activation of RNase H by forming RNA/DNA duplex 
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1.4.5.1 Phosphodiester oligonucleotides 
Phosphodiester backbone oligonucleotides (Figure 1.11) were the first generation of 
antisense molecules used for inhibiting protein expression. They display high affinity 
for target mRNA sequences and the resultant duplex activates RNase H-mediated 
cleavage of the mRNA strand (Agrawal et al., 1990). 
Figure 1.11 Example of a phosphodiester backbone. 
1oB 




Despite the size and the polyanionic nature of phosphodiester oligonucleotides 
numerous studies have demonstrated that they are internalised, especially in vivo 
(Lebedeva et al., 2000). However, in vitro uptake of all types of oligonucleotide is less 
effective and may require the use of a carrier system to transport the oligonucleotide 
into the cell and this is believed to be due to the fact that internalisation of 
oligonucleotides is an active process (Lebedeva et al., 2000). 
The rational for backbone modification was primarily to increase stability due to the 
rapid degradation of phosphodiester oligonucleotides by nucleases. Pharmacokinetic 
studies have shown that, in vitro, phosphodiester oligonucleotides display a half-life of 
-5 min (Agrawal et al., 1997a). This rapid breakdown of the molecules necessitates 
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repeated, or continuous, administration of large dose of the oligonucleotide in order to 
achieve a sufficient concentration inside the cell to inhibit translation. However, the 
brain and cerebrospinal fluid (CSF) contains relatively few nucleases and these 
oligonucleotides have been successfully utilised in vivo (Kathmann et al., 1999; 
Kolesnikov et at., 1997; Wahlestedt et at., 1993). 
1.4.5.2 Phosphorothioate oligonucleotides 
Phosphorothioate oligonucleotides were developed in an attempt to overcome the 
problem of nuclease stability by substituting one of the non-bridging oxygen atoms in 
the phosphate backbone with a sulphur atom (Figure 1.12). The half-life of the 
antisense oligonucleotides containing this backbone modification is markedly improved, 
as a result of a 100 - 300 fold increase in nuclease resistance (Cummins et al., 1995). 
The pharmacokinetic analysis of a single intravenous injection of phosphorothioate 
antisense oligonucleotides showed an initial plasma half-life of 0.95 h compared with 
the aforementioned 5 min half-life of phosphodiester oligonucleotides (Agrawal et al., 
1997a). 





One of the non-bridging oxygen atoms is replaced by a sulphur atom. 
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The addition of a sulphur atom also provides another benefit, as phosphorothioate 
oligonucleotides demonstrate high binding affinity to a number of cell-surface proteins, 
which is a crucial stage before internalisation into an endocytic compartment and then 
into the cell nucleus (Lebedeva et al., 2000). Phosphorothioate oligonucleotides retain 
affinity for mRNA, although not as high as that displayed by phosphodiesters (Agrawal, 
1996). Phosphorothioate oligonucleotides also activate RNase H upon the formation of 
the duplex but to a lesser extent than phosphodiester oligonucleotides, possibly due to 
higher duplex stability or inhibition of RNase H catalytic activity at high concentrations 
(Agrawal et al., 1990; Gao et al., 1992). 
However, the price to pay for the addition of a sulphur moiety is increased toxicity 
compared with phosphodiester oligonucleotides. Although, phosphorothioate antisense 
administration does demonstrate high tolerability in rats and mice, with an LD50 (lethal 
dose) of 500 mg/kg (Agrawal et al., 1997a). However, there are a number of dose 
dependent side effects, including splenomegaly, thrombocytopenia and elevation of 
liver transaminases (see Agrawal et al., (1997a) & Levin, (1999) for reviews). 
Intravenous injection of phosphorothioate oligonucleotides also dose-dependently 
causes complement activation, prolongation of activated partial thromboplastin time 
(Kandimalla et al., 1998) and increased arterial blood pressure in monkeys (Agrawal et 
al., 1997a). These undesirable effects can be avoided by altering the administration rate 
or route. These side effects are related to the polyanionic nature of phosphorothioate 
antisense oligonucleotides as other polyanionic molecules, such as dextran sulphate, 
show similar biological effects when administered (Agrawal et al., 1997a). 
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1.4.5.3 Newer modifications and Mixed backbone oligonucleotides 
The bid to optimise antisense therapeutics has led to new generation of chimeric 
oligonucleotides, which incorporate different modifications into one antisense 
oligonucleotide. The idea behind such oligonucleotides is to decrease the undesired 
effects of phosphorothioate oligonucleotides and introduce the favourable 
characteristics of other modifications, while retaining RNase H activity. Many different 
modifications have been attempted but 2'-O-methyl ribonucleotides and 
methylphosphonates are the most extensively studied due to their advantageous 
properties (See Table 1.10). 
Mixed backbone oligonucleotides can incorporate the changes at either the 5'- or 3'-end 
of the sequence (End-modified) or at the centre (Centrally-modified) but at least four 
contiguous phosphodiester or phosphorothioate linkages are required to retain an 
oligonucleotide, which forms a duplex that activates RNase H (Shen et al., 1998). 
These oligonucleotides combine the advantageous properties of each modification and 
the disadvantages are minimised i. e. toxicity is decreased due to less sulphur linkages 
and RNase H activation is incorporated. These oligonucleotides are becoming the most 
commonly utilised in antisense therapeutics for the reasons listed above and Table 1.10. 
50 
Z ... ý, 
> U 00 





;4 rn C/) C.. ) ö ö 










W ý ý ý ö ö 
> 1 -0 Q 
a It . 




0 0 ¢ 
ä "ý u 
a E 
ö E 04 
Ed» >1 









dq C .1 "ý .ý 
U Ü p 
Q C ý 
m mmI co ý 
ýýý0 







ý a ö 
a) ö 
z 
ä , >~ a. O O N 
Chapter 1 General Introduction 
1.4.6 Antisense technology in the CNS 
There are numerous examples of successful application of antisense oligonucleotides 
directly into the CNS in the literature. These studies have utilised different chemical 
modifications, from unmodified phosphodiesters (Shaker-like Kvl. l; Kathmann et at., 
(1999); neuronal nitric oxide synthase, Kolesnikov et al., (1997); N-methyl-D-aspartate 
(NMDA) receptor, Wahlestedt et al., (1993), phosphorothioate (ml muscarinic receptor, 
Zang et at., (1994); D2-receptor, Zhou et al., (1994), to newer modifications including 
end-capped oligonucleotides; prodynorphin, Broberger et al., (2000). Unlike in vitro 
assays, antisense oligonucleotide application in vivo does not require a carrier system, as 
the examples above involve administration of the oligonucleotide alone; either via 
osmotic minipumps or direct application. This repeated or continuous infusion is 
necessary because of the breakdown of antisense oligonucleotides by nucleases 
(Crooke, 1999; Sands et al., 1995). As witnessed by the examples cited, antisense 
technology can be used to target proteins as diverse as receptors, ion channels and 
enzymes, and have provided valuable information regarding their in vivo functions. 
Antisense oligonucleotides are particularly beneficial for studying proteins which have 
no (or few) selective ligands, as is the case for Ih channels. They can provide selective 
and reversible knockdown of the target protein enabling behavioural and biochemical 
measurements to be performed (Robinson et al., 2000). 
52 
Chapter 1 General Introduction 
1.5 The present study 
Investigation of Ih channels have been limited by the lack of highly selective ligands 
and it is currently unknown whether Org 34167 mediates its proposed antidepressant- 
like action via these channels. Antisense oligonucleotides provide an in vivo technique 
to investigate the behavioural effects of downregulation of HCN channel isoforms in 
rat. It would then be possible to determine whether functional downregulation of the 
proposed molecular identity of Ih channels effected a similar antidepressant-like action 
by performing behavioural and biochemical tests. Another novel approach to assist the 
understanding of the effects of Org 34167 is to study the expression profile of 
immediate-early genes, such as c-fos and Egr-1. Induction of these genes is widely 
believed to correlate to increased neuronal activity and lead to long term alterations in 
cellular phenotype (Beckmann et al., 1997; Chaudhuri, 1997; Herdegen et al., 1998; 
Herrera et al., 1996; Ziolkowska et al., 2002). This can provide information related to 
brain regions that are affected by drug administration. Finally, drug treatment has been 
shown to modulate gene expression in a number of different systems, and can be used to 
determine whether chronic administration alters HCN mRNA levels. The main aims of 
this project were therefore: 
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1. To design and characterise antisense oligonucleotide sequences to the HCN 2 
transcript in vivo, using 3- or 7-day administration to identify an antisense 
sequence which downregulated HCN 2 mRNA or protein expression. 
2. To profile the effect of Org 34167, on c-fos and Egr-1 mRNA expression 
throughout the rat brain and compare these with known antidepressants. 
3. To determine the effects of chronic administration of Org 34167 and a number 
of antidepressants on the expression levels of HCN 1- 3 mRNA in the rat brain. 
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Chapter 2 Antisense approaches to the HCN channel 
2.1 Introduction 
The lack of selective ligands to modulate Ih channel has hindered insight into the 
functions mediated by the channel in vivo. Despite substantial knowledge concerning 
the structural and physical properties of Ih and HCN channels, relatively little is known 
regarding their physiological functions. As discussed in Section 1.2, Ih channels 
regulate rhythmicity of neuronal networks, and their interaction with Ca2+ channels in 
the thalamus generates spindle waves during sleep (McCormick et al., 1997). This 
involvement, in the sleep-wake cycle, is to date, the main evidence (alongside Org 
34167) supporting a possible role of these channels in depression, given the altered 
sleep patterns witnessed in depressed patients and animal models (Thase, 1999). 
Additionally, it has recently been proposed that these channels, couple presynaptically 
with the vesicular release machinery to increase neurotransmitter release, which 
provides another possible link (Beaumont et al., 2000). 
It is still unconfirmed that Org 34167's antidepressant-like activity is due to blockade of 
HCN channels. A possible approach to address this is the use of antisense technology, 
to specifically and reversibly inhibit protein expression (See Section 1.4). In this 
manner a specific HCN isoform can be targeted, and if successful down-regulation of 
the protein is achieved in vivo, rats can be introduced to a number of behavioural 
paradigms to ascertain the effects of down-regulation of the HCN isoform as well as 
challenging the rats with Org 34167. As the half-life of the HCN channel is unreported, 
both 3- and 7-day antisense infusion periods were attempted to ensure sufficient 
administration time to down-regulate expression. Other ion channels, such as the Naa 
channel and two subunits of the NMDA ion channel have half-lives in the range of 10 - 
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18 h (Chen et al., 1997; Monjaraz et al., 2000). It is presently unknown whether Org 
34167 displays any isoform specificity, it blocks HCN1 and HCN2 in cell lines at 
similar concentrations of 1µM (Mason, Personal communication), and it is unclear 
whether one isoform is more important in the proposed antidepressant effect. Given the 
number of brain regions affected in depression, the HCN2 isoform was targeted, as this 
subtype exhibits the highest and most widespread expression level of the four HCN 
genes in the brain (Monteggia et al., (2000); Moosmang et al., (1999); Figure 1.3). The 
methods available for the quantification of HCN2 gene expression were in situ 
hybridisation to examine the level of HCN2 mRNA expression and [3H]-Org 34167 
autoradiography, which, given the in vitro data, is predicted to be specific for HCN 
channels (Ruigt, Personal communication). Organon Laboratories did commission the 
production of HCN1 and HCN2 antibodies but these were not validated for Western 
blotting or immunohistochemistry at the time of study. 
The aim of the experiments performed in the current chapter was to examine the effect 
of i. c. v. infusion of antisense oligonucleotides targeted to HCN2 isoform mRNA. A 
number of different trials were performed, utilising both 3- and 7-day infusion protocols 
of sequences designed to target different regions along the mRNA and finally 
modification of the oligonucleotide chemistry (See Table 2.1 for details of the 
experiments performed). The reasons for these alterations were to attempt to find an 
efficacious antisense sequence with minimal toxicity. [3H]-Org 34167 autoradiography 
has been performed before (Makkink, Personal communication) but further method 
validation was carried out during this study prior to analysis of antisense-treated brain 
sections. 
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Chapter 2 Antisense approaches to the HCN channel 
2.2 Materials and methods 
2.2.1 Antisense oligonucleotide infusion targeting the initiation codon of 
HCN2 
2.2.1.1 Animals and experimental procedure 
Male Wistar rats (Bantin and Kingman) weighing 230 - 250 g were housed in groups of 
four or five on a 12 h light/dark cycle (lights on 07: 00 h) at 22 ±2 °C. Rats were given 
free access to tap water and standard rat diet and allowed to habituate for 1 week prior 
to surgery. 
The antisense sequence targeted a region of the HCN2 mRNA transcript, which 
included the initiation-codon. A mismatch sequence was designed incorporating two 
paired base switches as an experimental control. The fully-modified phosphorothioate 
oligonucleotides were designed and synthesised by Professor Len Hall (Biochemistry 
Department, University of Bristol). The oligonucleotides were administered using 
osmotic mini-pumps combined with a brain infusion kit (Alzet, Charles River, U. K. ). 
The pumps were primed for 4h in saline solution at 37 °C, with vehicle (saline), 
antisense or mismatch oligonucleotide where the experimenter was unaware of the 
contents of the mini-pump. The weight of the mini-pump was recorded before and after 
filling to ensure correct loading; if less than 90 % filling was achieved the pump was 
reloaded. Two trials were performed, a three day infusion, using Alzet osmotic 
minipump model 1003D, and a seven day infusion using Alzet osmotic minipump 
model 1007D. In both trials, antisense or mismatch oligonucleotides were administered 
at an infusion rate of 6.5 µg/pl/h via the Alzet osmotic minipumps, or vehicle (0.9 % 
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saline) at 1 µl/h. The rats were weighed between 08: 00 - 09: 00 h on the day of the 
surgery and each day during the infusion. 
On the day of surgery rats were anaesthetised using sodium pentobarbitone (Sagatal, 
Rhone Merieux) and then placed into a stereotaxic frame (Stoelting Co, Illinois, USA). 
The top of the rat's head was shaved and cleaned with 70 % ethanol. A sterile scalpel 
blade was used to cut an incision along the midline of the skull and the perioistum 
cleared from the surface of the skull. The blood was swabbed using cotton buds and the 
skin held apart using artery forceps. Blunt scissors were then used to create a 
subcutaneous pocket to place the osmotic minipump in the midscapular region, 
connected to the cannulae by 4 cm of polyethylene tubing. A stainless steel skull screw 
(BN650 DIN 84A, Allscrews Ltd, U. K. ) was then inserted in to the skull to secure the 
cannula in place. 
The cannula was placed directly over bregma using a cannula holder specifically 
designed for Alzet cannulae (Model 1766-AP, David Kopf Instruments), and the brain 
co-ordinates relative to bregma recorded. The cannula was then moved 0.9 mm caudal 
to bregma and 1.4 mm lateral, to locate it above the left lateral ventricle (Paxinos et al., 
1986). A small hole was drilled through the skull at these co-ordinates and the dura was 
pierced using a 21 gauge needle, and again any blood was swabbed using cotton buds. 
Superglue was applied to the bottom of the cannula, which was then lowered and 
secured onto the skull. Spacers on the cannula ensured its placement 2.5 mm below the 
surface of the dura; into the lateral ventricle (Paxinos et al., 1986). The cannula holder 
was removed and dental cement (methyl methacrylate and acrylic, Sigma, U. K. ) was 
placed around the cannula and the skull screw to provide extra security. The skin was 
then closed using surgical staples. 
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On the final infusion day, between 09: 00 and 11: 00 h, the animals were deeply 
anaesthetised with sodium pentobarbitone (90 mg/kg.; Sagatal, Rhone Merieux). A 
midline incision, from the diaphragm to the throat, was made and then one set of ribs 
cut through, followed by the diaphragm, taking care to avoid the heart and lungs. The 
second set of ribs were then cut and the chest cavity exposed by clamping the sternum 
to hold the chest wall back. A transcardiac perfusion of the rat with ice-cold, phosphate 
buffered, physiological saline (- 250 ml, 10 mM, pH 7.4 see Appendix A) was 
performed by inserting a steel cannula into the left ventricle and cutting the right 
ventricle. Brains were removed rapidly over ice and frozen in isopentane cooled on dry 
ice to -32 °C and then stored in a -80 °C freezer. 
2.2.1.2 Cryostat sectioning 
The brains were removed from the -80 °C freezer and allowed to thaw to -20 °C before 
20 pm brain sections were cryostat-cut onto superfrost slides (BDH) from - 1.2 mm to 
-2.3 mm relative to bregma in 5 series each containing 12 slides (with 3 sections on 
each slide). Sections were stored at -80 °C until required. 
2.2.1.3 In situ hybridisation 
Sections were fixed in a4% paraformaldehyde, 0.9 % saline solution, made using 
diethylpyrocarbonate (DEPC)-treated water, for 10 min, rinsed in DEPC-treated water 
and incubated for 10 min in a 0.25 % solution of acetic anhydride in 0.1 M 
triethanolamine in 0.9 % DEPC-saline (pH 8). Sections were dehydrated in ethanol 
(diluted in DEPC-treated water); 1 min in 70 %, 1 min in 80 %, 2 min in 95 % and I 
min in 100 %, defatted for 5 min in 100 % chloroform and then re-hydrated for 1 min in 
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100 % ethanol and 1 min in 95 % ethanol. Slides were then dried at room temperature 
and then placed in an air-tight hybridisation box containing swabs soaked in 50 % 
formamide / 50 % DEPC-treated water solution to maintain humidity. 
Synthetic oligonucleotide probes designed to be complementary to the HCN2 transcript 
(see Appendix B) were synthesised by Life Technologies (Gibco, BRL, U. K. ). 
Specificity of the sequences was assessed using the NCBI database to verify that the 
sequences would not hybridise to any other known sequences. Additionally, the probe 
was checked against the antisense sequences to ensure that it targeted a different region 
of the HCN2 transcript. 
The oligonucleotide probes were 3'-end labelled using [33P]-dATP. Each 
oligonucleotide probe, at a concentration of 2 pmol, was tailed by the isotope at an 
incubation temperature of 37 °C in a reaction containing, 20 µl terminal transferase 
reaction buffer, 5 µl terminal deoxynucleotide transferase (pH 7.2; Promega), 8 µl [33P]- 
dATP (3000 Ci/mmol, NEN) and made up to a final volume of 100 µl with DEPC- 
treated water. The reaction mixture was heated to 70 °C for 10 min followed by 1h 
incubation at 37 °C to terminate the reaction. Unlabelled probe and isotope were 
separated out from the labelled probe using Micro Bio-Spin chromatography columns 
(P-30 Tris RNase-free, Bio-Rad, U. K. ) centrifuged for 4 min at 3,300 r. p. m. in a 
desktop centrifuge (Centrifuge 5415 D, Eppendorf UK Ltd. ). To assess the efficacy of 
radioactive labelling, 1 µl of the probe was removed and counted by a liquid 
scintillation counter (Tricarb, 1500 Packard). The labelled probe was then added to 
`maximalist' (Henry et al., 1999) hybridisation buffer (50 % formamide, 4x Standard 
Sodium Citrate (SSC), 10 % dextran sulphate, 5x Denhardt's solution, 200 µg/µ1 
Salmon testes DNA, 100 µg/gl Poly-adenosine (poly-A) and 2% (10 mM) dithiothreitol 
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(DTT)) to give a final concentration of 0.5 pmol/ml hybridisation solution. The final 
hybridisation buffer was used the same day. Hybridisation solution was pipetted onto 
each slide in the hybridisation box (150 µl per slide), which were then covered with 
Hybrislips (Sigma) and incubated in a hybridisation oven at 42 °C for 18 h. 
All the solutions used in the post-hybridisation stages were diluted using distilled water 
(dH2O) as the oligonucleotide probe / mRNA duplex is resistant to RNases (except 
RNase H, which selectively cleaves the RNA strand of a RNA / DNA duplex). 
Following the 18 h incubation, the Hybrislips were floated off using 2x standard 
sodium citrate (SSC) and the slides were placed in racks for further processing. 
Stringent washes were carried out for 30 min at room temperature in 1x SSC, followed 
by 30 min at 55 °C in 1x SSC and finally 10 min at 55 °C in 0.1 x SSC. Sections were 
then dehydrated for 2 min in 70 % ethanol and 2 min in 95 % ethanol and then allowed 
to air dry. 
Once dry the sections were placed in a hypercassette (Amersham) and exposed to X-ray 
film (BioMax MR-1, Kodak) under `safe' red light conditions for the required number 
of days (see Appendix B) at room temperature. An autoradiographic [14C] micro-scale 
(Amersham) of known radioactivity (range 31 - 833 nCi/g) was also placed in each 
cassette to allow conversion of the optical density measurements to nCi/g. The films 
were then developed under `safe' light conditions for 3 min in Kodak GBX 
developer/replenisher (20 % aqueous), rinsed briefly in water, fixed for 5 min in Kodak 
GBX fixer/replenisher (20 % aqueous), and washed for 5 min in tap water, and finally 
air-dried. 
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2.2.1.4 In situ probe validation 
Specificity of the oligonucleotide probes was further assessed by RNase pre-treatment 
of brain sections, and by the addition of 100-fold excess non-labelled probe to separate 
control slides. After fixation in 4% paraformaldehyde solution and incubation in acetic 
anhydride, brain sections were incubated in 10 mg/ml Ribonuclease A (RNase A) 
solution (Sigma) in phosphate buffered saline (PBS) at 37 °C for 30 min or PBS buffer 
alone. The sections were then processed for in situ hybridisation as described in Section 
2.2.1.3. For controls involving excess non-labelled probe, in situ hybridisation was 
performed as described in Section 2.2.1.3 with the addition of 50 pmol/ml of non- 
labelled oligonucleotide probe added to the hybridisation buffer prior to hybridisation. 
2.2.1.5 Analysis of in situ hybridisation 
Densitometric analysis of autoradiographs was performed using a Microcomputer 
Imaging Device (MCID, InterFocus, Ltd., Haverhill, Suffolk, U. K. ) system. Optical 
density measurements were obtained by calculating the average of the three sections on 
each slide for each brain region examined and used to determine the mean t s. e. mean 
of each treatment group (n =4- 5). These values were converted to nCiIg by creating a 
standard curve from [14C]-standards. Values were calculated for the left and right 
hemispheres for each brain region analysed. 
2.2.1.6 (°H]-Org 34167 autoradiography 
The conditions for [3H]-Org 34167 autoradiography were based on those previously 
used to demonstrate binding of [3H)-Org 34167 throughout the brain (Makkink, 
Personal communication). A number of scientists at Organon Laboratories had 
attempted to use this protocol but achieved a negligible level of specific binding. 
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Therefore, the protocol was subjected to a number of variations, utilising control rat 
brain sections of 20 µm. These variations included altering the concentration of [3H]- 
Org 34167, fixation of the tissue with 4% paraformaldehyde (dissolved in PBS) for 30 
min at room temperature, buffer used, and duration of post-incubation washes. 
Following the post-washes, brain sections were scraped into scintillation vials using a 
scalpel-blade, before being counted in a liquid scintillation counter (TriCarb, 1500 
Packard). The protocol which yielded the highest percentage of specific binding (See 
Tables 2.2 & 2.5) was then performed on the brain sections obtained from 3-day 
vehicle, antisense or mismatch infused rats. All slides were pre-washed for 20 min in 
50 mM Tris-buffer containing 0.1 % BSA and 1 mM MgC12, or 50 mM phosphate 
buffer, at room temperature and then dried under a stream of constant cool air. Once 
dry a hydrophobic barrier was then created around the outside of the slide using an 
"ImmEdge" pen. The slides were incubated for 40 min at room temperature in 200 µl 1, 
10,20 or 30 nM [3H]-Org34167 in the relevant buffer to determine the total 
radioactivity binding. Exactly the same protocol was followed to determine the non- 
specific binding but 20 µM Org 34167 was added to the incubation buffer. The assay 
was terminated by performing three post-washes in the same buffer as the incubating 
solution and then a final dip rinse in ice-cold distilled water. The slides were finally 
dried under a stream of cool air and placed into cassettes and exposed to X-ray film 
(BioMax MR-1 film, Kodak) for 2 weeks at 4 °C. An autoradiographic [3H] micro- 
scale (Amersham) of known radioactivity (range 31-833 nCi/g) was also placed in each 
cassette. The film was then developed as described in Section 2.2.1.3. 
2.2.1.7 Statistical analyses 
Data from each brain region of interest in the in situ hybridisation and [3H]-Org 34167 
autoradiography experiments were analysed by One-way analysis of variance followed 
64 
Chapter 2 Antisense approaches to the HCN channel 
by Bonferroni post-hoc multiple comparison test in the 3-day infusion study. The 
mismatch group from the 7-day trial were excluded due to an insufficient n number to 
perform statistical analysis, and an unpaired t-test was used to compare vehicle and 
antisense groups only. Significance in each statistical test was assigned when P<0.05, 
and the analysis was performed using GraphPad Prism v3.02 (GraphPad Software Inc). 
2.2.1.8 Histological staining 
Slides from animals treated for both the 3- and 7- day infusions were subject to cresyl 
violet staining. The sections utilised for this protocol had undergone no previous 
manipulation except from cryostat sectioning and all washes were diluted in dH2O. 
Firstly, the sections were equilibrated to room temperature for 30 min, then transferred 
to dH2O for 30 s and then dehydrated for 30 s in an ascending series of ethanol washes 
(50,95, and 100 %). The sections were then incubated for 7 min in 0.25 % cresyl violet 
in 200 mM acetate buffer, pH 4 (see Appendix A), then washed for 30 s in dH2O, 70 % 
ethanol and then 90 % ethanol. To differentiate the staining the sections were washed 
for 3 min in 0.4 % glacial acetic acid in ethanol (see Appendix A) then 30 s in 95 % and 
100 % ethanol. Finally, the sections were cleared in xylene for 4 min and immediately 
mounted in DPX mounting medium. 
2.2.1.9 Drugs and chemicals 
The following drugs and chemicals were all purchased from Sigma: formamide, NaCl, 
tri-sodium citrate, dextran sulphate, Denhardt's solution, salmon testes DNA, Poly-A, 
2D 7288, DTT, DEPC, tris-HCI, ethanol, xylene, di-sodium hydrogen orthophosphate 
(Na2HPO4) and sodium di-hydrogen orthophosphate (NaH2PO4; all Sigma). Terminal 
transferase (TT) buffer, TT (Promega), sodium pentobarbitone (Sagatal; Rhone 
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merieux), Gill No 2 (haematoxylin), 1% eosin solution, acetic anhydride, 
triethanolamine, NaOH, isopentane, cryoembed (all BDH), and halothane (Animal Unit, 
University of Bristol) were also used in these experiments. 
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2.3 Results 
2.3.1 Antisense oligonucleotide infusion targeting the initiation codon of 
HCN2 
2.3.1.1 Effect of 3- or 7-day infusion on rat body weight 
Individual body weights were taken each day from each animal and meaned to give the 
group daily body weight. There was no significant difference between each of the 
treatment groups, most probably due to the large variations in weight within each group 
(see Figures 2.1 & 2.2). During the course of the 7-day infusion, three mismatch rats 
were euthanased prior to the completion of the infusion. The toxicity observed in these 
three rats, coupled with the weight loss meant they had to be euthanased under the 
Home Office licence guidelines. All rats in the 3-day study completed the i. c. v 
infusion. 
Figure 2.1 Total weight change of rats given a 3-day i. c. v infusion of vehicle (saline), antisense 
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Total weight change was recorded for the 3 day infusion and 1 day baseline. Data represent means ± s. e. 
mean for 4 animals per group. Vehicle ( ), Antisense (o) or Mismatch (a). 
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Figure 2.2 Total weight change of rats given a 7-day i. c. v. infusion of vehicle (saline), antisense 
(targeting the initiation codon), or mismatch oligonucleotide 
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Total weight change was recorded for the 3 day infusion and l day baseline. Data represent means ± S. C. 
mean for 5 animals in the vehicle and antisense groups and an n=2 shows median and range for the 
mismatch group. Vehicle (. ), Antisense (Q) or Mismatch ( ). 
2.3.1.2 (`? HJ-Org 34167 autoradiography 
The results obtained using the established protocol for [3H]-Org 34167 autoradiography 
(Makkink, Personal communication) proved difficult to reproduce at Organon 
Laboratories, Newhouse. Therefore, various protocols were attempted in an effort to 
find a viable and consistent methodology for use. All the autoradiography trials were 
based on that of Makkink and co-workers with the differences being concentration of 
radioligand, buffer type, duration of post-incubation washes and fixation of the tissue in 
4% paraformaldehyde. There were notable differences in the levels of specific binding 
attained between the different 50 mM Tris-buffer protocols with the duration of the 
wash having the greatest effect (Table 2.2). 
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NSB (CPM) SPECIFIC 
I nM H-Org: 41/( paraformaldehyde 802.17 ± 522.1 789 ± 332 4 2% 
+2x20 s washes . 
1 nM 3H-Org: 2x20 s washes 831.5 ± 294.6 859 ± 514.6 -3% 
1 nM H-Org: 4% paraformaldehyde 275.33 ± 8.5 254 67 t 21 9 8% 
+3x10 min washes . . 
1 nM 3H-Org: 3x10 min washes 479.17 ± 290.6 521.17 t 301.4 -8% 
10 nM H-Org: 4% 13895.77 ± 1793.3 6214.11 ± 55% 
paraformaldehyde +2x20 s washes 1316.9 
10 nM 3H-Org: 2x20 s washes 7195.24 ± 3853.4 3292.5 ± 1452.3 54% 
10 nM H-Org: 4% 3985.86 ± 2901.7 2461 ± 811 3 38% 
paraformaldehyde +3x10 min washes . 
10 nM 3H-Org: 3x10 min washes 2819.67 ± 422.9 764.67 ± 378.6 73% 
20 nM H-Org: 4% 34088.33 ± 44766.3 17 ± 1488 12969 62% 
paraformaldehyde +2x20 s washes . 
20 nM 3H-Org: 2x20 s washes 17625.1 ± 16659 
10078.51 ± 43% 
738.7 
20 nM H-Org: 4% 13248 ± 834.2 3442.5 ± 988 6 74% 
paraformaldehyde +3x10 min washes . 
20 nM 3H-Org: 3x10 min washes 3035.17 ± 1713.3 2134.67 ± 579.5 30% 
Autoradiography scrapes of [3H]-Org 34167 performed on 20 gm brain sections. Sections have been 
subjected to different protocols. Data represent CPM mean ± St. Dev (n = 3). 
The results of the initial experiment demonstrate that fixation of the tissue in 4% 
paraformaldehyde increased total binding and non-specific binding; although it did 
produce the protocol with the highest percentage of specific binding (20 nM, 3x 10 min 
washes; Table 2.2). The concentration which provided the most consistent assay, with a 
high level of specific binding and low NSB was 10 nM [3H]-Org 34167. Therefore, the 
experiment was performed again as described in section 2.2.1.4 but only at a 10 nM 
concentration of the radiolabel and no fixation. Additionally, a further post-incubation 
wash protocol (3 x1 min washes) was added (Table 2.3). 
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2x 20sec washes 11030.5 ± 1159.2 3843.2 ± 1325.5 6590 
3x1 min washes 8182.7 ± 672.3 2964.8 ± 770.5 64% 
3x 10min washes 4220.6 ± 837.1 1770.2 ± 783.6 52% 
Autoradiography scrapes of 10 nM [3H]-Org 34167 performed on unfixed 20 µm brain sections with 
different post-incubation wash durations. Data represent CPM mean ± St. Dev (n = 6). 
Comparison of the level of specific binding achieved using the same protocol revealed a 
high level of inconsistency in the assay, where 2x 20 s washes produced 54 and 65 %, 
and 3x 10 min washes, 73 and 64 % specific binding (Tables 2.2 & 2.3). Therefore, 
further optimisation was attempted using 50 mM phosphate buffers at varying pH and 
ion consistencies. Of the buffers attempted 50 mM phosphate buffer at pH 7.4 was 
observed to produce the highest, and most consistent across the varying ion and [3H]- 
Org 34167 conditions (see Table 2.4). The experiment was performed again using 50 
mM phosphate buffers, pH 7.4. Similar to the Tris-buffer observations, phosphate 
buffer produced variable specific binding at all concentrations of [3H]-Org 34167 
between experiments (see Tables 2.4 & 2.5). 
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Table 2.4 Initial 50 mM phosphate buffer optimisation of [3H]-Org 34167 autoradiography 
BUFFER % BUFFER % BUFFER % 
COMPOSITION SPECIFIC COMPOSITION SPECIFIC COMPOSITION SPECIFIC 
pH 7 No Ions 
-257.38 
PH 7.4 No Ions 
-48.49 
pH 8 No Ions 42 27 10nM IOnM I OnM . 
pH 7 150mM 17.35 PH 7.4 150mM -1836.40 
PH 8 150mM NaCl 
-270 06 NaCl I OnM NaCl lOnM I OnM . 
PH 7 5mM KCI 
-47.94 
pH 7.4 5mM KCI 0.76 pH 8 KCI 5mM -18.42 1 OnM 1 OnM I OnM 
PH 1 mM MgCI2 1.63 pH 7.4 1 mV1 85.01 PH 81 mM MgCl, 12 -42 1Onm MgCL IOnM 1OnM . 
pH 7 all ions 
-448.49 
PH 7.4 all ions 47.62 pH 8 all ions 1 OnM 38.95 lOnM IOnM 
pH 7 no ions 12.73 PH 7.4 no ions 3.71 pH 8 no ions 20nM 12.91 20nM 20nNI 
pH 7 150mM 22 46 PH 7.4 150mM 3.90 pH 
8 150mM NaCl 76 -15 NaCl 20nM . NaCl 20nM 20nM . 
pH 7 5mM KCI 34 98 PH 7.4 5mM KCI -1.53 
pH 8 5mM KCI 31.92 
20nM . 20nM 20nNI 
pH 7l mM 52 07 pH 
7.4 1 mM 16.34 pH 81 mM MgCl2 24.84 
_MgCl, 
20nM . MgCl, 20nM 20nM 
pH 7 All ions 
-105 33 
PH 7.4 All ions 
-6.99 
PH 8 All ions 
-17.28 20nM . 20nM 20nM 
pH 7 no ions 
-8.43 
pH 7.4 no ions 66.53 pH 8 no ions 30nM 65.59 30nM 30nM 
pH 7 150mM 55 13 PH 7.4 150mM 8.10 PH 
8 150mM NaCl 35.23 
NaCI 30nM . NaCI 30nM 30nM 
pH 7 5mM KCI 
-36 09 
PH 7.4 5mM KCI 11.55 PH 
8 5mM KC1 
12.27 
30nM . 30nM 30nM 
pH 71 mM 41 69 PH 7.4 1 mM 18.91 pH 
81 mM MgCI2 
-5.63 MgCl2 30nM . M C1,30nM 30nM 
pH 7 All ions 7 73 pH 7.4 All 
ions 26.75 pH 8 All ions 29.52 
3OnM . 30nM 3OnM 
Table 2.5 Final 50 nLM phosphate buffer optimisation of [3H1-Org 34167 autoradiography 
`TOTAL BLNDING NSB 
PROTOCOL SPECIFIC 
CPM SD CPM SD 
IOnM [3H]-Org No ions 5559.00 ± 258.10 2594.70 ± 146.90 53.32 
lOnM [311]-Org 150mM NaCl 4594.10 t 140.70 2524.50 ± 25.50 45.05 
IOnM [3H]-Org 5mM KC1 5210.20 t 179.10 2385.20 ± 120.20 54.22 
IOnM [311]-Org 1mM MgC1z 6720.30 ± 206.00 3310.00 ± 181.70 50.75 
20nM [ 3H ]-Org No ions 6059.00 ± 73.00 2857.00 ± 148.80 52.85 
20nM [3H1-Org 150mM NaCl 4972.80 ± 140.70 2851.30 ± 302.40 42.66 
20nM (3H]-Org 5mM KC1 5571.40 ± 10.60 2495.70 ± 77.60 55.21 
20nM [3H]-Org ImM MgCI2 7452.60 ± 377.50 3389.40 ± 700.00 54.52 
3OnM ]3H]-Org 15334.70 ± 1013.40 5638.00 ± 178.30 63.23 
30nM [3H]-Org 150mM NaCl 8301.10 ± 252.90 4584.00 ± 345.30 44.78 
30nM [3H]-Org 5mM KCI 8834.60 ± 717.00 3984.70 ± 147.90 54.90 
I 3OnM [3H]-Org 1 mM MgCI2 11998.10 ± 298.30 6535.60 ± 688.90 45.53 
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Despite the substantial inter-assay variability in [3H]-Org 34167 binding, 
autoradiography was performed on oligonucleotide-infused brain sections from the 3- 
day trial. The 50 mM Tris-buffer, using 10nM [3H]-Org 34167 and 3x1 min post- 
washes protocol was performed (see Figure 2.3 for representative autoradiographs). 
There were significant differences between the treatment groups at the majority of brain 
regions analysed (Table 2.6). Both significant increases and reductions in specific 
binding for the same treatment group were observed at different levels examined. These 
inconsistencies may be due, in part, to the low level of specific binding achieved despite 
the optimised protocol displaying -60% specific binding. The levels of binding are 
expressed in relative optical density (ROD) because the standards that were employed 
were not exposed to the film for sufficient time. 
Table 2.6 [3H]-Org 34167 autoradiography on 3-day vehicle, antisense or mismatch treated brain 
sections 
REGION VEHICLE INFUSION 
ANTISENSE INFUSION MISMATCH INFUSION 
mean ± s. e. mean mean t s. e. mean mean ± s. e. mean 
Lcft Cg ctx 0.369 _ 
0.0022 0.0392 t 0.0047t 0.0128 t 0.00895* 
Left rDM Str 0.0286 t 0.0017 0.0298 t 0.0043t 0.0028 t 0.0085* 
-0.7mm Left rVM Str 0.0305 0.0008 0.0283 t 0.0032t 0.0004 ± 0.0084** 
bregma Right Cg ctx 0.0339 t 0.0021 0.0385 t 0.0031 0.0160 t 0.0099 
Right rDM Str 0.0256 ± 0.0014 0.0289 t 0.0035t 0.0029 t 0.0093 
Right rVM Str 0.0273 t 0.0021 0.0297 t 0.0042 0.0061 t 0.0088 
Left pCg ctx 0.0218 t 0.0032 0.0293 ± 0.0147 0.0289 t 0.0091 
Left cDM Str 0.0115 t 0.0030 0.0205 t 0.0103 0.0167 t 0.0079 
-1.5mm 
Left cVM Str 0.0118 ± 0.0024 0.0175 t 0.0088 0.0241 t 0.0091 
bregma Right pCg ctx 0.0171 t 0.0044 0.0284 t 0.0142 0.0274 t 0.0068 
Right cDM Str 0.0134 ± 0.0034 0.0151 t 0.0076 0.0183 ± 0.0067 
Right cVM Str 0.0120 ± 0.0017 0.0209 ± 0.0105 0.0223 t 0.0090 
Left RS Cu 0.0086 ± 0.0008 0.0209 ± 0.0016** 0.0150 t 0.0023 
-2.3mm Left D Thal 0.0006 t 0.0027 0.0114 t 0.0044 0.0082 t 0.0009 
bregma Right RS Ctx 0.0019 t 0.0010 0.0129 t 0.0014** 0.0109 t 0.0015** 
Right D Thal 0.0021 f 0.0014 0.0067 ± 0.0023 0.0111 t 0.00195* 
Quantified data for specific [ H]-Org 34167 binding (10 nM) to rat brain sections following a 3-day i. c. v 
infusion with vehicle (saline), antisense (targeting the initiation codon) or mismatch oligonucleotide. 
Results represent mean specific binding ± s. e. mean (relative optical density) for 3-4 rats per group, three 
sections per animal. *P<0.05, ** P<0.01 oligonucleotide compared with vehicle, tP<0.05 antisense 
compared with mismatch. Abb: c, caudal, Cg ctx, cingulate cortex, D, dorsal, DM Str, dorsomedial 
striatum, p, posterior, r, rostral, RS ctx, retrosplenial cortex, Thal, thalamus, VM Str, ventromedial 
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A= Vehicle treatment Total binding, B= Vehicle treatment NSB, C= Mismatch Total Binding, D= 
Mismatch NSB, E= Antisense treatment Total Binding and F= Antisense treatment NSB. 
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2.3.1.3 Effect of 3- and 7-day i. c. v. infusion on HCN2 mRNA expression 
Infusion of the antisense oligonucleotide targeting the initiation codon only significantly 
decreased HCN2 mRNA levels in the right anterior cingulate cortex compared with 
mismatch infusion following a 3-day infusion (Table 2.7). No further significant 
differences were observed at this, or the regions analysed between 0 to -1.5 mm relative 
to bregma in either the 3- or 7-day studies (Tables 2.8 & 2.9). In the left anterodorsal 
thalamus a significant decrease in HCN2 mRNA expression was observed in the 
antisense-treated group compared with vehicle infusion in the 7-day trial (P < 0.05; 
Table 2.10). No significant differences were observed in the 3-day trial, nor were there 
any differences observed in the most caudal brain regions analysed (Table 2.11). 
Mismatch data from the 7-day trial are provided for information only, and therefore 
shown in italics. A significant antisense effect can only be regarded in the case of a 
significant alteration from both vehicle and mismatch infusions. 
Table 2.7 Effect of 3- and 7-day i. c. v. vehicle, antisense or mismatch infusion on HCN2 mRNA 




Mean s. e. mean 
ANTISENSE 
INFUSION 
Mean s. c. mean 
MISMATCH 
INFUSION 
Mean s. e. mean 
Left Ant Cg ctx 142.37 ± 3.04 139.90 ± 7.70 154.00 ± 4.39 
3 Left Rost DM Str 113.55 t 3.61 117.01 t 11.60 133.16 ± 4.94 
D Left Rost VM Str 101.22 ± 2.95 105.58 t 11.24 120.87 ± 6.98 
A Right Ant Cg ctx 141.66 ± 6.24 124.66 ± 7.88+ 157.56 ± 7.93 
Y Right Rost DM Str 106.38 ± 3.95 112.23 ± 8.98 119.08 ± 4.99 
Right Rost VM Str 97.22 ± 2.61 100.83 ± 8.96 106.86 ± 4.81 
Left Ant Cg ctx 162.84 ± 12.66 146.90 ± 10.28 155.54 ± 
7 Left Rost DM Str 124.28 ± 9.71 116.92 ± 6.64 120.53 ± 
D Left Rost VM Str 107.00 ± 8.81 102.54 ± 3.75 106.58 ± 
A Right Ant Cg ctx 165.18 ± 14.51 145.46 ± 6.74 138.59 ± 
Y Right Rost DM Str 120.48 ± 11.01 108.46 ± 6.48 103.41 ± 
Right Rost VM Str 107.17 ± 10.72 92.87 t 3.13 101.75 ± 
Data represent mean ± s. e. mean of three sections per animal (n =4 rats for all groups in 3-day infusion 
and n=5 rats for vehicle and antisense groups in 7-day infusion and n=2 rats for 7-day mismatch 
infusion). Optical density readings have been converted to nCi/g of tissue. +P<0.05 compared with 
mismatch. Abb: Ant Cg ctx, anterior cingulate cortex, Rost DM Str, rostra] dorsomedial striatum, Rost 
VM Str, rostral ventromedial striatum (Paxinos et al., 1986). 
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Table 2.8 Effect of 3- and 7-day i. c. v. vehicle, antisense or mismatch infusion on HCN2 mRNA 




Mean s. e. mean 
ANTISENSE 
INFUSION 
Mean s. e. mean 
MISMIATCH 
INFUSION 
Mean s. c. mean 
Left Cg ctx 123.26 ± 7.39 128.88 ± 3.85 111.65 ± 6.06 
3 Left DM Str 91.17 ± 6.40 97.01 ± 3.82 93.34 ± 5.61 
D Left VM Str 96.29 ± 4.99 102.87 ± 2.60 93.63 ± 8.41 
A Right Cg ctx 127.16 ± 6.55 113.80 ± 4.40 122.16 ± 8.18 
Y Right DM Str 87.70 ± 9.17 98.38 ± 4.82 85.12 ± 5.90 
Right VM Str 84.34 ± 6.97 96.45 ± 7.04 81.59 ± 5.98 
Left Cg ctx 116.55 ± 3.50 110.83 ± 7.29 121.30 ± 
7 Left DM Str 89.10 ± 3.10 75.25 ± 5.01 82.75 ± 
D Left VM Str 80.48 ± 3.02 77.19 ± 2.78 85.73 ± 
A Right Cg ctx 123.57 ± 3.88 117.57 ± 2.53 117.13 ± 
Y Right DM Str 84.82 ± 3.96 78.84 ± 5.55 83.45 ± 
Right VM Str 79.67 ± 2.47 63.44 ± 5.82 80.27 ± 
Data represent mean ± s. e. mean of three sections per animal (n =4 rats for all groups in 3-day infusion 
and n=5 rats for vehicle and antisense groups in 7-day infusion and n=2 rats for 7-day mismatch 
infusion). Optical density readings have been converted to nCi/g of tissue. Abb: Cg ctx, cingulate cortex, 
DM Str, dorsomedial striatum, VM Str, ventromedial striatum (Paxinos et al., 1986). 
Table 2.9 Effect of 3- and 7-day i. c. v. vehicle, antisense or mismatch infusion on HCN2 mRNA 




Mean s. e. mean 
ANTISENSE 
INFUSION 
Mean s. e. mean 
MISMATCH 
IN FUSION 
Mean s. e. mean 
Left Cg ctx 115.34 ± 6.44 117.14 ± 8.72 113.86 ± 10.24 
3 Left cDM Str 64.94 ± 7.07 82.08 ± 7.04 75.39 ± 4.40 
D Left cVM Str 77.39 ± 5.65 89.05 ± 5.17 85.58 ± 6.77 
A Right Cg ctx 110.21 ± 5.18 106.76 ± 7.41 123.07 ± 6.88 
Y Right cDM Str 68.05 ± 12.60 84.97 ± 4.82 84.47 ± 4.55 
Right cVM Str 69.60 ± 16.01 103.18 ± 7.22 96.59 ± 6.08 
Left Cg ctx 127.15 ± 3.70 128.91 ± 8.63 114.73 ± 
7 Left cDM Str 83.93 ± 6.69 88.40 ± 6.71 75.79 ± 
D Left cVM Str 95.96 ± 3.74 102.40 ± 4.14 85.51 ± 
A Right Cg ctx 131.84 ± 3.50 125.59 ± 4.02 111.48 t 
y Right cDM Str 92.62 ± 2.74 90.96 ± 6.26 76.52 ± 
Right cVM Str 100.65 ± 4.12 99.76 ± 6.73 79.83 ± 
Data represent mean ± s. e. mean of three sections per animal (n =4 rats for all groups in 3-day infusion 
and n=5 rats for vehicle and antisense groups in 7-day infusion and n=2 rats for 7-day mismatch 
infusion). Optical density readings have been converted to nCi/g of tissue. Abb: Cg ctx, cingulate cortex, 
cDM Str, caudal dorsomedial striatum, cVM Str, caudal ventromedial striatum (Paxinos et al., 1986). 
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Table 2.10 Effect of 3- and 7-day i. c. v. vehicle, antisense or mismatch infusion on HCN2 mRNA 




Mean s. c. mcan 
ANTISENSE 
INFUSION 
Mean s. c. mcan 
MISMATCH 
INFUSION 
Mean s. c. mean 
3 Left Post Cg Ctx 124.33 ± 3.77 124.63 ± 8.65 101.30 ± 11.87 
D Left AD Thal 249.49 ± 8.54 224.86 ± 5.98 234.49 ± 18.62 
A Right Post Cg ctx 124.25 ± 4.50 120.99 ± 8.55 114.43 ± 8.94 
Y Right AD Thal 240.68 ± 13.47 230.01 ± 9.68 221.02 ± 15.14 
7 Left Post Cg ctx 122.21 ± 2.33 115.84 ± 9.72 133.91 ± 
D Left AD Thal 220.92 ± 4.95 185.71 ± 9.25* 185.24 ± 
A Right Post Cg ctx 124.41 ± 7.12 106.01 ± 9.16 129.63 ± 
Y Right AD Thal 203.59 ± 7.89 175.14 ± 8.83 162.87 ± 
Data represent mean ± s. e. mean of three sections per animal (n =4 rats for all groups in 3-day infusion 
and n=5 rats for vehicle and antisense groups in 7-day infusion and n=2 rats for 7-day mismatch 
infusion). Optical density readings have been converted to nCi/g of tissue. *P<0.05 compared with 
vehicle. Abb: Post Cg ctx, posterior cingulate cortex, AD Thal, anterodorsal thalamus (Paxinos et al., 
1986). 
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Table 2.11 Effect of 3- and 7-day i. c. v. vehicle, antisense or mismatch infusion on HCN2 mRNA 




Mean s. e. mean 
ANTISENSE 
INFUSION 
Mean s. e. mean 
MISMATCH 
INFUSION 
Mean s. e. mean 
Left RS ctx 133.33 ± 3.52 127.25 ± 7.68 123.69 ± 11.23 
3 Left D Thal 226.74 ± 18.07 253.63 ± 8.01 265.58 ± 12.42 
D Left CA3 208.02 ± 7.97 186.11 ± 10.25 213.11 ± 7.35 
A Right RS ctx 126.19 ± 8.22 103.08 ± 1.86 115.68 ± 8.66 
Y Right D Thal 215.24 ± 20.72 206.31 ± 13.32 242.57 ± 12.38 
Right CA3 212.73 ± 5.43 185.46 ± 19.83 213.33 ± 16.43 
Lcft RS ctx 118.27 ± 4.48 130.11 ± 10.27 125.32 ± 
7 Left D Thal 241.02 ± 6.11 238.40 ± 15.33 254.34 ± 
D Left CA3 207.00 ± 5.17 184.63 ± 17.03 192.12 ± 
A Right RS ctx 116.50 ± 5.13 122.48 ± 7.44 134.21 ± 
Y Right D Thal 237.32 ± 9.19 219.58 ± 8.65 241.00 ± 
Right CA3 195.56 ± 11.87 201.58 ± 20.72 205.41 ± 
Data represent mean ± s. e. mean of three sections per animal (n =4 rats for all groups in 3-day infusion 
and n=5 rats for vehicle and antisense groups in 7-day infusion and n=2 rats for 7-day mismatch 
infusion). Optical density readings have been converted to nCi/g of tissue. Abb: RS ctx, anterior 
retrosplenial cortex, D Thai, dorsal thalamus (Paxinos et al., 1986). 
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2.2.2 Design and investigation of six antisense sequences to the HCN2 
gene 
2.2.2.1 Design of six antisense sequences to the rat HCN2 gene using mfold 
Utilising the secondary structure prediction computer modelling program, "mfold", 
antisense sequences were designed along the length of the rat HCN2 mRNA transcript 
(Accession number: AF247451). These sequences were then examined for possible 
complementarity to other known genes using the NCBI database and rejected if 
significant homology (5 bases) was observed. This is with the exception of other HCN 
genes, as Sequence 6 was complementary to HCN1,2 and 4 and Sequences 3 and 5 to 
HCN2 and 3. Furthermore, the sequences were checked for any possible active motifs 
(see Section 1.4.3) and their percentage GC content. If active motifs were present, or 
the GC content too high or low (accepted between 33 - 60 %), sequences were rejected. 
Finally, the sequences were examined for possible hairpin loops, or self-annealing 
sequences, using an oligonucleotide properties calculator and rejected in either case 
(http: //www. basic. nwu. edu/biotools/oligocalc. html). Using this selection procedure, six 
antisense sequences were chosen (See Table 2.12). The sequences were fully-modified 
phosphorothioate oligonucleotides and synthesised by MWG Biotech (Germany). 
Table 2.12 Six antisense sequences designed using enfold secondary structure prediction 
NAME SEQUENCE (5'- Y) 
COMPLEMENTARY BASES 
(AF247451) 
Sequence 1 CAA GGG TCA CAA GTT GGA 2493 -2511 
Sequence 2 TTG AAG AAA GTG ATG 528 - 542 
Sequence 3 GGG AGA ACT TGT TGA CG 354 - 370 
Sequence 4 GGA TGA TGT AGT CT 1536 - 1553 
Sequence 5 AGA TGG AGT TCT TCT 1823 - 1840 
Sequence 6 CAG GTC GTA GGT CAT GTG 895 - 911 
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2.2.2.2 Animals and experimental procedure 
Housing conditions, filling of the osmotic minipumps, and implantation of the cannula 
were performed as described in section 2.2.1.1 with the use of different anaesthesia. On 
the day of surgery rats were anaesthetised with halothane using a rodent ventilator, 
which maintained an O-, flow rate of 1.5 I/min and NO2 flow rate of 2 l/min. 
Anaesthesia was induced using 3% halothane via a nosepiece that was connected to the 
rodent ventilator and a Fluovac (International Market Supply) fitted with a Cardiff 
Aldasorber (Shirley Aldred & Company Ltd, U. K. ) to scavenge the halothane. Once 
anaesthetised the rat was transferred to a stereotaxic frame (Stoelting Co, Illinois, USA) 
with a specially adapted nosepiece, which was connected to the rodent ventilator via the 
Fluovac with 1.5 -2% halothane, to maintain anaesthesia for the duration of the 
surgery (see Figure 2.4). 
Figure 2.4 Representative image of stereotasic surgery procedure 
Image shows rat in sterotaxic frame with the adapted nose-piece, which maintains the halothane 
anaesthesia. A pair of artery forceps keeps the skin clear of the skull to enable the cannula to be 
implanted i. c. v. and then application of dental cement to secure the cannula to the skull and bone screw. 
Following surgery the rat is removed from the sterotaxic frame and the skin is stapled together to seal the 
surgery. 
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The fully-modified phosphorothioate oligonucleotides were administered at a rate of 
4 pg/gUh with two animals in each treatment group. On the final day of the 3-day 
infusion the rats were perfused and the brains collected and stored as described in 
Section 2.2.1.1. 
Additionally, because no mismatch oligonucleotide control sequences were employed, 
behavioural observations of the rats were performed to assess potential toxicity or 
behavioural effects of the different antisense administration. These observations were 
based upon time-sampling (adapted from Reinstein & Isaacson (1977)) and were 
performed during the first four (07: 30 - 11: 30 h) and last four (15: 30 -18: 50 h) hours of 
the light-phase. The behaviour of each rat was recorded for 15 s every 60 s, for a total 
of 10 min in each hour. The behaviours were exclusive and only one parameter could 
be scored for each recording (see Table 2.13 for list of behavioural measures). The first 
observed behaviour was given a score in each minute meaning that the maximum score 
per day for any given behaviour was 80 for each rat. Food and water intake, as well as 
body weights, were measured immediately after the first and last behavioural 
observations. These observations were performed for two-days prior to surgery and 
two-days post-surgery (i. e. during infusion). No behavioural observations were 
performed on the day of surgery, only food, water and body weight measurements were 
recorded. 
2.2.2.3 In situ hybridisation protocol 
Brain sections were cryostat-cut onto superfrost slides (BDH) from -0 mm bregma to 
- -2.5 mm bregma in 4 series each containing 8 slides (with 3 sections on each slide) as 
described in Section 2.2.1.2. Sections were stored at -80 °C until required. In situ 
hybridisation was performed, as described in Section 2.2.1.3, using the complementary 
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oligonucleotide to HCN2 (see Appendix B for sequence details) and one slide for each 
brain was subjected to cresyl violet staining as described in Section 2.2.1.9. 
2.2.2.4 Statistical analyses 
No statistical analyses were performed due to an insufficient n number. This was due to 
the preliminary nature of the experiments performed in the trial. 
Table 2.13 Description of behavioural parameters measured during oligonucleotide infusion 
BEHAVIOUR DESCRIPTION 
Locomotion Movement around the home cage 
Wall Climbing Forepaws resting against the side of the cage and an elevated posture 
Rearing Elevated posture with forepaws in the air 
Grooming Any grooming of rat, with either tongue or paws 
Scratching Scratching with hind paw 
Eating Eating of standard rat diet, sawdust or faeces 
Drinking Drinking of water 
ACTIVITY Total score of all above behaviours 
ST AWAKE Stationary awake 
ST ASLEEP Stationary asleep 
Sniffing Sniffing of air or cage 
Head weaving Continuous head movement in horizontal and/or vertical planes 
Arched back Back in an elevated posture 
I muscle tone Decreased muscle tone (only performed during weighing of rat) 
Hindlimb stretch Stretching of hindlimbs 
Tremor Tremor 
Ataxia Uncoordinated locomotion 
Wet dog shake Whole body shake 
Forepaw treading Forepaws in the air moving consistently 
Yawning Yawning 
The behaviours listed below St asleep are those which were employed to observe for signs of toxicity 
following oligonucleotide administration. Only one behaviour above activity could be recorded at one 
observation but those listed below St. asleep could be recorded at the same time as they were employed to 
look for signs of toxicity. 
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2.3.2 Design and investigation of six antisense sequences to the HCN2 
gene 
2.3.2.1 Body weight, food and water intake and behavioural observations 
With the preliminary nature of this study no statistical analyses were performed as there 
was an insufficient n number (n = 2). Consequently, the data for each rat is graphically 
represented. Differential effects were observed on the total weight gain of rats receiving 
different antisense sequences targeted to varying regions along the HCN2 transcript. 
Sequences 1-3 infusions resulted in an increase in total body weight over the five-day 
time course, whereas Sequences 4-6 caused a decrease in body weight (Figure 2.5). 
This trend was similar to the daily food intake of the rats; although all groups displayed 
a marked decrease in food intake on the day of surgery. Sequence 4 and 6 infusions 
decreased food intake over the infusion period compared with the corresponding 
baseline period. Sequences 1,2 and 3 infused rats recovered to baseline readings 
following surgery and Sequence 5 administration caused the least fluctuation in daily 
food intake (Figure 2.6). Infusions of Sequence 1,2,3 and 5 resulted in an increase in 
daily water intake for the duration of the infusion compared with the corresponding 
baseline recordings, whilst infusion of Sequence 4 infusion caused no apparent 
alteration to this parameter. Infusion of Sequence 6 resulted in decreased water intake 
during the infusion period compared with baseline (Figure 2.6). Median total activity 
scores of all antisense sequences were increased compared with vehicle infusion, with 
the exception of Sequence 6 where a decrease was observed (Figure 2.7). 
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Results are shown for each of the two animals for the duration of the five day time course study. 
Sequence 6 displays the total weight gain for one rat, which completed the five day study (Wk 1) and one 
which was euthanased I day into the infusion (Wk 2). All other rats completed the time-course. 
Figure 2.6 Effect of 3-day infusion of six antisense sequences designed using mfold on daily food 
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Results are shown for each of the two animals for the duration of the five day time course study. 
Sequence 6 displays the total parameter for one rat, which completed the five day study (Wk I) and one 
which was euthanased I day into the infusion (Wk 2). All other rats completed the time-course. 
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Results represent the total median activity of each rat over the course of the two days pre-surgery and two 
days post-surgery observations (see Table 2.13). The maximum score recordable was 320. Results are 
shown for each of the two animals for the duration of the five day time course study. Sequence 6 displays 
the total parameter for one rat, which completed the five day study (Wk 1) and one which was euthanased 
I day into the infusion (Wk 2). All other rats completed the time-course. 
2.3.2.2 In situ hybridisation following 3-day i. c. v. infusion of six antisense 
sequences 
Due to the small n number the nCi/g tissue values obtained following HCN2 mRNA in 
situ hybridisation were normalised to vehicle control. At the most rostral and caudal 
brain regions analysed all antisense sequences displayed an apparent down-regulation 
compared with vehicle, which was only observed for Sequences 1,3 and 5 at -0.7 mm 
relative to bregma. Sequence 3 was the only treatment group where a decrease in 
mRNA was observed at -1.5 mm relative to bregma. There is significant intrasequence 
variation present in each anti sense-treatment group, with Sequence 6 displaying the 
largest variance, most probably due to the brains receiving different infusion-times, 
while Sequence 4 demonstrated the least variation (see Table 2.14). 
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2.2.3 Further investigation of two antisense sequences obtained from 
those designed by mfold 
2.2.3.1 Animals and experimental procedure 
Using the data from the first mfold trial (See Section 2.3.2), two of the most promising 
sequences were selected. Sequence 1 was chosen due to the behavioural observations, 
which demonstrated an increase in overall rat activity compared with vehicle (see 
Figure 2.7) and Sequence 4 was chosen after analysis of both the in situ hybridisation 
data and activity data (see Figure 2.7 & Table 2.14). Mismatch sequences were 
designed by incorporating two paired base switches, which were subjected to the same 
scrutiny as described in Section 2.2.2.1 for the antisense sequences. These sequences 
were namely, Mismatch 1: 5' - AAA TGG TCA CAA GTG CGG - Tand Mismatch 4: 
5' - GCG TGG TAT AAT GT - 3'. Both mismatch oligonucleotides were synthesised 
to the same modifications as the antisense oligonucleotides; fully-modified 
phosphorothioates. Similar to the previous trial (Section 2.2.2) the oligonucleotides 
were infused at a rate of 4 pg/µl/h, but with five rats in each treatment group. 
Behavioural observation were performed as described in Section 2.2.2.2, except from 
rat body weight measurements, which were only taken immediately after the first 
behavioural observations each day. Surgical implantation of the cannula was performed 
as described in Section 2.2.2.2 and the osmotic minipumps used were Model 1003D, for 
a 3-day infusion period. 
Brain sections were cryostat-cut onto superfrost slides (BDH) from -0 mm bregma to 
-2.5 mm bregma in 4 series each containing 8 slides (with 3 sections on each slide). 
Sections were stored at -80 °C until required. The first slide from each of the four brain 
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series collected was subjected to HCN2 in situ hybridisation and the second slide to 
ß-actin (see Appendix B for probe details). Specificity of the oligonucleotide probes 
was assessed as described in Section 2.2.1.4 and the autoradiograph images are shown 
in Appendix C. 
2.2.3.2 Histological staining (haematoxylin and eosin) 
One slide from each series was subjected to haematoxylin and eosin histological 
staining. The haematoxylin and eosin stain was applied to brain sections which had 
been subjected to the pre-hybridisation washes described in Section 2.2.1.3. Sections 
were first re-hydrated using 95- and 70 % ethanol and then immersed in distilled water 
for 2 min. The sections were then incubated for between 50 - 100 s in haematoxylin 
(Gill No 2 Haematoxylin solution, BDH, UK) and washed in distilled water for 5 min 
before being immersed in 1% eosin (BDH, UK) for 90 - 120 s. Finally, sections were 
dehydrated for 30 s in a series of ascending concentrations of ethanol (70,90 and 100 
%, diluted in distilled water) and then immersed in xylene for 2 min and immediately 
mounted in DPX mounting medium. The stained sections were then observed using a 
microscope connected to an image capture device (Olympus Provis AX camera linked 
to image analysis software, AnalySIS, Version 3.2, Soft Imaging Systems), which 
enabled images to be collected at x1.5 magnification. 
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2.3.3 Further investigation of two antisense sequences designed using 
mfold 
2.3.3.1 Body weight, food and water intake and behavioural observations 
There was a trend towards an increase in total weight gain in all of the oligonucleotide 
infusion groups compared with vehicle, but this did not reach significance for any group 
(Figure 2.8). Daily food and water intake was not significantly altered at any time point 
(Figure 2.9). The median total behavioural activity parameter was elevated in both 
Sequence 1 and Mismatch 1 infused rats compared with vehicle, whereas Sequence 4 
and Mismatch 4 infusions did not cause an apparent increase in activity (Figure 2.10). 
All rats in the trial completed the five-day time course. 
Figure 2.8 Effect of 3-day infusion of two antisense sequences on total weight gain 
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Total weight gain was recorded for the 3 day infusion and I day baseline. Data represent mean ± s. e. 
mean for 5 animals per group. Vehicle (s), Sequence 1 (Q), Mismatch 1 (a), Sequence 4(), or 
Mismatch 4(). 
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Daily food and water intake was recorded for the 3 day infusion and I day baseline. Data represent mean 
± s. e. mean of food and water intake in g per kg rat for 5 animals per group. 













Q ýýa ýýa 
Total activity, stationary awake and stationary asleep scores for the duration of the five day time course 
(see Table 2.1 ). Data represent the median frequency score + upper range for 5 animals per group. . 
Vehicle (. ). 0.4 µg/µl/h antisense (a), 0.4 µg/. tI/h mismatch ( ), 4 µg/µl/h antisense (. ), or 4 4g/pl/h 
mismatch ("). 
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2.3.3.2 Effect of 3-day i. c. v. infusion of two antisense sequences on HCN2 
mRNA expression 
There was an apparent reduction of HCN2 mRNA observed following Sequence 1&4 
infusion, with a corresponding increase in the control, ß-actin mRNA expression 
compared with vehicle. However, these observed differences in mRNA patterns 
compared with vehicle-infused brain sections were observed in brain regions, which 
show high levels of damage as demonstrated on the haematoxylin and eosin stained 
sections i. e. around the cannula tract (Figure 2.11). Therefore, no quantification of the 
HCN2 mRNA in situ hybridisation was performed for this study due to the toxicity 
following the oligonucleotide-infusion. 
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Figure 2.11 Representati%e autoradiograph images of HCN2 and ß-actin in situ hybridisation and 
haematox-, 'Iin and eosin stained sections 
A 
D 
7 mm ýýýý ;, n 4 .2ý 
Comparison of ni situ hybridisation autoradiographs utilising [' P] labelled oligonucleotide probes 
targeted against HCN 2 mRNA (first column) and ß-actin mRNA (second column) and representative 
haematoxylin and eosin stained sections (third column). A= Vehicle, -I mm relative to bregma, 
B= Sequence I, -l mm relative to bregma, C= Vehicle, -2.3 mm relative to bregma, D= Sequence 4, 
-2.3 mm relative to bregma. 
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2.2.4 Mixed backbone oligonucleotide infusion 
2.2.4.1 Animals and experimental procedure 
The oligonucleotide sequences used in this trial were Sequence 1 (see Table 2.12) and 
its corresponding control; Mismatch 1 (see Section 2.2.3.1). In this study however, 
mixed backbone oligonucleotides were employed, in which the first four bases at the 5' 
end of the sequence were phosphorothioate-linkages as were bases 14 - 17. The middle 
section of the oligonucleotide consisted of phosphodiester linkages, as was the 3'-base 
because the company supplying the oligonucleotide could not synthesise a 
phosphorothioate linkage here (GibcoBRL, UK). Additionally, two concentrations of 
each sequence were infused; 0.4 and 4 pg/pl/h, due to the toxicity of the previous 
administration study (see Figure 2.11). Phosphorothioate oligonucleotides were 
administered using 7-day osmotic mini-pumps (Alzet, Charles River, U. K., 1µl/h, 
Model 1007D) combined with a brain infusion kit. No behavioural observations were 
performed in this study, except for informal monitoring of rat cage behaviour. Surgery 
was performed as described in Section 2.2.2.2., with cryostat sections, in situ 
hybridisation and histological staining performed as described in Sections 2.2.3.1 and 
2.2.3.3 respectively. 
2.2.4.2 Statistical analyses 
Data for each brain region of interest were analysed by one-way analysis of variance 
followed by Student Newman Keuls post-hoc multiple comparison test, as more than 3 
groups were compared. Significance was assigned when P<0.05 and analysis was 
performed using GraphPad Prism v3.02 (GraphPad Software Inc). 
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2.3.4 Mixed-backbone oligonucleotide infusion 
2.3.4.1 Effect of 7-day infusion on rat body weight 
Individual body weights were taken daily to determine the total body weight gain over 
the course of the study and collated to calculate the mean ± s. e. mean value for each 
treatment group (Figure 2.12). There was no significant difference between any of the 
treatment groups (P > 0.05). During the course of the study no animals required 
euthanasia, and infusion had no discernable effect on "normal" cage behaviour. 












Weight gain of rats given a7 day i. c. v. infusion of antisense to the HCN 2 transcript, mismatch 
oligonucleotide or vehicle (saline). Total weight gain was recorded for the 7 day infusion and I day 
baseline. Values represent means ± s. e. mean for 5 animals per group. Vehicle (. ), 0.4 pg/pl/h antisense 
(Q), 0.4 pg/pl/h mismatch (a), 4 pg/pl/h antisense ( ), or 4 pg/pl/h mismatch (`: ). 
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2.3.4.2 HCN2 and ß-actin in situ hybridisation 
A 7-day infusion of mixed backbone oligonucleotides significantly altered HCN2 and 
3-actin mRNA expression in a number of regions which were not confined to the 
unilateral hemisphere of surgery. However, this was not significant compared with both 
controls and cannot therefore be deemed a successful antisense effect. In the most 
rostral brain regions examined 0.4 µg/pl/h mismatch oligonucleotide infusion 
significantly increased HCN2 mRNA levels in the anterior cingulate cortex, rostral 
dorsal striatum and rostral ventral striatum of both hemispheres (P < 0.001). Infusion of 
4 µg/pl/h antisense and 4 pg/µl/h mismatch oligonucleotide also significantly increased 
HCN2 mRNA expression in the left cortex (P < 0.05). Therefore, the increase in HCN2 
expression observed in the left cortex following antisense administration cannot be 
considered to be significant as it only differs from vehicle and not mismatch infusion. 
Furthermore, 4 µg/pl/h antisense infused rats were also observed to significantly 
increase HCN2 mRNA in the right anterior cingulate cortex (P < 0.05). The only 
treatment to significantly alter the corresponding ß-actin mRNA expression was 
4 pg/µl/h mismatch oligonucleotide infusion, lowering expression in the left dorsal 
striatum and right ventral striatum (P < 0.05). No significant effect of oligonucleotide 
infusion was observed throughout the septum, thalamus or CA3 field of the 
hippocampus on either HCN2 or ß-actin mRNA expression, as there was considerable 
variation within each treatment group, especially beside the cannula tract (Figures 2.13 
- 2.20). ß-actin mRNA levels were significantly higher following 4 pg/µl/h mismatch 
oligonucleotide infusion compared with saline control in the left ventral hippocampal 
commissure (Figures 2.17 & 2.18). 
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Figure 2.13 Effect of vehicle, antisense or mismatch infusion 
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Data represent mean ± s. e. mean of three sections per animal (n =4- 5). Optical density readings have 
been converted to nCi/g of tissue. Treatment groups represented; Vehicle (. ), 0.4 pg/pl/h antisense (o), 
0.4 pg/µl/h mismatch (a), 4 pg/pl/h antisense () or 4 . tg/µ1/h mismatch One-way ANOVA with 
Student Newman Keuls post-hoc test was performed, *P<0.05 and *** P<0.001 compared with 
vehicle. Abb: Ant Cg ctx, anterior cingulate cortex, Rost DM Str, rostra] dorsomedial striatum, Rost VM 
Str, rostral ventromedial striatum (Paxinos et al., 1986). 
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Figure 2.14 Representative in situ hybridisation and haematoxylin and eosin images of vehicle, 





Comparison of in situ hybridisation autoradiographs utilising ["P] - labelled oligonucleotide probes 
targeted against HCN 2 mRNA (first column) and ß-actin mRNA (second column). Representative H& 
E stained sections (third column) are also shown for comparison (A = vehicle, B=0.4 mg/mI antisense, C 
= 0.4 mg/ml mismatch, D=4 mg/ml antisense and E=4 mg/ml mismatch). 
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Figure 2.15 Effect of vehicle, antisense or mismatch infusion on HCN2 and ß-actin mRNA 
expression (-- -0.8 mm relative to bregma) 
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Data represent mean ± s. c. mean of three sections per animal (n =4- 5). Optical density readings have 
been converted to nCi/g of tissue. Treatment groups represented; Vehicle (a), 0.4 µg/. tl/h antisense (o), 
0.4 pg/pl/h mismatch (a), 4 µg/. tIh antisense () or 4 µg/µ1/h mismatch O. One-way ANOVA with 
Student Newman Keuls post-hoc test was performed. Abb: Cg ctx, cingulate cortex, DM Str, 
dorsomedial striatum, VM Str, ventromedial striatum (Paxinos et al., 1986). 
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Figure 2.16 Representative in situ hybridisation and haematoxylin and eosin images of vehicle, 






Comparison of in situ hybridisation autoradiographs utilising ["P] - labelled oligonucleotide probes 
targeted against HCN 2 mRNA (first column) and 3-actin mRNA (second column). Representative H& 
E stained sections (third column) are also shown for comparison (A = vehicle, B=0.4 mg/ml antisense, C 
= 0.4 mg/ml mismatch, D=4 mg/ml antisense and E=4 mg/ml mismatch). 
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Figure 2.17 Effect of vehicle, antisense or mismatch infusion on HCN2 and ß-actin mRNA 
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Data represent mean ± s. e. mean of three sections per animal (n =4- 5). Optical density readings have 
been converted to nCi/g of tissue. Treatment groups represented; Vehicle (. ), 0.4 pg/pl/h antisense (Q), 
0.4 µg/pUh mismatch (a), 4 pg/µUh antisense () or 4 µg/pl/h mismatch ( ). One-way ANOVA with 
Student Newman Keuls post-hoc test was performed, *P<0.05. Abb: AD Thal, anterodorsal thalamus, 
AV Thal, anteroventral thalamus, Post Cg ctx, posterior cingulate cortex, Str, striatum, VHC, ventral 
hippocampal commissure (Paxinos et al., 1986). 
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Figure 2.18 Representative in situ hybridisation and haematoxylin and eosin images of vehicle, 
antisense and mismatch brain sections (- -1.5 mm relative to bregma) 
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Comparison of in situ hybridisation autoradiographs utilising [`P] - labelled oligonucleotide probes 
targeted against HCN 2 mRNA (first column) and ß-actin mRNA (second column). Representative H& 
E stained sections (third column) are also shown for comparison (A = vehicle, B=0.4 mg/ml antisense, C 
- 0.4 mg/ml mismatch, D=4 mg/ml antisense and E=4 mg/ml mismatch). 
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Figure 2.19 Effect of vehicle, antisense or mismatch infusion on HCN2 and ß-actin mRNA 
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Data represent mean ± s. e. mean of three sections per animal (n =4- 5). Optical density readings have 
been converted to nCi/g of tissue. Treatment groups represented; Vehicle (. ), 0.4 pg/pl/h antisense (Q), 
0.4 pg/pl/h mismatch O, 4 pg/pl/h antisense () or 4 µg/pl/h mismatch One-way ANOVA with 
Student Newman Keuls post-hoc test was performed. Abb: Thal, thalamus (Paxinos et al., 1986). 
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Figure 2.20 Representative in situ hybridisation and haematoxylin and eosin images of vehicle, 





! 'ýi   
Comparison of in situ hybridisation autoradiographs utilising ["P] - labelled oligonucleotide probes 
targeted against HCN 2 mRNA (first column) and ß-actin mRNA (second column). Representative H& 
E stained sections (third column) are also shown for comparison (A = vehicle, B=0.4 mg/ml antisense, C 
= 0.4 mg/ml mismatch, D=4 mg/ml antisense and E=4 mg/mI mismatch). 
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2.4 Discussion 
The present chapter has examined the effects of different antisense oligonucleotides, 
complementary to the HCN2 transcript, on [3H]-Org 34167 autoradiography, HCN2 
mRNA expression, as well as behavioural and physiological parameters, following 3- or 
7-day i. c. v. infusion. The aim of the experiments was to identify an antisense 
oligonucleotide, which when administered in vivo, down-regulated HCN2 protein 
expression. 
With no antibody available, at the time of study, to directly measure HCN 2 protein 
levels, optimisation of [3H]-Org 34167 autoradiography was attempted, as in vitro data 
suggest that this compound is a selective blocker of HCN channels (Ruigt, Personal 
communication). Optimisation of the Makkink et al., (Personal communication) [3H]- 
Org 34167 autoradiography protocol was performed with variation of the buffer, 
fixation and post-wash steps. Substantial variability was observed, not only between 
the different protocols attempted, but also for the same assay conditions (Tables 2.2 - 
2.5). The protocol which proved the most consistent and achieved a high level of 
specific binding (50 mM Tris-buffer; 10 nM [3H]-Org 34167; 3x1 min post-washes) 
was chosen to perform autoradiography on sections from the 3-day infusion of the 
initiation-targeted oligonucleotide. However, when this protocol was applied to the 
treated brain sections and exposed to tritium-sensitive film, negligible specific binding 
was achieved (Table 2.6 & Figure 2.3). This could have been as a result of the 
hyperfilm reaching saturation, because too high a concentration of [3H]-Org 34167 was 
employed. However, similar negligible binding was observed when the treated sections 
were exposed to film for less time (results not shown). The more likely explanation is 
that the tritiated ligand had broken down, or the substantial inter-assay variability makes 
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this ligand unsuitable for autoradiographical use. Therefore, with the failure of [3H]- 
Org 34167 to demonstrate HCN protein binding levels, and no available HCN2 
antibody, only in situ hybridisation to study HCN2 mRNA was available to study the 
effect of antisense administration. 
The studies, which employed an antisense oligonucleotide complementary to a region 
encompassing the initiation codon did not significantly alter mRNA expression. 
Despite the majority of early antisense experiments targeting this region, as this was 
believed to lead to the highest probability of success, it is now generally accepted that 
this is not the case (Smith et al., 2000). Furthermore, a number of reportedly successful 
antisense experiments in the literature are now believed to be the result of non-specific 
antisense action (Smith et al., 2000). There are two main reasons for this; firstly, 
sequences surrounding the initiation codon are more highly conserved than other 
regions (Crooke, 1999), which can result in non-specific interactions with non- 
homologous sequences, especially for GC-rich oligonucleotides (Lebedeva et al., 2000; 
Smith et al., 2000). Secondly, in targeting this region biologically active motifs within 
the sequence may be unavoidable (See Section 1.4.3); although this was not the case for 
any of the sequences investigated in this study. One of the newer backbone 
modifications, which have been utilised for antisense oligonucleotides, is the 
morpholino phosphorodiamidate. These oligonucleotides do not activate RNase H and 
achieve inhibition of translation only if targeted to a region incorporating the 5'-UTR 
through to 20 translated bases, solely via a steric mechanism (Nasevicius et al., 2000; 
Summerton, 1999). It is possible that in targeting a similar region that the main 
mechanism of action of the oligonucleotide targeted to the initiation codon could be 
steric hindrance of the ribosome. 
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Therefore, with no down-regulation of HCN2 mRNA observed following infusion of a 
sequence targeting the initiation codon, six new sequences were designed. It has been 
shown that roughly 1 in 8 to 1 in 10 antisense sequences are successful at inhibiting 
protein expression and the main reason for this low success rate is believed to be 
accessibility to the targeted mRNA (Amarzguioui et al., 2000; Milner et al., 1997; Slew 
Peng et al., 1998). A number of researchers have attempted to circumvent this problem 
by designing antisense oligonucleotides using secondary structure prediction computer 
modelling programs. However, these modelling programs are limited in their use, as 
the mechanism employed, calculation of global minimum free energy, returns numerous 
possible folds, especially for large sequences (see Section 1.4.2.2). 
Of the sequences designed using mfold, Sequence 6 was 100 % complementary to 
HCN1,2 and 4 transcripts, and when infused, severely altered rat physiological and 
behavioural functions. Indeed, the two rats administered with this antisense sequence 
demonstrated behaviours, including tremors, convulsions, weight loss and muscle 
wasting and were humanely killed. Similar behaviours (decreased movements and 
convulsions) have been observed previously when infusing mismatch oligonucleotides 
(Le Cone et al., 1997), which may account for them in the present study. Another 
possibility is that this sequence knocked down HCN 1,2 and 4 protein expression, 
which then lead to the observed behaviours. High doses of Org 34167 (> 0.5 mg/kg) 
also induce tremor and convulsions in rats, which are believed to be cerebellar in origin 
as they resemble harmaline-induced tremors and are linked to intentional movements 
(Blackburn-Munro et al., Personal communication). Sequences 1,2 and 4 were 
observed to elevate median daytime activity of rats compared with vehicle, while 
Sequences 1,3 and 4 were noted to decrease HCN 2 nnRNA in a number of brain 
regions analysed (Table 2.14). Furthermore, Sequence 4 infused rats were observed to 
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display the most consistent findings in the in situ hybridisation study. Sequences 2 and 
5 were discarded due to an increase in behavioural signs of toxicity (Table 2.13), as was 
Sequence 6 due to neither rat completing the 3-day infusion. Therefore, based on these 
observations Sequences 1 and 4 were chosen to perform an extended trial on. 
When the two sequences were subjected to a full-trial, with corresponding mismatch 
oligonucleotides, Sequence 1 again displayed a similar increase in total median rat 
behavioural activity, but there was also an increase in Mismatch 1 rat behavioural 
activity, suggesting this may be due to a non-specific mechanism (Figure 2.10). All 
oligonucleotides in this trial showed a trend towards an increase in total body weight, 
which was reflected in a similar trend in food and water intake during the 3-day infusion 
(Figures 2.8 & 2.9). This suggests a non-specific action of oligonucleotide infusion is 
to increase water intake, and it has previously been shown that oligonucleotide infusion 
caused a non-sequence-dependent suppression of food and water intake (Schobitz et al., 
1997). The authors hypothesised that the mechanism for the decreased food, water and 
locomotor parameters may be a direct result of modified nucleic acid administration, or 
indirectly via degradation products. However, phosphorothioate oligonucleotides have 
been demonstrated to cause brain inflammation and tissue damage, via granulocyte and 
macrophage entry into the parenchyma (Elepfandt et al., 2002). This activation of the 
immune system by oligonucleotide infusion may provide an alternative explanation for 
the alteration in food and water intake. Furthermore, administration of a mismatch 
oligonucleotide (to an a2, vo phosphorothioate antisense oligonucleotide) has been 
demonstrated to increase daily water intake (Robinson, Personal communication). 
Histological staining of the 3-day i. c. v. infusion of Sequence 1 and 4 treated brain 
sections revealed significant tissue damage, especially in regions close to the cannula 
106 
Chapter 2 Antisense approaches to the HCN channel 
tract. Similar damage to the brain has been reported previously following infusion of 
phosphorothioate oligonucleotides (Broberger et al., 2000), which is mainly as a result 
of the incorporation of the sulphur atoms in the backbone to protect the oligonucleotide 
from degradation by nucleases. Therefore, no quantification of HCN2 or ß-actin 
mRNA expression was performed because of the toxicological damage incurred 
following the infusion of the oligonucleotides (similar damage was observed in the 
mismatch control rats). This tissue damage may also explain the non-specific elevation 
of water intake. 
A mixed backbone oligonucleotide infusion was used in an attempted to decrease the 
toxicity observed following oligonucleotide infusion, via reduction of their sulphur 
content. Sequence 1 was chosen for this trial due to the increase in rat behavioural 
activity observed in both the preliminary mfold study (Figure 2.7) and the full-trial 
(Figure 2.10). There was no significant alteration of HCN2 mRNA expression 
following 7-day antisense oligonucleotide infusion compared with both vehicle- and 
mismatch administration. Only the higher concentration of antisense (4 µg/pl/h) 
resulted in a significant change, an increase in HCN2 mRNA expression compared with 
vehicle, in the rostral left anterior cingulate cortex (P < 0.05, Figure 2.13). However, 
this cannot be considered a specific antisense effect as both concentrations of mismatch 
oligonucleotide (0.4- and 4-µg/. tUh) were observed to increase mRNA levels in this 
brain region (P < 0.001, Figures 2.13 & 2.14) and there was no significant difference 
compared with antisense administration. This may have been a result of tissue damage 
in the cingulate cortex by the cannula. Therefore, the antisense sequences administered 
did not result in a significant alteration in HCN 2 mRNA expression compared with 
both vehicle and mismatch treatment. 
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The second aim of lowering toxicity of oligonucleotide infusion by reducing the sulphur 
content of the oligonucleotides was achieved, as has been shown throughout the 
literature (Agrawal et al., 1997b; Sands et al., 1995). Comparison of the histology 
between the corresponding brain regions of the fully-modified oligonucleotides and the 
mixed-backbone oligonucleotides infusions reveals less toxic damage of the brain 
regions surrounding the lateral ventricle (Figure 2.11,2.16,2.18 & 2.20). Additionally, 
the fact that there was little significant alteration in the housekeeping gene, ß-actin, 
which was employed as a control gene, suggests that the toxicity was decreased. There 
were a number of brain regions where expression of the housekeeping gene (3-actin's 
mRNA was increased following infusion of the higher concentration of mismatch 
oligonucleotide (4 pgtpl/h) but the only region this reached significance was the ventral 
hippocampal commissure (P < 0.05; Figure 2.17). However, there was considerable 
variation within each treatment group, especially in regions close to the cannula tract 
(see Figures 2.13 - 2.20), It has previously been demonstrated that cells within 200 pm 
of the cannula tract are heavily labelled with fluorescent oligonucleotide (Grzanna et al., 
1998), which may explain some of the variation in ß-actin mRNA levels. The 
haematoxylin and eosin staining demonstrates an increased number of nuclei around the 
cannula tract, which may be due to the damaged tissue resulting in an immune response. 
This increase in cells may therefore be the cause of the variation and increase in ß-actin 
mRNA observed. Additionally, the histological evidence showing damage incurred 
when implanting the cannula may be responsible for the variation in the activation of 0- 
actin mRNA, as some surgery may have involved more extraneous movement of the 
cannula. 
The fact that there was no significant alteration of HCN2 mRNA expression does not 
necessarily lead to the conclusion that there was no antisense-mediated down-regulation 
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of HCN2 protein. Despite examples in the literature of successful antisense sequences 
down-regulating the target mRNA expression (see Table 2.15) there are also numerous 
reports of successful down-regulation of the target protein without a corresponding 
affect on the mRNA expression (see Table 2.15). All the examples in Table 2.15 use 
phosphodiester or phosphorothioate oligonucleotides, similar to those used in the 
present study, which are believed to mediate their antisense effect through two main 
mechanisms; RNase H activation and steric hindrance of the ribosome (see Section 
1.4.2). There are a number of possible explanations for not observing a down- 
regulation of target mRNA expression. Firstly, and most likely, is that none of the 
sequences employed resulted in successful antisense-mediated down-regulation of 
HCN2 protein expression. This could not be confirmed at the time of study because of 
the lack of a specific antibody and the failure of [3H]-Org 34167 autoradiography to 
provide meaningful results. The main obstruction for antisense therapeutics has been to 
overcome the problem of targeting an accessible site on the mRNA, which is devoid of 
secondary and tertiary structure (or at least displays minimal folding). This is believed 
to be the main reason why only -- 1 in 10 sequences are successful. Despite a number of 
the current sequences being designed with the aid of the computer modelling program 
mfold (http: l/bioinfo. math. rpi. edu/--mfold/rna/) to target a region of the mRNA which 
was predicted to be predominantly single-stranded, in the optimal folds, these prediction 
programs are limited in predicting accurately, especially for large sequences. 
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Table 2.15 Literature examples of antisense oligonucleotide administration on mRNA and protein 
levels 
EFFECT ON GENE EXPRESSION 
TARGET OLIGOIS'UCLEOTIDE REFERENCE 
mRNA Protein 
Phosphodiester 18 mer (Wahlestcdt et 
NMDA-R1 No change 1 35 % 
i. c. v. 80 Ng x 4/2d al., 1993) 
1 64 % in 
Phosphorothioate 16 mer Superior cervical (Zang et al., 
m1 mACh 140% 
5 µg/µl/h 3d ganglia cells (not 1994) 
done in vivo) 
Phosphodiester 18 mer (Kathmann et al., 
CB1 No change 135 % 
IOnM x 2/3d 1999) 
Phosphorothioate 20 mer (Zhou et al., 
D2 120% 115% 
16 µg i. c. v 9d 1994) 
Phosphodiester 20 mer 2 (Kolesnikov et 
nNOS-1 160% n. d. 
µl i. c. v al., 1997) 
Phosphodiester 20 mer 2 (Kolesnikov et 
nNOS-2 175% n. d. 
µl i. c. v. al., 1997) 
Abb: CBI, cannabinoid-1 receptor. D2, Dopaminc2-receptor. m, muscarinic. nNOS, neuronal nitric oxide 
synthase. n. d. = not defined. 
Alternatively, it may be that these oligonucleotides' main mechanism of action is via 
steric hindrance, which would prevent translation but not cause a corresponding 
degradation of the mRNA by RNase H. This theory is supported by the fact that 
backbone modifications, including locked nucleic acids (Kurreck et at., 2002) and 2'-O- 
methoxyethyl (Baker et al., 1997) have been demonstrated to achieve down-regulation 
of the target protein but do not activate RNase H and therefore do not alter mRNA 
expression. The oligonucleotides may act by preventing transportation of the target 
mRNA, which similarly would prevent translation (Alama et al., 1997). There may be a 
compensatory up-regulation of mRNA as a consequence of increased turnover of 
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mRNA due to digestion by RNase H and a decrease of protein levels although there is 
no evidence in the literature to support this. Another possible reason for detecting no 
change in HCN2 mRNA expression in any of the current studies is that the 
concentration of antisense oligonucleotide was not sufficient. As can be seen in Table 
2.15 a wide range of concentrations have been used to successfully down-regulate the 
target protein. This is believed to relate to each individual sequence, backbone 
modifications and accessibility to the targeted region of the mRNA (see Crooke, (1999) 
for a review). A behavioural assay can be performed to assess for an antisense- 
mediated down-regulation of the target gene (Robinson et al., 2000). However, there 
were no such assays available at the time of study. Electrophysiological recording of 
the properties of the HCN channel, in either brain slices or human HCN2 cell lines 
could have been performed after in vitro or in vivo administration of antisense 
oligonucleotide but there was no opportunity to perform such an experiment. The final 
option to assess for a specific antisense-effect is by performing an agonist-induced 
behavioural response (Robinson et al., 2000). At the time of writing there are no 
available compounds for the HCN channel with which to perform such an experiment. 
In conclusion the antisense oligonucleotides used in the present studies, despite the 
majority of sequences being designed with the aid of a secondary structure prediction 
program, were not observed to alter HCN2 mRNA expression in vivo. The use of an 
end-modified oligonucleotide resulted in a lower degree of toxicity. This is apparent 
from the histological images of the brain sections compared with the corresponding 
fully-modified oligonucleotides, as has been demonstrated throughout the literature. A 
successful antisense action cannot presently be completely rejected, as direct 
measurement of HCN2 protein expression has not been performed, or a behavioural 
assay examined, neither of which could be attempted at the time of study. 
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Chapter 3 Comparison of Org 34167 induced changes in c-fos 
expression to that of known antidepressants 
3.1 Introduction 
In the late 1980s, it was discovered that the Fos-oncogene, isolated from the Finkel- 
Biskis-Jinkins murine sarcoma virus (Curran et al., 1982) was derived from a normal 
cellular gene (Sagar et al., 1988). There are a now a number of similar genes identified; 
of which the Fos-, Jun- and Egr- families are the most extensively studied (Beckmann et 
al., 1997; Cochran et al., 2002). These products are classed as immediate early genes 
(IEG; Herdegen et al., 1998; Hoffman et al., 2002), or inducible transcription factors 
(ITF; Herdegen et al., 1998); although not all IEGs function as transcription factors. 
Currently, four protein members of the Fos-family have been identified; c-Fos, FosB, 
Fra-1 and Fra-2 (Cohen et al., 1990; Greenberg et al., 1984; Nishina et al., 1990; Zerial 
et al., 1989). 
IEGs are so called due to their rapid expression in the absence of new protein synthesis, 
governed by pre-existing, constitutive transcription factors (Herdegen et al., 1998). 
Therefore, lEG induction, in response to a stimulus, represents one of the earliest 
cellular effects, and can be detected using in situ hybridisation (Ziolkowska et al., 2002) 
or immunohistochemistry (Dragunow et al., 1989). c-Fos protein, following 
dimerisation with a member of the Jun-family (c-Jun, JunB or JunD) form Activator 
protein (AP)-1, which binds to consensus DNA sequences to enhance or repress 
transcription (Herdegen et al., 1998). This protein dimer also controls the expression of 
IEGs, which are synthesised in the cytoplasm and translocated to the nucleus (Herrera et 
al., 1996). 
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Under basal conditions c-fos mRNA and protein expression are very low, displaying a 
widespread, but not ubiquitous, distribution. However, they are rapidly induced 
following a variety of stimuli (see Figure 3.1; Herrera et al., 1996; Hoffman et al., 
2002). It is generally believed that Fos-induction can be considered to reflect neuronal 
activity due to it's function of controlling gene transcription (Chaudhuri, 1997; 
Dragunow et al., 1989; Herrera et al., 1996; Hoffman et al., 2002). These properties 
have rendered Fos the most commonly utilised IEG for mapping neuronal activity. The 
pathways which lead to the activation of c-Fos are the best studied of the IEGs; with 
three main regulatory sites present on the protein (See Figure 3.1). A calcium response 
element (CRE) is activated via phosphorylation of CREB by cAMP, PKA, or Ca 2+ entry 
(Herrera et al., 1996; Sheng et al., 1990). This appears to be the dominant pathway of 
c-fos activation, as NMDA-receptor antagonists prevent Ca2+ entry in to the cell and 
also prevent the induction of c-fos (Ziolkowska et al., 2002). Growth factors and 
cytokines, via mitogen activated protein (MAP) kinases and Janus protein kinases 
(JAK), also lead to the induction of c-fos through serum-response factors and the signal 
transducer and activator of transcription (STAT) on tyrosine kinases respectively 
(Herrera et al., 1996; Pennypacker, 1998). It is the presence of these different 
promoters on c-Fos, which makes it an ideal gene to study neuronal activation, as a 
wide variety of stimuli lead to alteration of the regulatory pathways. Induction of c-Fos 
is not simply related to cellular activity as a number of studies have demonstrated that 
alterations in Fos expression are not related to depolarisation but changes in second 
messenger systems caused by drug administration (Young et al., 1991). 
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Figure 3.1 Major induction pathways of c-fos 
Adapted from Hoffman & Lyo (2002) and Pennypacker (1998). Abb: AC, adenylyl cyclase, cAMP, 3' 5' 
monophosphate, CaM, calcium calmodulin, JAK, Janus activated protein, MAP, mitogen activated 
protein, SRF, serum response factor, SRE, serum response element, CRE, calcium response element, 
STAT, signal transducer and activator of transcription. 
The ability to utilise IEGs as markers of neuronal activity has been used to study both 
acute and chronic antidepressant administration (although the latter is normally 
followed by an acute challenge), and a number of animal models of depression (see 
Discussion). In the majority of these studies, only a few brain regions have been 
examined for Fos alterations, which does not enable the different classes of 
antidepressant to be compared with Fos neuronal activity throughout the CNS. 
Additionally, many of these studies have focussed on similar brain regions, for example 
Beck (1995) demonstrated that the central amygdala was activated by all 
antidepressants studied; fluoxetine (10 and 15 mg/kg, i. p. ), desipramine (TCA inhibits 
NA reuptake and 5-HT to a lesser extent; 10 mg/kg, i. p. ), bupropion (inhibits mainly 
DA reuptake; 20 mg/kg, i. p. ), tranylcypromine (monoamine oxidase inhibitor, 7.5 
mg/kg), nortriptyline (TCA, inhibits NA reuptake; 15 mg/kg, i. p), imipramine (20 
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mg/kg, i. p. ) and citalopram (SSRI; 5 mg/kg, i. p. ), findings repeated by Ducan et at., 
(1996), Morinobu et al., (1997) and Tones et al., (1998). Therefore, it would appear 
that classes of compound may cause similar, although not identical, induction of c-fos in 
several brain regions. This knowledge can therefore be utilised to study novel 
compounds to determine whether they possess a similar IEG profile as drugs already in 
clinical use. Therefore, as Org 34167 is currently undergoing clinical trials as an 
antidepressant, it is possible to determine whether acute administration induces c-fos 
expression in similar brain regions to other classes of antidepressant. This could, in 
turn, provide useful information regarding the brain regions targeted by antidepressants 
and whether different drugs acutely affect similar brain areas. 
There are a number of considerations to be taken in to account when using c-Fos as a 
neuronal activity marker. The major drawback is that in some brain regions Fos is not 
basally expressed, while in others studies have shown that a wide variety of stimuli do 
not induce the gene above basal (Chaudhuri, 1997; Labiner et al., 1993). The substantia 
nigra is one such region in which few stimuli in rodents induce c-fos (Dragunow et al., 
1989; Labiner et al., 1993). Therefore, this may be the case in other brain regions, 
which implies that a lack of Fos induction need not necessarily mean a lack of neuronal 
activity. Another consideration in the use of IEGs for neuronal activity mapping is the 
transient nature of their expression. Time-course studies have shown that c-fos mRNA 
is rapidly activated, within 30 - 60 min of an acute challenge with fluoxetine (Torres et 
al., 1998), or light stimulation (Zangenehpour et al., 2002). Protein levels of c-fos reach 
a peak 2-6h after the stimulus, by which time mRNA expression has returned to 
baseline (Torres et al., 1998; Zangenehpour et al., 2002). The protein expression 
returns to baseline within 24 h following the acute stimulus (Zangenehpour et al., 
2002). A problem with the present study is that the rat brain does not necessarily reflect 
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the situation in human (Ongur et al., 2000). Although chronic antidepressant 
administration is required to be clinically beneficial it is possible using c-fos neuronal 
mapping, to demonstrate which brain regions are activated following an acute injection. 
Due to the role of c-fos in activating or repressing gene translation, this immediate early 
gene marker can be considered to reflect, to a certain degree, long-term changes in 
cellular phenotype. 
The rationale for the present study was to examine the c-fos mRNA expression of Org 
34167 and to compare it with a number of different classes of antidepressants and a 
mood stabiliser. Fluoxetine, imipramine and lithium (LiCI) were chosen due to the 
already existing extensive literature concerning their c-fos induction profile, while 
mirtazapine was included to provide proof of concept, as there were no previous reports 
examining this novel antidepressant. Furthermore, as previous literature suggests that 
the central amygdala is a common site of antidepressant action, the current study aimed 
to assess this area plus a number of other brain regions associated with depression to 
determine whether there are additional sites of common acute antidepressant action. 
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3.2 Materials and methods 
3.2.1 Animals and experimental procedure 
Adult male Sprague-Dawley rats (Harlan Olac, U. K. ) weighing 200 - 250 g were 
housed in groups of 6 on a 12 h light/dark cycle (lights on at 06: 00 h) at 22 ±2 °C for 7 
days with access to standard rat diet and tap water ad libitum. Previous studies have 
demonstrated that habituation to handling, prior to the acute stimulus, reduces non- 
specific background levels of c-fos mRNA (Hess et al., 1995). Therefore, on each day 
the rats were handled for 5 min and weighed to minimise handling stress. 
Animals received a single intraperitonal injection of vehicle (5 % mulgofen in 0.9 % 
saline), LiCI (75 mg/kg), mirtazapine (2 mg/kg), fluoxetine (5 mg/kg), imipramine (15 
mg/kg) or Org34167 (0.5 mg/kg), n=6 for each treatment group. All drugs were 
dissolved in a5% mulgofen, 0.9 % saline solution, and administered at 1 mg/kg. 
Following the injection the rats were returned to their home-cage for 45 min. Injection 
of the groups was staggered between 09: 30 - 12: 00 h in order to maintain a 45 min 
sacrifice time post-injection. Rats were sacrificed in a C02-chamber, at a flow-rate of 6 
1/min then decapitated using a guillotine. The brains were carefully removed using 
scissors to cut away the skull, placed on a slide (Suprafrost Plus, VWR formally BDH) 
and then snap frozen in isopentane cooled on dry-ice to -32 °C. The brains were then 
stored at -80 °C until required for cryostat sectioning. The Org 34167 dose was selected 
based on previous behaviourally-active concentrations (see Table 1.1) while the 
antidepressant doses were chosen to reflect those used in previous literature c-fos 
reports (Beck, 1995; Dahmen et al., 1997; Morinobu et al., 1997; Torres et al., 1998). 
The LiCI dose was chosen to reflect the dose, which has been demonstrated to be the 
lowest active dose in the conditioned taste aversion paradigm (Spencer et al., 2001). 
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3.2.2 Cryostat-sectioning 
The brains were removed from -80 °C freezer and allowed to thaw to -18 ±2 °C inside 
a Bright OTF cryostat for 30 min before mounting on to a Bright orientating specimen 
holder with Cryo-M-bed (Bright Ltd., U. K. ). Once solidly mounted, the chuck was 
attached to the microtome, with the blade aligned at an angle of 15 ° and set to collect 
sections of 20 pm. Sections were thaw-mounted on to Superfrost Plus electro-statically 
charged nuclease-free slides (VWR, formally BDH, UK) in 7 series of 13 slides, with 3 
sections per slide. The series were chosen to maximise the number of brain areas, 
which have been implicated in depression (See Table 3.1) 
Identification of sections was performed with the aid of a rat brain atlas (Paxinos et al., 
1986) and also by collecting sections and performing histological staining at routine 
intervals. The staining comprised 1 min in 100 % ethanol, followed by 1 min in Gills 
No 2 haematoxylin solution (BDH) and a final dip rinse in distilled water. These two 
control procedures enabled accurate and consistent sectioning to be maintained 
throughout each of the brains. The slides were stored at -80 °C until required for in situ 
hybridisation. 
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Table 3.1 Brain co-ordinates of sections collected for c-fos study and brain regions analysed. 
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3.2.3 c-fos in situ hybridisation 
In situ hybridisation was performed as described in Section 2.2. utilising the two 
complementary probes to the c-fos transcript (see Appendix B for probe details) both at 
a final concentration of 2 pmol. Specificity of the probe was assessed as described in 
Section 2.2. (see Appendix C for autoradiograms) and the results analysed as described 
in Section 2.2. 
3.2.4 Acetylcholinesterase activity 
In order to assist histological verification of the brain regions analysed, sites of 
acetylcholinesterase activity were examined. Untreated cryostat sections were removed 
from the -80 °C freezer and thawed to room temperature for 1h before use. While the 
slides were thawing 0.1 M acetate buffer (pH 6.0) and acetylcholinesterase incubating 
medium (see Appendix A) were prepared immediately before use. Ethopropazine, as a 
butyrylcholinesterase inhibitor, ensured that only acetylcholinesterase sites were 
demonstrated. The slides were then incubated in the acetylcholinesterase medium for 
2h at room temperature in the dark (wrapped in tinfoil) then washed in dH2O for 1 min. 
The sections were then subjected to a1% ammonium sulphide solution (prepared in 
dH2O) for 1 min, to visualise the sites of acetylcholinesterase activity. The slides were 
then rinsed in several dH2O incubations and allowed to air-dry. Once dry the sections 
were dehydrated and cleared by incubating in 100 % acetone (BDH) for 2 min, 50 % 
acetone : 50 % xylene solution for 2 min and finally via two separate 2 min 100 % 
xylene washes. The method was modified from Bancroft and Stevens (1996). 
Control reactions were performed as described above, but with the omission of the 
substrate, acetylthiocholine iodide, from the incubating medium. 
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3.2.5 Statistical analyses 
Data for each region of interest were analysed by One-way analysis of variance 
followed by Student Newman-Keuls post-hoc multiple comparison test. Significance 
was assigned when P<0.05 and performed using GraphPad Prism v3.02 (GraphPad 
Software Inc). Due to the number of comparisons performed all the statistical 
significance is reported as P<0.05, even if the value was lower, for simplicity. 
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3.3 Results 
3.3.1 Effect of treatment on c-fos mRNA expression 
In situ hybridisation utilising two probes complementary to the rat c-fos transcript 
following acute antidepressant administration demonstrate differing expression profiles 
for each treatment group. In vehicle-treated animals a low level of c-fos mRNA 
expression was observed throughout the rostrocaudal extent of the rat brain as 
previously described (Cochran et al., 2002; Dragunow et at., 1989; Hoffman et al., 
2002). Each of the different drug-treatment groups displayed different regulation of c- 
fos mRNA expression, with both increased and decreased levels compared with all other 
treatment groups observed. The alteration of c-fos mRNA following acute drug 
administration is discussed by brain region relative to bregma below. 
3.3.2 Effect of treatment on c-fos mRNA (4.7 to 4 mm relative to bregma) 
Forty-five minutes following acute administration of Org 34167 (0.5 mg/kg) a 
significant increase, compared with vehicle, imipramine, mirtazapine, LiCI and 
fluoxetine in c-fos expression was observed in the anterior secondary motor cortex 
(P < 0.05; Figure 3.2 and Table 3.2). LiCI also increased c-fos expression compared 
with vehicle and fluoxetine (P < 0.05). Ventromedial orbital cortex c-fos mRNA levels 
were significantly elevated by fluoxetine administration compared with all other 
treatment groups (P < 0.05; Figure 3.2 and Table 3.2). No significant differences were 
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Figure 3.2 Representative autoradiograms of acute drug administration on c-fos mRNA expression 
(4.7 to 4 mm relative to bregma) 
A B 
F 
Representative autoradiographs of in situ hybridisation utilising 
33P-labelled oligonucleotide probes 
targeted against the c-fos transcript in coronal sections of rat brain following 45 min acute administration 
of vehicle (A), Org 34167 (0.5 mg/kg, B), imipramine (15 mg/kg, 
C), mirtazapine (2 mg/kg, D), LiCI 
(75mg/kg, E) or fluoxetine (5mg/kg, F). Also shown is a schematic representation of the brain regions 
analysed. Abb: M2, anterior secondary motor cortex, PrL, prelimbic cortex, VM Orb, ventro-medial 
orbital cortex, Ant. olfact nuc, anterior olfactory nucleus (Paxinos et al., 1986). 
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3.3.3 Effect of treatment on c-fos mRNA (2.2 to 1.5 mm relative to bregma) 
A significant decrease in c-fos expression was observed following acute administration 
of all drugs compared with vehicle-treatment in the septum (P < 0.05) and all drugs 
increased c-fos mRNA in the anterior insular cortex (P < 0.05). No significant 
differences between any of the other treatment groups were observed in either brain 
region. Imipramine-, LiCl- and fluoxetine-treated animals displayed a significant 
decrease in mRNA expression compared with the vehicle group in the anterior piriform 
cortex (P < 0.05). Increased levels of c-fos mRNA were observed in the anterior 
cingulate cortex, rostral dorsomedial- and dorsolateral striatum in the fluoxetine-treated 
group compared with all other treatments, except mirtazapine treatment in the rostral 
dorsomedial striatum (P < 0.05). Additionally, in the rostral ventromedial striatum, 
fluoxetine-treatment induced c-fos mRNA expression compared with vehicle- and 
mirtazapine groups (P < 0.05). In the nucleus accumbens shell region, mirtazapine-, 
LiCl- and fluoxetine-treatment induced almost a doubling of c-fos mRNA levels 
compared with vehicle-, Org 34167- and imipramine-administration (P < 0.05). Similar 
observations were demonstrated in the nucleus accumbens core, where mirtazapine-, 
LiCl- and fluoxetine-treatment increased c-fos mRNA expression compared with the 
vehicle control group. Mirtazapine-treatment also increased c-fos mRNA compared 
with Org 34167 and imipramine administration (P < 0.05). All the results are displayed 
































+1 +I +1 +1 +1 +1 +I +1 +1 +1 +1 
C n N °O N 
.ý 














J O N . -- 
N ^ ^ N , _, O 
N 
+1 +I ++ +i +1 +I +I +I, tl +I +I 
wl q 
000 0 0ý0 






























+i +1 +I -H +1 +I +I ++ +I +I +I 









4 N - 
.4 










y ,_ vi N 0 0 ^ 
O ^ 












[ý O r1 
E 
ý 
M N ý v O 00 00 
ý 
ýp yj r ýc C, j r. . -- . 
p 
G7 +1 +I +1 +I -H +1 +I +1 +I +1 +1 
O 
cC0 'I; 










ý Lrý N C T N O O O ^ ý 
ý ^ 
C 







+i +1 +1 +I +4 +I -H +1 +I +1 +1 
0C OC OC OC 
W-, 





ý ^ t, a OC 
Z 





^ O N 









ý ý «r ý .r ý 
.r ý 




















on b- ° \M 












-ýi ý ý 
ý U 
a 














Chapter 3 Acute antidepressant administration effect on c fos mRNA 
Figure 3.3 Representative autoradiograms of acute drug administration on c fos mRNA expression 
(2.2 to 1.5 mm relative to bregma) 
A 
Representative autoradiographs of in situ hybridisation utilising 33P-labelled oligonucleotide probes 
targeted against the c-fos transcript in coronal sections of rat brain following 45 min acute administration 
of vehicle (A), Org 34167 (0.5 mg/kg, B), imipramine (15 mg/kg, C), mirtazapine (2 mg/kg, D), LiCI 
(75mg/kg, E) or fluoxetine (5mg/kg, F). Also shown is a schematic representation of the brain regions 
analysed. Abb: Sep, septum, Cg, anterior cingulate cortex, Ins ctx, anterior insular cortex, Pir, anterior 
piriform cortex, DM Str, rostral dorsomedial striatum, DL Str, rostra] dorsolateral striatum, VM Str, 
rostral ventromedial striatum, VL Str, rostra] ventrolateral striatum, AcbC, nucleus acumens core, AcbSh, 
nucleus accumbens shell (Paxinos et al., 1986). 
3.3.4 Effect of treatment on c-fos mRNA (-0.8 to -1.5 mm relative to bregma) 
In this more caudal region of the insular cortex a significant increase in c-fos mRNA 
expression was observed following all drug treatments (P < 0.05) except that of 
fluoxetine. Additionally, the induction of c-fos mRNA following Org 34167- 
administration was statistically greater than all other drug groups (P < 0.05). In every 
cortical region examined Org 34167-treated animals displayed a marked elevation of c- 
fos mRNA compared with all other treatment groups, with two exceptions. No 
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induction of c-fos was observed in the piriform cortex, and both fluoxetine and Org 
34167-treatment increased expression in the caudal secondary motor cortex, compared 
with the other four treatment groups (P < 0.05). Down-regulation of c-fos mRNA was 
observed following LiCI and Org 34167 administration in the piriform cortex compared 
with fluoxetine-treatment (P < 0.05). Relative to vehicle, down-regulation induced by 
LiCI was significant but although Org 34167 decreased c-fos this did not reach 
significance. There was no significant alteration of c-fos mRNA expression in the 
anterior paraventricular thalamic nucleus, or in the bed nucleus of the stria terminalis 
between any of the treatment groups. Similar to the observations in the rostral 
dorsomedial- and dorsolateral-striatum (Table 3.4), fluoxetine-treatment in the more 
caudal part of these regions induced c-fos expression compared with all other treatment 
groups (P < 0.05; Figure 3.4 & Table 3.4). These findings agree with previous reports 
of 10 mg/kg fluoxetine-treatment elevating c-fos in neurones of the caudate putamen, 
mainly close to the lateral ventricle (Torres et al., 1998). In the caudal ventral striatum 
a marked induction of c-fos expression was observed following Org 34167-treament 
compared with all other groups; with the most robust being a four-fold increase over 
vehicle and fluoxetine-treatment (P < 0.05). Imipramine-, mirtazapine- and LiCI- 
administration also up-regulated c-fos levels in the caudal ventral striatum compared 
with the saline controls (P < 0.05). All treatment groups were observed to decrease c- 
fos expression in the nucleus of the lateral olfactory tract compared with vehicle-treated 
animals (P < 0.05). The most robust increase in c-fos expression was observed in the 
supraoptic nucleus where LiCI induced a ten-fold elevation compared with saline- 
treatment and a five-fold increase compared with all other treatment groups (P < 0.05; 
Figure 3.4; Table 3.4). A previous study reported that fluoxetine caused a significant 
increase in c-Fos-like immunoreactivity (FLI) in this region (Tones et al., 1998) and 
despite the mean values in the present study being two-fold greater for the fluoxetine- 
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treatment group this was not significant. There was a trend towards a down-regulation 
of c-fos in the suprachiasmatic nucleus in all treatment groups in comparison with saline 
controls, which reached significance for Org 34167-, mirtazapine-, and fluoxetine 
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Figure 3.4 Representative autoradiograms of acute drug administration on c fos mRNA expression 
(-0.8 to -1.5 mm relative to bregma) 
ABC D 
Bregma - L30 mm 
Representative autoradiographs of in situ hybridisation utilising 
33P-labelled oligonucleotide probes 
targeted against the c-fos transcript in coronal sections of rat brain following 45 min acute administration 
of vehicle (A), Org 34167 (0.5 mg/kg, B), imipramine (15 mg/kg, C), mirtazapine (2 mg/kg, D), LiCI 
(75mg/kg, E) or fluoxetine (5mg/kg, F). Also shown is a schematic representation of the brain regions 
analysed. Abb: Cg, posterior cingulate cortex, M2, posterior secondary motor cortex, SI BF, primary 
somatosensory cortex, barrel field, S2, anterior secondary somatosensory cortex, Ins ctx, insular cortex, 
Pir, piriform cortex, Pv, anterior paraventricular thalamic nucleus, DM Str, caudal dorsomedial striatum, 
DL Str, caudal dorsolateral striatum, V Str, caudal ventral striatum, LOT, nucleus of the lateral olfactory 
tract, BSTMPL, nucleus of the stria terminalis, medial division, posterolateral part, SON, supra-optic 
nucleus, S, suprachiasmatic nucleus (Paxinos et al., 1986). 
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3.3.5 Effect of treatment on c-fos mRNA (-2.5 to -3.2 mm relative to bregma) 
Brain regions within these bregma co-ordinates represent the area where most previous 
studies have focussed, particularly the central amygdaloid complex. These studies 
suggest that a common feature of all antidepressant compounds tested to date, including 
fluoxetine (10 and 15 mg/kg, i. p. ), desipramine (10 mg/kg, i. p. ), bupropion (20 mg/kg, 
i. p. ), nortriptyline (15 mg/kg, i. p), imipramine (20 mg/kg, i. p. ) and citalopram (5 mg/kg, 
i. p. ) is to induce an increase in c-fos or c-Fos expression in the central amygdala (Beck, 
1995; Morinobu et al., 1997; Torres et al., 1998). Similar findings were observed in the 
current study where every treatment group induced c-fos expression in the central 
amygdala compared with vehicle (P < 0.05; Figure 3.6; Table 3.5). Histological 
verification of the amygdaloid region was performed by overlaying a c-fos 
autoradiogram image with that of a serial acetylcholinesterase stained section (Figure 
3.5). 
Similar to the more rostral regions analysed, Org 34167-treatment elevated c-fos mRNA 
levels in all cortical regions analysed with the exception of the piriform cortex were no 
difference was observed between any treatment group (P < 0.05; Figure 3.6; Table 3.5). 
The most robust increase in c-fos was observed in the anterior retrosplenial cortex, 
where Org 34167 administration induced a two-fold increase in c-fos compared with all 
other treatments (P < 0.05). An increase in mRNA expression was also seen in the 
caudal secondary somatosensory cortex compared with all other treatments (P < 0.05). 
In the same region, a down-regulation was also observed following mirtazapine and 
LiCI treatment compared with vehicle and fluoxetine administration (P < 0.05). Acute 
administration of mirtazapine and LiCI also caused a down-regulation of c-fos in the 
primary somatosensory cortex compared with imipramine and fluoxetine, as well as Org 
34167 treatment (P < 0.05). Similar to Org 34167, imipramine-treatment elevated c-fos 
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expression in the caudal insular cortex compared with vehicle, mirtazapine and LiCI but 
not fluoxetine (P < 0.05). LiCI was demonstrated to down-regulate c-fos compared with 
fluoxetine in this region (P < 0.05). In the rostral CAI, CA2 and dentate gyrus regions 
of the hippocampus, Org 34167-treated animals displayed an up-regulation of c-fos 
mRNA expression compared with all other groups, with the exception of fluoxetine in 
the dentate gyrus (P < 0.05). In the rostral CA3 field of the hippocampus Org 34167 
treatment induced an increase of c-fos mRNA compared with mirtazapine-, LiC1- and 
fluoxetine-treated animals (P < 0.05). The level of c-fos expression in the thalamus 
produced the most varied results; Org 34167-treatment induced an increase compared 
with vehicle, mirtazapine-, LiCI- and fluoxetine-administration resulted in a 
downregulation of c-fos compared with both vehicle and Org 34167 groups (P < 0.05). 
Imipramine treatment, despite showing no significant difference from the saline-control 
group, demonstrated a decrease in c-fos response compared with Org 34167 but an 
increase compared with mirtazapine- and LiCI-treatment (P < 0.05). 
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Figure 3.5 Representative c fos autoradiographic, acetylcholinesterase and overlaid images 








Representative c-fos autoradiographs of vehicle (A), Org 34167 (B), imipramine (C), mirtazapine (D), 
LiCI (E) or fluoxetine (F). Corresponding acetylcholinesterase images (A' - F) and overlaid images 
(A" - F"). The acetylcholinesterase staining enables 
delineation between the central amygaloid nucleus 
(CeA) and basolateral amygaloid nucleus (BIA), which when overlaid with the autoradiograms shows the 
CeA as the site of cfos induction. 
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Figure 3.6 Representative autoradiograms of acute drug administration on c-fos mRNA expression 
(-2.5 to -3.2 mm relative to bregma) 
Arernna -2.90 mm 
Representative autoradiographs of in situ hybridisation utilising 33P-labelled oligonucleotide probes 
targeted against the c-fos transcript in coronal sections of rat brain following 45 min acute administration 
of vehicle (A), Org 34167 (0.5 mg/kg, B), imipramine (15 mg/kg, C), mirtazapine (2 mg/kg, D), LiCI 
(75mg/kg, E) or fluoxetine (5mg/kg, F). Also shown is a schematic representation of the brain regions 
analysed. Abb: RS, anterior retrosplenial cortex, S1 Tr, primary somatosensory cortex, trunk region, S2, 
posterior secondary somatosensory cortex, Ins ctx, posterior insular cortex, Pir, piriform cortex, CA], 
rostra] field CA] of hippocampus, CA2, rostra] field CA2 of hippocampus, CA3, rostral field CA3 of 
hippocampus, Dg, dentate gyrus, CeA, central amygdaloid nucleus, Thal, thalamus (Paxinos et al., 1986). 
3.3.6 Effect of treatment on c-fos mRNA (-4.8 to -5.5 mm relative to bregma) 
The elevation of c-fos mRNA caused by Org 34167-administration observed in the 
anterior retrosplenial cortex compared with all other treatment groups was again 
apparent in this more posterior region (P < 0.05; Figure 3.7; Table 3.6). There was also 
a strong cortical activation of c fos mRNA following fluoxetine administration, in both 
the secondary visual cortex and primary auditory cortex, where the c-fos levels were 
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significantly higher than every other group except Org 34167 (P < 0.05). In these 
regions mirtazapine- and LiCI-treatment also showed significant downregulation of 
c-fos compared with the Org 34167 group (P < 0.05). All drug treatments, except 
mirtazapine, induced c-fos expression in the perirhinal cortex compared with the control 
group (P < 0.05). Additionally, the level of c-fos mRNA in the fluoxetine treatment 
group in this region was significantly higher than all other drugs (P < 0.05; Figure 3.7; 
Table 3.6). The c-fos level following mirtazapine-treatment was also significantly 
lower than LiCl-, Org 34167- and imipramine-administration in the perirhinal cortex 
(P < 0.05). Fluoxetine-treatment was demonstrated to induce c-fos mRNA expression 
in the periaqueductal grey and posteromedial cortical amygdaloid nucleus compared 
with mirtazapine- and LiCI-administration (P < 0.05). Imipramine-treatment in this 
latter region showed significantly increased c-fos expression relative to vehicle-, Org 
34167-, mirtazapine- and LiCl-treated animals (P < 0.05). Fluoxetine-treated animals 
were observed to display a significantly higher level of c-fos mRNA than every other 
group in the ventral tegmental area, except imipramine (P < 0.05). Although no 
significant differences were observed between any groups in the CA2 or dentate gyrus 
regions of the hippocampus, a significant increase in c-fos mRNA expression was 
observed in the dorso-caudal CAI field of the hippocampus of Org 34167-treated 
animals compared with all other groups (P < 0.05). In the caudal CA3 region a down- 
regulation of c-fos was observed following mirtazapine administration compared with 
all other treatment groups, and LiCI compared with Org 34167 administration 
(P < 0.05). Expression of c-fos in the geniculate nucleus was down-regulated following 
mirtazapine-, LiCI- and fluoxetine-treatment compared with both vehicle and 
Org 34167-treated animals (P < 0.05). Acute administration of imipramine was 
observed to increase c-fos expression compared with mirtazapine and LiCI treated 
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animals (P < 0.05), but to a lower level than Org 34167 (P < 0.05). All these results are 
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Figure 3.7 Representative autoradiograms of acute drug administration on c-fos mRNA expression 
(-4.8 to -5.5 mm relative to bregma) 
&cgma -320 flint 
Representative autoradiographs of in situ hybridisation utilising 
33P-labelled 
oligonucleotide probes 
targeted against the c-fos transcript in coronal sections of rat brain following 45 min acute administration 
of vehicle (A), Org 34167 (0.5 mg/kg, B), imipramine (15 mg/kg, C), mirtazapinc (2 mg/kg, D), LiC1 
(75mg/kg, E) or fluoxetine (5mg/kg, F). Also shown is a schematic representation of the brain regions 
analysed. Abb: RS, retrosplenial cortex, V2, secondary visual cortex, lateral area, Au ctx, primary 
auditory cortex, PRh, perirhinal cortex, CAI, dorsocaudal field CAI of hippocampus, CA2, caudal field 
CA2 of hippocampus, CA3, caudal field CA3 of hippocampus, Dg, caudal dentate gyrus, PAG, anterior 
periaqueductal grey, Gen, geniculate nucleus, VTA, ventral tegmental area, PMCo, posteromedial cortical 
amygdaloid nucleus (Paxinos et al., 1986). 
3.3.7 Effect of treatment on c-fos mRNA (-6.8 to -7.5 mm relative to bregma) 
As observed in the anterior and medial retrosplenial cortex, Org 34167-treatment 
induced c-fos expression in the posterior region almost two-fold compared with every 
other treatment group (P < 0.05). Org 34167 and fluoxetine administration were 
observed to elevate c-fos mRNA expression compared with the other four treatment 
groups in the ectorhinal cortex (P < 0.05). Similar to the rostral periaqueductal grey, 
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fluoxetine was demonstrated to activate c-fos in this more caudal region compared with 
mirtazapine- and LiCl-administration, but also compared with vehicle (P < 0.05). There 
were no other significant alterations observed in this region. There was a trend towards 
an increase in c-fos induction in the dorsal raphe by all drug treatments compared with 
vehicle, which did not reach significance due to the large experimental error (Figure 
3.8; Table 3.7). Mirtazapine- and LiCI treatment caused a downregulation of c-fos 
mRNA in the primary and secondary visual cortices, as well as the temporal association 
cortex compared with vehicle, Org 34167 and fluoxetine administration (P < 0.05). 
Additionally, in the secondary visual cortex, mirtazapine and LiCI treated animals 
demonstrated a significantly lower c-fos level than imipramine, which was also 
observed in the temporal association cortex in the case of LiCI only (P < 0.05). 
However, imipramine administration significantly decreased c-fos mRNA expression in 
the temporal association cortex compared with fluoxetine (P < 0.05). In the lateral 
entorhinal cortex mirtazapine- and LiCl-administration were found to significantly 
downregulate c-fos mRNA compared with both vehicle and Org 34167 treatment groups 
(P < 0.05). Similar to the CA 1 field of the hippocampus observations, Org 34167 was 
observed to activate c-fos expression in the subiculum and post-subiculum regions of 
the hippocampus compared with all other treatments (P < 0.05). Moreover, a down- 
regulation of c-fos expression, in comparison with vehicle, was noted for every other 
treatment group in these two regions (P < 0.05), with the exception of fluoxetine in the 
subiculum (Figure 3.8 and Table 3.7). The only other significant finding in these two 
hippocampal regions was that LiCl-treatment significantly lowered c-fos expression in 
the subiculum compared with fluoxetine (P < 0.05). Acute administration of Org 34167 
also activated c fos in the superior colliculus in comparison with vehicle, mirtazapine 
and LiCI (P < 0.05). In addition, mirtazapine and LiCI treated animal were observed to 
display a significantly lower expression of c-fos when compared with vehicle-, 
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imipramine- and fluoxetine administration (P < 0.05). Finally, LiCI treatment down- 
regulated c-fos expression in the nucleus of the brachium of the inferior colliculus 
compared with vehicle-, imipramine- and fluoxetine-administration (P < 0.05). 
Mirtazapine also demonstrated significantly lower c-fos expression in this region 
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Chapter 3 Acute antidepressant administration effect on c fos mRNA 
Figure 3.8 Representative autoradiograms of acute drug administration on c-fos mRNA expression 
(-6.8 to -7.5 mm relative to bregma) 
E 
Representative autoradiographs of in situ hybridisation utilising 33P-labelled oligonucleotide probes 
targeted against the c fos transcript in coronal sections of rat brain following 45 min acute administration 
of vehicle (A), Org 34167 (0.5 mg/kg, B), imipramine (15 mg/kg, C), mirtazapine (2 mg/kg, D), LiCI 
(75mg/kg, E) or fluoxetine (5mg/kg, F). Also shown is a schematic representation of the brain regions 
analysed. Abb: RS, posterior retrosplenial cortex, VI, primary visual cortex, V2, secondary visual cortex, 
TeA, temporal association cortex, Ect, ectorhinal cortex, LEnt, lateral entorhinal cortex, PAG, posterior 
periaqueductal grey, DR, dorsal raphd, Sup Col, superior colliculus, BIC, nucleus of the brachium of the 
inferior colliculus, P, post-subiculum, S, subiculum (Paxinos et al., 1986). 
3.3.8 Effect of treatment on c-fos mRNA (-9.3 to -10 mm relative to bregma) 
In this most caudal region of the rat brain examined, c-fos mRNA levels of Org 34167- 
treated animals were significantly higher compared with vehicle-, mirtazapine- and to 
that of LiCI-administration in the inferior colliculus (P < 0.05). A significantly lower c- 
fos expression was also observed in this region following LiCI-treatment compared with 
fluoxetine (P < 0.05). Despite a trend towards an increase in c-fos expression following 
all drug treatments in the locus coeruleus compared with saline control, this only 
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reached significance with the fluoxetine group, which was also observed over 
imipramine treatment (P < 0.05; Figure 3.9 and Table 3.8). LiCI treatment down- 
regulated c fos expression compared with vehicle- and Org 34167- groups in the 
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Chapter 3 Acute antidepressant administration effect on c fos mRNA 
Figure 3.9 Representative autoradiograms of acute drug administration on c fos mRNA expression 




Representative autoradiographs of in situ hybridisation utilising 
33P-labelled oligonucleotide probes 
targeted against the c-fos transcript in coronal sections of rat brain following 45 min acute administration 
of vehicle (A), Org 34167 (0.5 mg/kg, B), imipramine (15 mg/kg, C), mirtazapine (2 mg/kg, D), LiCI 
(75mg/kg, E) or fluoxetine (5mg/kg, F). Also shown is a schematic representation of the brain regions 
analysed. Abb: Inf Col, inferior colliculus, LC, locus coerulcus, Pd, posterodorsal tegmental nucleus 
(Paxinos et al., 1986). 
All of the results from each brain region analysed, relative to vehicle administration, are 
provided in Table 3.9 in order to provide an overall summary. 
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Table 3.9 Overview of c-fos profile of compounds compared with vehicle 
Data represent effect of acute antidepressant treatment compared with vehicle treatment. T represents 
significant increase in c-fos mRNA expression (P < 0.05), H represents no significant difference in c-fos 
mRNA expression and 'L represents significant decrease in c-fos mRNA expression (P < 0.05). Abb: 
Fluox, fluoxetine, Imip, imipramine, Mirtaz, mirtazapine, Org, Org 34167,2°, secondary, ctx, cortex, 
VM, ventromedial, DM, dorsomedial, DL, dorsolateral, VL, ventrolateral, SIBF, primary somatosensory 
cortex, PVA, anterior paraventricular thalamic nucleus, LOT, nucleus of the lateral olfactory tract, 
BSTMPL, nucleus of the stria terminalis medial division posterolateral part, SlTr, primary 
somatosensory cortex trunk region, 1 °, primary, PMCo, posteromedial cortical amygdaloid nucleus, BIC, 
nucleus of the brachium of the inferior colliculus, Pd, posterodorsal tegmental nucleus (Paxinos et al., 
1986). 
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Chapter 3 Acute antidepressant administration effect on c fos mRNA 
3.4 Discussion 
The aim of the present study was to examine the effects on c-fos mRNA expression, of 
antidepressants from different classes and a mood stabiliser, after acute administration 
(a single i. p. injection). Overall, some of the brain regions shared a common c-fos 
profile following acute antidepressant administration but a number of individual 
differences between the drugs were identified. All drugs tested, including the novel 
antidepressant Org 34167, induced c-fos expression in the central amygdala and anterior 
insular cortex (P < 0.05; Tables 3.3 & 3.5). A downregulation of c-fos mRNA, 
compared with vehicle, was observed for all treatment groups in the septum and nucleus 
of the lateral olfactory tract (P < 0.05; Table 3.3). The first three of these areas have 
been implicated in depression, with human neuro-imaging studies showing an abnormal 
increase in metabolic activity in the insula and amygdala (Drevets, 2000). Additionally, 
in the case of the amygdala, Beck (1995) and Duncan et al., (1996) previously reported 
that this was the only brain region were an increase in c-fos expression was observed 
following all different antidepressant administrations. These alterations in c-fos 
expression underline long-term changes in cellular phenotype, which provide insight 
into the brain regions that these antidepressants are acting. 
The principle behind the present study was to determine whether the c-fos profile of the 
novel antidepressants Org 34167 and mirtazapine corresponded with the profile of 
known antidepressants. The c-fos profile of mirtazapine was observed to be most 
similar to that of imipramine (see Table 3.9). Mirtazapine is a noradrenergic and 
specific serotonergic antidepressant (NaSSA), which results in increased NA and 
5-HT1 transmission (de Boer, 1996). Imipramine also increases available NA and 5-HT 
by blocking reuptake, therefore, both drugs increase available NA and 5-HT although 
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their mechanisms of action are different. The fact that mirtazapine (previously 
undocumented) induces c-fos expression in the central amygdala and anterior insular 
cortex, which all other antidepressants in the present study and in the literature (see 
Beck, (1995)) provides proof of concept for the use of neural activity mapping with 
c-fos as a technique to characterise novel compounds. 
The orbitofrontal circuit has been shown to be present in rats, monkeys and humans 
(Ongur et al., 2000) and has been implicated in depression. This circuit consists of 
direct pathways from the orbital cortex to the ventral striatum (including the nucleus 
accumbens), then to the globus pallidus and finally to the mediodorsal thalamic nucleus 
(Ongur et al., 2000; Tekin et al., 2002). This system interacts with the anterior 
cingulate cortex, which projects to the caudate, then to the substantia nigra, which 
projects to the ventroanterior thalamus. The thalamic areas in each pathway provide 
reciprocal connections with their respective cortical origins (Tekin et al., 2002; See 
Figure 3.10). Results presented here for fluoxetine suggest that these circuits are 
activated. 
Figure 3.10 Orbito-frontal circuitry 
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The orbitofrontal circuit has been implicated in mood disorders by animal and human 
studies. Lesions of the orbital cortex are associated with social apathy (Tekin et al., 
2002) and cause animals to lose their position in the social hierarchy or become solitary 
(reviewed by Ongur et al., (2000)). Human neuroimaging studies have shown that in 
familial major depressive disorder there is abnormally elevated cerebral blood flow and 
glucose metabolism in the orbital, ventral anterior cingulate cortex, anterior insular 
cortex, ventral striatum, amygdala and medial thalamus (see Drevets, (2000) for 
review). The orbital cortex has extensive reciprocal connections with limbic structures, 
including the amygdala, subiculum and CAI field of the hippocampus, and the 
entorhinal and perirhinal cortices (reviewed by Ongur et al., (2000)). In all of these 
structures, as well as the direct orbitofrontal circuit, only fluoxetine administration was 
observed to induce c-fos expression compared with vehicle, with the exception of the 
subiculum and CAI (the globus pallidus, substantia nigra and mediodorsal thalamic 
nucleus were not analysed). Particularly strong activation was noted throughout the 
striatum, including the nucleus accumbens core and shell regions (Tables 3.3 and 3.4). 
The ventral striatum also projects to the VTA and PAG, in which c-fos induction 
following fluoxetine administration was observed (Table 3.6). 
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Although previous reports have demonstrated an increase in c-fos in the amygdala 
following acute fluoxetine (15 mg/kg) administration (Beck, 1995; Duncan et al., 1996; 
Morinobu et at., 1997) there are no reports concerning the other regions in the circuit. 
The current findings are suggestive that fluoxetine, one of the most commonly 
prescribed antidepressants, targets a number of brain regions after acute administration, 
which are abnormal in depression. The induction of c-fos leads to long-term alterations 
in gene transcription via the AP-1 complex. However, despite substantial knowledge 
regarding the activation of c-fos (See Herrera and Robertson (1996) for review), and the 
availability of a verified antisense oligonucleotide targeting the c-fos transcript, little is 
known regarding the genes which are targeted by AP-1 (Hoffman et al., 2002). It is 
also possible that fluoxetine administration only targets a few of the brain regions in this 
circuitry but due to the reciprocal connections shared between them, the increase in 
neuronal activity in one region affects others. This is a possibility as it has been 
demonstrated that c-fos can be activated in neurones removed from the site of direct 
neuronal stimulus (Ziolkowska et al., 2002). Nevertheless, it is striking that fluoxetine 
(when given acutely) targets so many brain regions associated with depression, 
especially as very few structures other than those mentioned were observed to be altered 
-VI-4 
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by fluoxetine compared with vehicle (piriform cortex, suprachiasmatic nucleus, primary 
somatosensory cortex, secondary visual cortex, auditory cortex, see Table 3.9). 
In addition to the increase in c-fos expression by fluoxetine in the majority of the 
regions associated with the orbitofrontal circuit, the other administered antidepressants 
were also observed to induce c-fos in a number of these areas. All drugs induced c-fos 
in the central amygdala compared with vehicle (Figure 3.6 and Table 3.5). Beck (1995) 
observed that this was the only brain region of those examined, in which all 
antidepressants (fluoxetine (10 and 15 mg/kg, i. p. ), desipramine (10 mg/kg, i. p. ), 
bupropion (20 mg/kg, i. p. ), nortriptyline (15 mg/kg, i. p), imipramine (20 mg/kg, i. p. ) 
and citalopram (5 mg/kg, i. p. )) induced c-fos expression. Therefore, that Org 34167 and 
mirtazapine (both previously undocumented) also display this attribute, adds support to 
the idea that a common mechanism of antidepressant administration is to alter activity 
in the central amygdala. This is also supported by the fact that chronic antidepressant 
treatment normalises the hyperactivity of the amygdala in rat and human (see Drevets 
(1999) for review). This adds further evidence in support of Org 34167 as a novel 
antidepressant; although non-antidepressants have also been reported to induce c-fos 
mRNA expression in this brain region, including diazepam (modulates GABAA 
receptor, 10 mg/kg; Salminen et al., (1996)), haloperidol (D2-receptor antagonist, 0.1 & 
1 mg/kg; Morelli et al., (1999); Sebens et al., (1996)), clozapine (broad spectrum 
antagonist acting at D1_5 receptors; also antagonistic at 5-HT2A and 2C, al and a2- 
adrenoceptors, histamine H1, and acetylcholine M1 receptors, 10 & 20 mg/kg; Morelli et 
al., (1999); Sebens et al., (1996)), cocaine (inhibits DA reuptake, 15 mg/kg; Day et al., 
(2001)) and amphetamine (inhibits NA and DA reuptake, 2&5 mg/kg; Day et al., 
(2001); Engber et al., (1998)). 
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The insular cortex is another brain region in which all drug treatments were observed to 
increase c-fos expression compared with the saline control. This increase was 
significant for all drugs in the anterior region (Table 3.3) and all except fluoxetine in the 
medial region (Table 3.4). As described above, the insular cortex is a region which is 
abnormally activated in patients with depression (Drevets, 2001; Drevets, 2000) and the 
fact that all these antidepressants induce neuronal activation in this region suggests that 
this is a region where they exert their influence. Similarly, all antidepressants, with the 
exception of mirtazapine significantly induced c-fos expression compared with vehicle 
in the perirhinal cortex (Table 3.6). The perirhinal cortex has been demonstrated to 
have reciprocal connections with the frontal cortex in rat and damage to this region 
impairs familiar object recognition in rats (Mumby et al., 2002). 
Fluoxetine treatment induced c fos expression in the anterior cingulate cortex compared 
with all other groups (Table 3.3). While this has previously been demonstrated for 
other antidepressants, it has also been shown in all studies involving the 
psychostimulants amphetamine (2.5 &5 mg/kg; Turgeon et al., (2001)), PCP (0.8 & 8.6 
mg/kg; Gao et al., (1993)) and MK-801 (antagonist at NMDA receptors, 0.2 & 0.4 
mg/kg; Wedzony et al., (1996), where the anterior cingulate cortex has been analysed. 
However, in the cingulate cortex, Org 34167 treatment induced c-fos mRNA expression 
compared with all other groups with no other significant alterations between the 
remaining drugs (Table 3.3); a fording similar to that observed following 
psychostimulant administration (Gao et al., (1993); Turgeon et al., (2001); Wedzony et 
al., (1996)). Intriguingly, at these bregma co-ordinates, for all cortical areas examined, 
with the exception of the piriform cortex, Org 34167 induced c-fos mRNA expression 
significantly compared with all other treatments, except fluoxetine in the caudal 
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secondary motor cortex (Table 3.4). This strong cortical induction of c-fos is more akin 
to that observed in studies involving psychostimulants as discussed above. Doses of 
Org 34167 similar to those used in the present study have been demonstrated to be 
active in the rat intracranial self-stimulation (Ruigt, Personal communication) and this 
pattern of c-fos induction provides some insight as to why this may be the case. The 
cortical increase in c-fos was most apparent throughout the retrosplenial cortex, where 
Org 34167 administration resulted in a doubling of c-fos expression compared with all 
other treatment groups, at the anterior, medial and posterior areas analysed (Tables 3.5 - 
3.7). It has previously been observed that the head-weaving behaviour following MK- 
801 administration is correlated with the level of c-fos induction in the retrosplenial 
cortex (O'Neill et al., 1998). Org 34167-administration also produces head-weaving in 
rats (0.01 mg/kg i. c. v. ) and the similar activation of c-fos in the retrosplenial cortex may 
indicate the possible mechanism of action. The strong cortical activation of c-fos 
following Org 34167-treatment mirrors the distribution of brain regions in which both 
HCN 1 and HCN2 mRNA expressions are high (Table 3.9 & 3.10; Monteggia et al., 
2000; Moosmang et al., 1999). Therefore, it is possible that the reason for the 
consistently high induction of c-fos is due to the presence of high expression of HCN1 
and HCN2 isoforms in the cortex (See Table 3.10). 
The septum is also believed to be an important brain region in animal models of 
depression. The helpless behaviour in learned helplessness is thought to be related to 
5-HT levels in the septum, as microinjection of 5-HT into the lateral septal nucleus 
reverses learned helplessness (Sherman et al., 1980). A recent study reported decreased 
c-Fos in the lateral septal nucleus of learned helpless rats, and it was hypothesised that 
this may represent the deficient 5-HT transmission of these rats (Steciuk et al., 1999). 
Another animal model of depression, the forced swim test, has been demonstrated to 
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increase c-Fos in the lateral septum (Duncan et al., 1996), which is reversed by pre- 
treatment with antidepressants (Duncan et al., 1996). Therefore, the fact that all drugs 
in the present study decreased c-fos mRNA expression in the septum would appear to 
contradict the findings from the learned-helplessness study but corroborate those of the 
forced-swim test. 
In the frontal cortex, both Org 34167 and LiCl-treatment induced c-fos expression in the 
anterior secondary motor cortex (Table 3.2). However, the only other component of the 
motor circuit analysed, the dorso-lateral striatum, did not differ significantly from 
vehicle (Tables 3.3. and 3.4). Interestingly, Org 34167 elevated c-fos significantly 
compared with all other treatment groups in the secondary motor cortex (P < 0.05). 
This induction has been demonstrated previously for psychostimulants, including 
cocaine (3 & 30 mg/kg; Johansson et al., (1994)) and amphetamine (2 &5 mg/kg; 
Badiani et al., (1998); Johansson et al., (1994)). Additionally, increased locomotor 
activity after low doses of Org 34167, manifested in adverse effects, such as tremor, 
head-weaving and forepaw treading is observed (Ruigt, Personal communication). The 
induction of c-fos was also observed in the posterior secondary motor cortex following 
Org 34167 administration but did not reach significance in the case of LiCI (Table 3.4). 
Fluoxetine-administration also induced c-fos in the posterior secondary motor cortex 
compared with all treatments, except Org 34167, which is interesting as fluoxetine 
increased mRNA in the dorsolateral striatum compared with all treatments. Therefore, 
fluoxetine increases neuronal activity in two regions of the motor circuit, whilst Org 
34167 only does so in one. 
The most robust induction of c-fos mRNA observed was in the supraoptic nucleus 
following LiCI administration (Table 3.4). A ten-fold increase compared with vehicle, 
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and five-fold compared with all other drug-treatments was seen. A likely explanation 
for this comes from the knowledge that the supraoptic nucleus is sensitive to osmotic 
balance (see Hussy et al., (2000) for a review) and the injection of a large number of Li' 
ions disrupts this balance. Despite a trend towards an increase following fluoxetine 
treatment, as previously reported by immunohistochemical studies (Torres et al., 1998) 
this did not reach significance compared with vehicle (Table 3.4). 
The c-fos profile of Org 34167 may also give some insight into a number of the side- 
effects, which were reported during Phase 1 clinical trials. Visual disturbances were the 
most frequently cited adverse effect following administration, and Org 34167 induces 
c-fos mRNA in the superior colliculus compared with vehicle, mirtazapine and LiCI 
(P < 0.05; Table 3.7). The superior colliculus is involved in the control of orientation, 
by use of eye and head movements, in many different species, including rats, monkeys 
and humans (see Guitton (1999) for review). Therefore, it is possible that Org 34167 
alters this control region, leading to the visual disturbances. No significant alterations 
were observed in the primary or secondary visual cortices compared with vehicle (Table 
3.7). Additionally, Ih channels are abundant in the retina and it is possible that the 
impairment in vision is due to Org 34167 acting directly on these channels; however, 
the retina was not examined in the present study. Furthermore, in the superior 
colliculus and the primary and secondary visual cortices, mirtazapine and LiCI- 
administration downregulated c fos mRNA compared with vehicle, and although visual 
disturbances are not reported as a side-effect of mirtazapine administration, lithium 
toxicity is associated with blurred vision. 
Imipramine administration resulted in little significant alteration from vehicle treatment 
out-with those areas already discussed, where the c-fos profile of all antidepressants 
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were similar (see Table 3.9). In addition to the anterior and medial insular cortex, 
imipramine induced c-fos expression in the posterior insular cortex, which is similar to 
the findings of Org 34167. This is consistent with the theory that the abnormalities 
observed in patients with familial major depression in the insular cortex (Drevets, 2001) 
are acutely targeted by antidepressant administration. Interestingly, imipramine induced 
c-fos expression in the posteromedial cortical amygdaloid nucleus (Table 3.6 & Figure 
3.7). This structure forms part of the vomeronasal system, which is implicated in the 
control of reproductive behaviour and in males contains a greater number of neurones 
than in females (Vinader-Caerols et al., 2000). One of the side-effects of imipramine is 
the interference of sexual function, which can be manifest in testicular enlargement. 
Recently, Vinader-Caerols et al., (2000) demonstrated that estradiol aromatisation from 
circulating testosterone masculinises this brain region. This may represent a possible 
explanation for the side-effects of imipramine, as this system conveys olfactory 
information related to reproductive behaviour, especially considering that imipramine 
also decreased c-fos expression throughout the piriform cortex, which is important in 
olfaction (Bouret et al., 2002). 
As previously stated fluoxetine-treatment did not significantly alter c-fos expression in 
the subiculum compared with vehicle. However, Org 34167 treatment significantly 
induced c-fos, compared with all groups, whereas imipramine, mirtazapine and LiCI- 
administration significantly decreased c fos compared with vehicle, Org 34167 and 
fluoxetine (Table 3.7). In other areas of the hippocampal complex, Org 34167 induced 
c-fos expression compared with all other groups, including the post-subiculum, rostral 
CAI and CA2 fields, and in the caudal CAI field (Tables 3.5 & 3.6). Similar to the 
strong cortical activation, the only previous compounds, which induced c-fos expression 
in the hippocampus were the psychostimulants PCP (40 mg/kg; Sharp, (1997)) and 
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caffeine (50 mg/kg; Singewald et al., (2003)). Therefore, it appears that the c fos 
profile of Org 34167 is a combination of that observed for antidepressants and that for 
psychostimulants. The similarity of the c-fos profile of Org 34167 to that of 
psychostimulant compounds (as discussed above) may partially explain the 
antidepressant-like properties of Org 34167, as amphetamine and cocaine were 
originally used to treat depression (see Section 1.3.2). Additionally, NMDA antagonists 
have been shown to have antidepressant-like activity. Trullas & Skolnick (1990) 
demonstrated that 2-aminophosphonoheptanoic acid (a competitive NMDA antagonist), 
1-aminocyclopropanecarboxylic acid (ACPC; a glycine partial agonist) and MK-801 (a 
use-dependent channel blocker) all reduced immobility time in the forced-swim test, as 
well as competitive NMDA antagonists displaying antidepressant-like activity in the 
Willner chronic mild stress model (Papp et al., 1994). Therefore, the cortical and 
hippocampal activation following acute Org 34167 may represent brain regions required 
for its proposed antidepressant activity. 
Hippocampal expression of HCN 1 and HCN2 mRNA is high, as was discussed 
concerning the cortex, adding further evidence that the brain regions in which strong 
induction of c-fos is observed following Org 34167 administration is associated with the 
presence of either, or both, of these isoforms (see Table 3.10). Furthermore, the high 
level of neuronal activity observed following Org 34167 administration suggests that 
the dose used in the present study acts throughout the CNS. Similar findings have been 
demonstrated with lithium, where a dose of 20 mg/kg (comparable with the human 
dose) only elevated c-Fos in the central amygdala, while 100 mg/kg induced Fos in a 
number of brain regions (Hamamura et al., 2000). Therefore, it would be interesting to 
perform a dose-response relationship to determine whether Org 34167 displays a similar 
characteristic. 
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Table 3.10 Distribution of HCN1-4 mRNA isoforms 
BRAIN REGION HCN I HCN 2 HCN 3 HCN 4 
Prefrontal cortex ++++ +++ + - 
Nucleus accumbens + ++ - - 
Caudate putamen + +++ - - 
Thalamus - ++++ - ++ 
Amygdala +++ ++(+) + - 
Hippocampus +++ ++++ + - 
Ventral tegmental area +++ ++ + + 
Subiculum ++++ +++ ++++ ++++ 
Locus coeruleus +++ ++++ +++ +++ 
Dorsal Raphe +++ ++++ + - 
Data adapted from (Monteggia et al., 2000; Moosmang et al., 1999). 
In the nucleus accumbens (core and shell regions), mirtazapine, LiCI and fluoxetine 
administration increased c-fos mRNA expression compared with vehicle, Org 34167 
and imipramine (Table 3.3). This has previously been noted following bupropion 
(20 mg/kg; Beck, (1995)) and fluoxetine (10 mg/kg; Cruise, Personal communication)). 
Patients with depression exhibit decreased cerebral blood flow and metabolism in this 
region (Drevets et al., 1992), which coupled with the role of the accumbens in emotion 
suggests it is possible that antidepressant treatment normalises the metabolism in this 
region. All antipsychotics and psychostimulants (where this region has been analysed) 
elevate c-fos in the nucleus accumbens (Badiani et al., (1998); Castner et al., (1996); 
Johansson et al., (1994); Morelli et al., (1999); Sebens et al., (1996); Singewald et al., 
2003)). The nucleus accumbens plays a role in reinforcing stimuli, such as food and 
sex, as well as mediating the reinforcement of drugs of abuse (Di Chiara, 2002). 
Therefore, it is unsurprising that all psychostimulants induce c-fos here, which would 
lead, in turn, to long-lasting gene alterations. While all antidepressants induce c-fos in 
the central amygdala, the nucleus accumbens appears to be the defining brain region of 
antipsychotic administration; being the only area activated by all. 
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Another important brain region in depression is the locus coeruleus, which is the major 
origin of noradrenergic projections in the CNS (Holets, 1990). Although all 
antidepressant groups elevated c-fos mRNA expression in this region, only the 
fluoxetine-evoked increase was significant (Table 3.8). Previous studies, which have 
analysed this brain region, have shown that the antidepressants desipramine (10mg/kg; 
Beck, (1995)), tranylcypromine (7.5 mg/kg; Beck, (1995)) and bupropion (20 mg/kg; 
Beck, (1995)) significantly elevate c-fos. That all antidepressants show a trend towards 
an increase in neuronal activity in this region is unsurprising given that most increase 
noradrenergic neurotransmission. Similar findings were observed in the dorsal raphe, 
with all drugs except LiC1 displaying a trend towards an increase in c-fos expression. 
However, no previous reports concerning the dorsal raphe have come to light. 
In conclusion, the c fos profile of Org 34167 shows a strong cortical and subcortical 
nature, which is similar to literature findings for psychostimulants. Additionally, this 
profile correlates with regions with high expression of both HCN1 and HCN2 mRNA, 
which given the in vitro data is suggestive that Org 34167 is blocking HCN channels, 
which in turn causes c-fos induction. All compounds tested in the present trial induced 
c-fos in the anterior insular cortex and central amygdala, and decreased c-fos in the 
septum and the nucleus of the lateral olfactory tract. Previous studies have shown that 
all antidepressants induce c-fos in the central amygdala, which was repeated in the 
present study, and shown for the first time for mirtazapine and Org 34167; two 
previously undocumented compounds. Additionally, all compounds in the present 
study induced c fos expression in the anterior insular cortex, a region linked with 
depression. These findings confirm the antidepressant profile of the clinically validated 
compound mirtazapine and provide an indication to the potential antidepressant profile 
of Org 34167. Furthermore, fluoxetine administration induced c-fos expression in every 
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region of the orbitofrontal circuit analysed, and a number of brain areas which possess 
reciprocal connections with the orbital cortex and nucleus accumbens. This circuit is 
altered in patients with depression and demonstrates that fluoxetine acutely targets these 
brain regions implicated in depression. 
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Chapter 4 Comparison of Org 34167 induced changes in Egr-1 
expression to that of known antidepressants 
4.1 Introduction 
The previous chapter detailed the effect of acute administration of antidepressants, and a 
mood stabiliser, on the expression of the immediate early gene, c-fos, throughout the rat 
CNS. It is now becoming a common practice to examine more than one immediate 
early gene in such experiments, due to the fact that only a subset of neurones express c- 
fos (Ziolkowska et al., 2002). Other genes utilised include members of the Jun family, 
such as c-jun, which dimerises with c-fos to form AP-1 (Herdegen et al., 1998). 
However, the similarity of these gene families is resulting in more researchers 
examining a different ITF family; namely the Early growth response (Egr) family. To 
date there are four known Egr protein members (Egr 1- 4), which are characterised by 
containing three zinc finger motifs, which recognise a9 base-pair segment of DNA 
(Leah et al., 2002). 
The most commonly utilised Egr gene for mapping neuronal activation is Egr-l (also 
termed zif268, Krox-24, NGFI-A, TIS8 and ZENK), which displays a widespread 
distribution in the CNS, with high expression throughout the cortex, hippocampus, 
striatum and amygdala (Schlingensiepen et al., 1991). Unlike c-fos, Egr-1 is 
characterised by high basal expression level (Leah et al., 2002). Basal Egr-1 expression 
appears to be, at least partially, under the control of NMDA-, dopamine- and 
noradrenergic- receptors. (Gass et al., 1993a; Gass et al., 1993b; O'Donovan et al., 
1999). Like c-fos, which has shown to be dependent upon Ca2+ entry into the neuron, 
L-type voltage-sensitive Ca 2+ antagonists block basal and kainate-induced Egr-l 
expression (Murphy et al., 1991). The strong cortical expression of Egr-1 is at least 
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partially under noradrenergic control, as lesioning of NA input decreases basal 
expression (O'Donovan et al., 1999) . 
Therefore, different subsets of neurones to that of 
c-fos may be activated by the same stimuli, given the different signal transduction 
pathways involved (see Figure 4.1). The temporal expression of Egr-1 is also different 
to that of c-fos, while mRNA expression reaches a peak level after 
30 - 60 min, the mRNA expression can remain near peak after 6h (Zangenehpour et al., 
2002). 
Figure 4.1 The major pathways involved in the induction of Egr-1 
('a 
The effect of a number of different antidepressants on Egr-1 expression has been 
examined. Acute desipramine (10 or 25 mg/kg i. p. ) has been shown to increase Egr-1 
expression in the hippocampus (Dahmen et al., 1997), as have acute electroconvulsive 
seizures in the rat frontal cortex (Morinobu et al., 1997). LiCI stress induces Egr-1 in 
the nucleus tractus solitarus, parabrachial nucleus, paraventricular nucleus and central 
nucleus of the amygdala (Lamprecht et al., 1995). However, to date there have been no 
reports concerning the affect of a wide-range of antidepressants on Egr-1 expression 
throughout the CNS. 
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The aim of the experiments performed in this chapter was to examine the effect of a 
number of different classes of antidepressant on Egr-1 mRNA expression levels, to 
determine which brain regions each affect. Comparison of Org 34167's Egr-1 profile 
with that of known antidepressants was peformed to determine whether similar brain 
regions were affected. Mirtazapine was included to discern whether it activated brain 
regions similar to those of other well-described classes of antidepressants. 
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4.2 Materials and methods 
4.2.1 Animals and experimental protocol 
See Section 3.2.1 for animal and experimental protocol. The same animals as used in 
the c-fos study were used for the present study. 
4.2.2 Cryostat sectioning 
See Section 3.2.2 for details of cryostat sectioning. 
4.2.3 Egr-1 in situ hybridisation 
In situ hybridisation was performed as described in Section 2.2 utilising a 
complementary probe to the rattus norvegius Egr-1 transcript at a final concentration of 
2 pmol (see Appendix B for details). Specificity of the probe was assessed as described 
in Section 2.2 (See Appendix C for autoradiograms) and the results analysed as 
described in Section 2.2. 
4.2.4 Acetylcholinesterase activity 
See Section 3.2.4 for protocol used for demonstrating sites of acetylcholinesterase 
activity. 
4.2.5 Statistical analyses 
Data for each region of interest were analysed by one-way analysis of variance followed 
by Student Newman-Keuls post-hoc multiple comparison test. Significance was 
assigned when P<0.05 and analysis was performed using GraphPad Prism v3.02 
(GraphPad Software Inc). 
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4.3 Results 
4.3.1 Effect of acute administration on Egr-1 mRNA expression 
Unlike the low expression of c-fos mRNA observed in vehicle-treated rats, Egr-1 
expression is much more prominent; displaying a pronounced rostral-caudal decline 
(Figures 4.2 - 4.8). Similar to the c-fos study there are alterations in the expression of 
this immediate early gene between each of the different treatment groups throughout the 
brain regions examined. 
4.3.2 Effect of treatment on Egr-1 mRNA (4.7 to 4 mm relative to bregma) 
Acute administration of Org 34167 was observed to significantly induce Egr-1 mRNA 
expression, compared with all other treatments, in the anterior olfactory nucleus 
(P < 0.05; Figure 4.2 and Table 4.2), and every group with the exception of fluoxetine 
in the secondary motor cortex (P < 0.05). This is similar to the c-fos findings in the 
secondary motor cortex where Org 34167 administration resulted in an elevation 
compared with every other group. LiCl-administration significantly lowered Egr-1 
mRNA levels in the ventromedial orbital cortex compared with Org 34167 and 
imipramine treatment (P < 0.05). No significant differences were found between any 
treatments in the prelimbic cortex. 
4.3.3 Effect of treatment on Egr-1 mRNA (2.2 to 1.5 mm relative to bregma) 
Acute administration of Org 34167 significantly induced Egr-1 mRNA, compared with 
all other groups, in all cortical regions (piriform, anterior cingulate and anterior insular), 
as well as the rostral dorso- and ventro-medial striatum (P < 0.05; Figure 4.3, Table 
4.2). This trend was observed in the nucleus accumbens core, rostral dorso- and ventro- 
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lateral striatum regions but only reached significance in the rostra! ventro-lateral 
striatum compared with vehicle, mirtazapine and LiC1 treatment (P < 0.05). No 
significant variation in Egr- I mRNA expression was observed in the septum or nucleus 
accumbens shell between any treatments. 
4.3.4 Effect of treatment on Egr-1 mRNA (-0.8 to -1.5 mm relative to bregma) 
The strong cortico-striatal activation of Egr-l expression following Org 34167 was 
again apparent at this more caudal region. Acute administration of the novel 
antidepressant induced Egr-1 expression compared with all other groups in the cingulate 
cortex and caudal dorsomedial striatum (P < 0.05). Imipramine-treated rats were 
observed to increase Egr-l expression compared with mirtazapine and LiCI in the 
caudal dorsomedial striatum (P < 0.05). In the caudal secondary motor cortex, Org 
34167 induced Egr-1 expression compared with every other treatment group except 
fluoxetine (P < 0.05), which is similar to the c-fos observations. In both the insular 
cortex and caudal ventral striatum, Org 34167 administration increased Egr-1 
expression significantly compared with vehicle (P < 0.05). In the somatosensory 
cortices, mirtazapine administration demonstrated a significantly lower level of Egr-1 
compared with Org 34167 in both the primary and secondary regions, and vehicle in the 
secondary somatosensory cortex (P < 0.05). In the piriform cortex and caudal 
dorsolateral striatum, LiCI administration resulted in significantly lower Egr-1 
expression compared with Org 34167 (P < 0.05). Acute administration of mirtazapine 
decreased Egr- I mRNA compared with Org 34167 in the caudal dorsolateral striatum (P 
< 0.05). No significant differences in Egr-1 mRNA levels in the anterior 
paraventricular thalamic nucleus, nucleus of the lateral olfactory tract or bed nucleus of 
the stria terminalis were observed. All these results are summarised in Table 4.3 and 
representative autoradiograph images are shown in Figure 4.4. 
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4.3.5 Effect of treatment on Egr-1 mRNA (-2.5 to -3.2 mm relative to bregma) 
As was observed in the corresponding c-fos study, Org 34167 administration induced 
Egr-1 mRNA compared with vehicle control in every cortical area examined, with the 
exception of the posterior piriform cortex (P < 0.05). Furthermore, each drug treatment 
induced Egr-1 mRNA, compared with vehicle, in the central amygdala, which was also 
observed with c-fos mRNA expression. LiCI-treatment significantly increased Egr-1 
mRNA compared with all other groups in the central amygdala (P < 0.05) and Org 
34167 significantly higher than all other treatments except LiCI (P < 0.05). Similar to 
the increased expression of c-fos observed following Org 34167 administration in the 
anterior retrosplenial cortex, Egr-1 expression was also significantly increased 
compared with all other treatments (P < 0.05). Mirtazapine- and LiCI-treated rats 
displayed lower Egr-1 expression in the primary somatosensory cortex compared with 
Org 34167 (P < 0.05). Org 34167 and imipramine Egr-1 mRNA levels were 
significantly higher than those following vehicle, mirtazapine and LiCI administration 
in the secondary somatosensory- and posterior insular cortices (P < 0.05). Rostral CAI 
Egr- l mRNA expression was significantly increased following Org 34167 
administration compared with all other treatments (P < 0.05), as was c-fos mRNA 
(Table 3.5). No significant variations in Egr-1 mRNA levels were observed in the 
posterior piriform cortex, rostral CA2, CA3 or dentate gyrus brain regions (Table 4.4). 
Thalamic Egr-1 mRNA expression was significantly higher following imipramine and 
fluoxetine administration than all other treatment groups (P < 0.05), although there was 
no significant difference between these two drugs. All these results are summarised in 
Table 4.4 and representative autoradiograph images are shown in Figure 4.5. 
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4.3.6 Effect of treatment on Egr-1 mRNA (-4.8 to -5.5 mm relative to bregma) 
The observation that Org 34167 administration elevated Egr-1 mRNA levels in the 
anterior retrosplenial cortex compared with all other treatments is replicated at this more 
caudal level of the brain (P < 0.05; Figure 4.6 & Table 4.5). However, the strong 
cortical activation is not apparent, with only mirtazapine and LiCI administration 
resulting in lower mRNA expression than Org 34167, and this only in the secondary 
visual cortex, where they were also significantly lower than fluoxetine-treated rats 
(P < 0.05). The only other significant differences, following drug treatment, were 
observed in the posteromedial cortical amygaloid nucleus where LiCl-treated animals 
were observed to have lower Egr-1 levels than vehicle and imipramine treatment groups 
(P < 0.05). 
4.3.7 Effect of treatment on Egr-1 mRNA (-6.8 to -7.5 mm relative to bregma) 
Acute administration of Org 34167 significantly induced Egr-1 mRNA expression, at 
these bregma co-ordinates, in almost every region analysed compared with saline 
control; only the primary visual cortex, periaqueductal grey and superior colliculus did 
not reach statistical significance (Figure 4.7 & Table 4.6). As was observed in the c-fos 
study, Org 34167-treated rats demonstrated significantly higher mRNA levels than all 
other treatment groups in the retrosplenial cortex, subiculum and post-subiculum 
(P < 0.05). Imipramine and LiCI treatment also down-regulated Egr-1 mRNA 
expression compared with vehicle in the post-subiculum (P < 0.05). In both the primary 
and secondary visual cortices, mirtazapine- and LiCI-treatment decreased Egr-1 mRNA 
compared with vehicle, Org 34167 and imipramine administration, as well as fluoxetine 
in the primary visual cortex (P < 0.05). Org 34167 administration resulted in 
significantly higher Egr-1 expression than mirtazapine, LiCI and fluoxetine treatment in 
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the temporal association cortex, ectorhinal cortex and lateral entorhinal cortex 
(P < 0.05). Ectorhinal cortex levels of Egr-1 mRNA were also induced following 
imipramine treatment compared with mirtazapine and LiCI administration (P < 0.05). 
Mirtazapine, LiCI and fluoxetine treatment resulted in lower Egr-1 mRNA expression in 
the dorsal raphe compared with vehicle and imipramine administration (P < 0.05). In 
the superior colliculus, Org 34167 administration induced Egr-1 mRNA compared with 
mirtazapine and LiCI treatment, as did imipramine relative to LiCl (P < 0.05). Acute 
administration of vehicle, mirtazapine and LiCI resulted in decreased Egr-1 mRNA in 
the nucleus of the brachium of the inferior colliculus compared with Org 34167- and 
imipramine-treated rats (P < 0.05). Fluoxetine administration resulted in elevated Egr-1 
expression compared with LiCI-treatment (P < 0.05). No significant effects of 
treatment were observed in the periaqueductal grey. 
4.3.8 Effect of treatment on Egr-1 mRNA (-9.3 to -10 mm relative to bregma) 
In the most caudal of the brain regions examined, acute administration of Org 34167 
was observed to induce Egr-1 mRNA expression in the posterodorsal tegmental nucleus 
compared with all other treatments (P < 0.05). The only other significant differences 
observed were decreased levels of Egr-1 mRNA in the inferior colliculus of mirtazapine 
and LiCI-treated rats compared with Org 34167 (P < 0.05; Figure 4.8 and Table 4.7). 
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Figure 4.2 Representative autoradiograms of acute drug administration on Egr- I mRNA expression 
(4.7 to 4 mm relative to bregma) 
Representative autoradiographs of in situ hybridisation utilising a 
33P-labelled oligonucleotide probe 
targeted against the Egr-1 transcript in coronal sections of rat brain following 45 min acute administration 
of vehicle (A), Org 34167 (0.5 mg/kg, B), imipramine (15 mg/kg, C), mirtazapine (2 mg/kg, D), LiCI 
(75mg/kg, E) or fluoxetine (5mg/kg, F). Also shown is a schematic representation of the brain regions 
analysed. Abb: M2, anterior secondary motor cortex, PrL, prelimbic cortex, VM Orb, ventro-medial 
orbital cortex, Ant. olfact nuc, anterior olfactory nucleus (Paxinos et al., 1986). 
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Chapter 4 Acute antidepressant effect on Egr- 1 mRNA 
Figure 4.3 Representative autoradiograms of acute drug administration on Egr-l mRNA expression 
(2.2 to 1.5 mm relative to bregma) 
E 
Representative autoradiographs of in situ hybridisation utilising a 33P-labelled oligonucleotide probe 
targeted against the Egr-1 transcript in coronal sections of rat brain following 45 min acute administration 
of vehicle (A), Org 34167 (0.5 mg/kg, B), imipramine (15 mg/kg, C), mirtazapine (2 mg/kg, D), LiCI 
(75mg/kg, E) or fluoxetine (5mg/kg, F). Also shown is a schematic representation of the brain regions 
analysed. Abb: Sep, septum, Cg, anterior cingulate cortex, Ins ctx, anterior insular cortex, Pir, anterior 
piriform cortex, DM Str, rostral dorsomedial striatum, DL Str, rostral dorsolateral striatum, VM Str, 
rostral ventromedial striatum, VL Str, rostral ventrolateral striatum, AcbC, nucleus acumens core, AcbSh, 
nucleus accumbens shell (Paxinos et al., 1986). 
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Chapter 4 Acute antidepressant effect on Egr- 1 mRNA 
Figure 4.4 Representative autoradiograms of acute drug administration on Egr- I mRNA expression 
(. 0.8 to . 1.5 nun relative to bregma) 








Representative autoradiographs of in situ hybridisation utilising a 
33P-labelled oligonucleotide probe 
targeted against the Egr- I transcript in coronal sections of rat brain following 45 min acute administration 
of vehicle (A). Org 34167 (0.5 mg/kg, B), imipraminc (15 mg/kg, C), mirtazapine (2 mg/kg, D), LiCI 
(75mg/kg, E) or fluoxetine (5mg/kg, F). Also shown is a schematic representation of the brain regions 
analysed. Abb: Cg, cingulate cortex, M2, secondary motor cortex, SI BF, primary somatosensory cortex, 
barrel field. S2, secondary somatosensory cortex, Ins ctx, insular cortex, Pir, piriform cortex, Pv, anterior 
paraventricular thalamic nucleus, DM Str, caudal dorsomedial striatum, DL Str, caudal dorsolateral 
striatum, V Str, caudal ventral striatum, LOT, nucleus of the 
lateral olfactory tract, BSTMPL, nucleus of 
the stria tcrminalis, medial division, posterolateral part, 
SON, supra-optic nucleus, S, suprachiasmatic 
nucleus (Paxinos et at', 1986). 
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Chapter 4 Acute antidepressant effect on Egr-1 mRNA 
Figure 4.5 Representative autoradiograms of acute drug administration on Egr-1 mRNA expression 
(-2.5 to -3.2 mm relative to bregma) 
Bnvn, ia t. llll mm 
Representative autoradiographs of in situ hybridisation utilising a 33P-labelled oligonucleotide probe 
targeted against the Egr-1 transcript in coronal sections of rat brain following 45 min acute administration 
of vehicle (A), Org 34167 (0.5 mg/kg, B), imipramine (15 mg/kg, C), mirtazapine (2 mg/kg, D), LiCI 
(75mg/kg, E) or fluoxetine (5mg/kg, F). Also shown is a schematic representation of the brain regions 
analysed. Abb: RS, anterior retrosplenial cortex, SITr, primary somatosensory cortex, trunk region, S2, 
posterior secondary somatosensory cortex, Ins ctx, posterior insular cortex, Pir, piriform cortex, CAI, 
rostral field CAI of hippocampus, CA2, rostral field CA2 of hippocampus, CA3, rostral field CA3 of 
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Chapter 4 Acute antidepressant effect on Egr-1 mRNA 
Figure 4.6 Representative autoradiograms of acute drug administration on Egr-l mRNA expression 
(-4.8 to -5.5 mm relative to bregma) 
keg- )ZU mm 
Representative autoradiographs of in situ hybridisation utilising a 33P-labelled oligonucleotide probe 
targeted against the Egr-1 transcript in coronal sections of rat brain following 45 min acute administration 
of vehicle (A), Org 34167 (0.5 mg/kg, B), imipramine (15 mg/kg, C), mirtazapine (2 mg/kg, D), LiCI 
(75mg/kg, E) or fluoxetine (5mg/kg, F). Also shown is a schematic representation of the brain regions 
analysed. Abb: RS, retrosplenial cortex, V2, secondary visual cortex, lateral area, Au ctx, primary 
auditory cortex, PRh, perirhinal cortex, CAI, dorsocaudal field CAI of hippocampus, CA2, caudal field 
CA2 of hippocampus, CA3, caudal field CA3 of hippocampus, Dg, caudal dentate gyrus, PAG, anterior 
periaqueductal grey, Gen, geniculate nucleus, VTA, ventral tegmental area, PMCo, posteromedial cortical 
amygdaloid nucleus (Paxinos et al., 1986) 
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Chapter 4 Acute antidepressant effect on Egr- 1 mRNA 
Figure 4.7 Representative autoradiograms of acute drug administration on Egr- I mRNA expression 
(-6.8 to . 7.5 mm relative to bregma) 
ý 
Representative autoradiographs of in situ hybridisation utilising a 
33P-labelled oligonucleotide probe 
targeted against the Egr- I transcript in coronal sections of rat brain following 45 min acute administration 
of vehicle (A), Org 34167 (0.5 mg/kg, B), imipraminc 
(15 mg/kg, C), mirtazapine (2 mg/kg, D), LiCI 
(75mg/kg, E) or fluoxetine (5mg/kg, F). Also shown is a schematic representation of the brain regions 
analysed. Abb: RS, posterior retrosplenial cortex, V1, primary visual cortex, V2, secondary visual cortex, 
TeA, temporal association cortex, Ect, ectorhinal cortex, LEnt, lateral entorhinal cortex, PAG, posterior 
periaqueductal grey, DR, dorsal raphr, Sup Col, superior colliculus, BIC, nucleus of the brachium of the 
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Chapter 4 Acute antidepressant effect on Egr- 1 mRNA 
Figure 4.8 Representative autoradiograms of acute drug administration on Egr-l mRNA expression 
(-9.3 to -10 mm relative to bregma) 
Representative autoradiographs of in situ hybridisation utilising a 
33P-labelled oligonucleotide probe 
targeted against the Egr-1 transcript in coronal sections of rat brain following 45 min acute administration 
of vehicle (A), Org 34167 (0.5 mg/kg, B), imipramine (15 mg/kg, C), mirtazapine (2 mg/kg, D), LiC1 
(75mg/kg, E) or fluoxetine (5mg/kg, F). Also shown is a schematic representation of the brain regions 
analysed. Abb: Inf Col, inferior colliculus, LC, locus coeruleus, Pd, posterodorsal tegmental nucleus 
(Paxinos et al., 1986). 
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Table 4.8 Overview of Egr-1 profile of acute antidepressant administration compared with vehicle 
Data represent effect of acute antidepressant treatment compared with vehicle treatment. T represents 
significant increase in Egr-1 mRNA expression (P < 0.05), H represents no significant difference in 
Egr-1 mRNA expression and represents significant decrease in Egr-1 mRNA expression (P < 0.05). 
Abb: Fluox, fluoxetine, Imip, imipramine, Mirtaz, mirtazapine, Org, Org 34167,2°, secondary, ctx, 
cortex, VM, ventromedial, DM, dorsomedial, DL, dorsolateral, VL, ventrolateral, Si BF, primary 
somatosensory cortex, PVA, anterior paraventricular thalamic nucleus, LOT, nucleus of the lateral 
olfactory tract, BSTMPL, nucleus of the stria terminalis medial division posterolateral part, S1Tr, primary 
somatosensory cortex trunk region, 1 °, primary, PMCo, posteromedial cortical amygdaloid nucleus, BIC, 



















ý+ rn 7 ý rn 
Ct 











Oq Ü U N 
Q 
M 
























. Ö C " 
UG 
' 
ý Ö U 
' 
U . Ö 
ý 









































ä ö o ý 













E 7 O 
K 































ý O ý O C 






> O VJ 
ý 
fx N ° "G 
^ rv ä 
> 
`o c i 
ro 
J 7 = Ü o 0 v fl . 




CC Q. ' C .3 
üý 





Chapter 4 Acute antidepressant effect on Egr-1 mRNA 
4.4 Discussion 
The aim of the present study was to examine the effect of a single i. p. injection of 
several antidepressants and a mood stabiliser on Egr-1 mRNA expression. Similar to 
previous studies a high level of Egr- I mRNA was observed in the cortex, hippocampus 
and striatum (Beckmann et al., 1997; Cochran et al., 2002; Thiriet et al., 2001), with a 
decrease along the rostrocaudal gradient. Each drug provoked differential Egr-1 mRNA 
expression throughout the brain regions analysed. In contrast to the corresponding c-fos 
study, drug-administration produced fewer significant alterations in Egr-1 compared 
with vehicle; with the exception of Org 34167, which induced the immediate early gene 
in the majority of cortical areas analysed. All drug treatments induced Egr-1 in the 
central amygdala compared with vehicle, a finding which has been shown following 
acute administration of LiCI (Lamprecht et al., 1995). A less extensive literature exists 
concerning drug modulation of Egr-1 mRNA than is available for c-fos; however, these 
studies demonstrate that Org 34167 displays characteristics akin to those of 
antidepressant and psychostimulant compounds. 
The general low induction of Egr- I mRNA in the present study has also been reported 
in previous studies examining more than one immediate early gene (Cochran et al., 
2002). The likely explanation for this is the different intracellular pathways by which, 
c-fos and Egr- I are induced. As stated before, Egr-1 tends to be used as a marker 
following sensory stimuli, whereas c-fos is used more extensively in both sensory and 
drug administration paradigms. 
The only site of common action of all the drugs in the current study was in the central 
amygdala, where all induced Egr-1 expression compared with vehicle (Table 4.4). 
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Previous studies have demonstrated that LiCI (Lamprecht et al., 1995), acute 
electroconvulsive shocks and tranylcypromine, but not 15 mg/kg imipramine (Morinobu 
et al., 1997), induce Egr-l expression in this region. Therefore, similar to c-fos, it 
appears that the central amygdala may be a region of common antidepressant action, as 
all compounds in the present study were observed to induce Egr-1 expression. 
However, methamphetamine (40 mg/kg; Thiriet et al., 2001), diazepam (2.5 &5 mg/kg; 
Malkani et al., 2000) and kainic acid induced seizures (Gass et al., 1993b) are other 
compounds, which induce Egr-1 expression in the central amygdala. The induction 
evoked by LiCl-administration was significantly greater than all other treatments, as 
was observed in the corresponding c-fos study. The reason for this is unclear, it is not 
simply due to stress, as restraint stress does not affect c-fos or Egr-1 expression in the 
central amygdala (Thiriet et al., 2001). Spencer et al., (2001) demonstrated that LiCI 
induced c fos as well as another transcription factor, inducible CAMP early repressor 
(ICER) mRNA, in the central amygdala, which is suggestive of a cAMP-dependent 
pathway. However, LiCI injection has been shown to phosphorylate MAP kinase in 
murine insular cortex and central amygdala 30 min after injection, which would lead to 
activation of the SRE in the promoter region of c-fos and Egr-1 genes. This may 
explain the high induction of the IEGs by LiCI in the central amygdala, as other 
antidepressants would be expected to only activate the CAMP-dependent elements in the 
immediate early gene promoters. Despite a trend of an increase in Egr-1 expression in 
the insular cortex following LiCl-treatment this did not reach significance. 
Similar to the c los study, Org 34167-treatment induced a robust expression of Egr-1 in 
the majority of cortical regions examined (Figures 4.2 - 4.8 and Tables 4.2 - 4.7). The 
two-fold increase in c fos observed in the retrosplenial cortex was apparent for Egr-1 
throughout this region, compared with all other treatment groups (Tables 4.4 - 4.6). 
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MK-801 (0.3 &3 mg/kg) has been demonstrated to induce the expression of both EEGs 
in this cortical region (Gass et al., 1993a). The cingulate cortex and dorsomedial 
thalamic nuclei are further areas that MK-801 induces Egr-1 protein (Gass et al., 1993a; 
Gass et al., 1993b), which were activated by Org 34167 in the present study. Therefore, 
the Egr-I profile of this novel antidepressant bears resemblance to that of 
psychostimulants, as was observed for the c-fos profile. 
The only treatment group, which induced Egr-1 mRNA expression in striatal regions, 
was the novel antidepressant Org 34167 (Tables 4.2 & 4.3). In the rostral and caudal 
dorsomedial and ventral striatum, with the exception of the nucleus accumbens core and 
shell regions, Org 34167 induced Egr-1 mRNA compared with all other treatments. 
This is in contrast to the c-fos observations, where Org 34167 only induced c-fos in the 
caudal striatum (Table 3.4). Previous studies that have reported an induction of Egr-1 
mRNA in the striatum include apomorphine (2 mg/kg) in reserpine (5 mg/kg) pretreated 
rats (Bhat et al., 1992a; Bhat et al., 1992b), as well as amphetamine (0.5 - 15 mg/kg) 
and cocaine (5,10 & 25 mg/kg; Moratalla et al., 1992) and haloperidol (1 mg/kg; 
Cochran et al., 2002). This is similar to agents, which induce c-fos expression in the 
striatum; mainly dopaminergic compounds. However, in vitro testing demonstrated that 
Org 34167 possessed low affinity for monoamine receptors and transporters, including 
dopamine (Ruigt, Personal communication). Therefore, it is possible that Org 34167, 
by blocking lb channels, alters the dopaminergic system in the striatum, which in turn 
gives rise to the induction of c-fos and Egr-1 mRNA. However, the appropriate 
experiments to verify this hypothesis, such as microdialysis, have not been performed to 
date. 
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The magnitude and widespread, induction of Egr-1 mRNA expression following acute 
Org 34167 administration, may be explained by the presence of HCNI and HCN2 
mRNA throughout the cortex (Monteggia et al., 2000; Moosmang et al., 1999). In fact, 
all the areas in which Egr-1 mRNA was induced by Org 34167 administration show 
high levels of HCN2 and HCNI mRNA, with the only exception being the striatum, 
where levels of HCNI mRNA are relatively low (Monteggia et al., 2000; Moosmang et 
al., 1999). In the ventral tegmental area and nucleus of the stria terminalis, HCN1 
mRNA is high and HCN2 expression is low and in these regions no alteration in Egr-1 
mRNA was observed; suggestive that Org 34167 effects HCNI more than HCN2. This 
coupled with the knowledge that monoamines alter the gating properties of the HCN 
channel, and also regulate the basal expression of Egr-1 in the cortex, may indicate a 
possible mechanism for the cortical induction. Another possibility is that Org 34167, by 
interacting with HCN channels, alters intracellular Ca 2+ levels, as the channel sets the 
resting membrane potential (Ludwig et al., 1998; Pape, 1996; Santoro et al., 1998). 
In conclusion, the findings of this study corroborate those of the parallel c-fos study, 
supporting a role of Org 34167 as both an antidepressant and psychostimulant. 
Furthermore, the only common site of action of all drugs examined was the central 
amygdala, where an induction of Egr-1 mRNA was observed. This provides further 
evidence supporting the use of immediate early gene mapping for the classification of 
novel compounds and identification of brain regions affected by acute drug 
administration. 
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Chapter 5 Chronic Org 34167 and antidepressant alteration of 
HCN mRNA 
5.1 Introduction 
Chronic drug treatment is often associated with alteration in the target receptor density 
and mRNA expression. This has been shown following chronic treatment with a 
number of different antidepressant drugs. Increases in glucocorticoid- and 
mineralocorticoid- receptor mRNA in the hippocampus after amitriptyline 
administration (10 mg/kg/2ld; Johansson et al., 1998). Imipramine (2x 10 mg/kg/14d), 
citalopram (2x 10 mg/kg/]4d) and lithium (6 mEq/kg/14d) treatments have been 
demonstrated to increase D2-receptor mRNA levels in the caudate putamen and nucleus 
accumbens (Dziedzicka-Wasylewska et al., 1996; Dziedzicka-Wasylewska, 1997). 
Recently, it has been demonstrated that chronic imipramine (10 mg/kg/14d) or 
electroconvulsive shock (150 mA, 0.5 s, 14d) results in an upregulation of alA- 
adrenoceptor mRNA expression (Nalepa et al., 2002). Furthermore, paroxetine (a 
SSRI) and fluoxetine (both 5 mg/kg) produced a significant downregulation of 5-HTIB 
receptor mRNA in the dorsal raphe (Anthony et al., 2000). Therefore, these examples 
provide evidence that it is possible to discern alterations at the level of mRNA, and not 
only protein, following chronic drug treatment. 
Given the knowledge that in vitro, Org 34167 only demonstrated affinity and efficacy 
for HCN channels, it may be that chronic in vivo administration leads to alteration in 
their expression. Furthermore, if I modulation is a common mechanism of 
antidepressant action it is possible that chronic administration of currently prescribed 
antidepressants affects these channels. Acute administration of fluoxetine does not alter 
HCN 1 or HCN2 channel properties in human cell lines, as determined by 
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electrophysiological recordings (Mason, Personal communication). However, with the 
knowledge that direct binding of cAMP, and PKA, modulate the properties of HCN and 
Ih channels (See Section 1.2.3) it is possible to hypothesise that chronic fluoxetine, 
which increases both cAMP and PKA (Edgar et al., 1999) may alter HCN channel 
function in vivo. Moreover, it has been demonstrated that 5-HT-receptor activation 
alters the properties of HCN channels; 5-HT-4 and 5-HT-7 receptor agonists shift the 
V1/2 to more positive potentials, whereas 5-HT1A receptor activation shifts the gating to 
more hyperpolarised potentials (Bickmeyer et al., 2002). 
The rationale for the present study was to determine whether chronic treatment of rats 
with fluoxetine, mirtazapine, lithium, or Org 34167 altered HCN channel expression. 
With no available antibody to study HCN isoform expression, in situ hybridisation 
utilising probes complementary to the different isoforms were used to determine 
whether there is a change at the mRNA level. This was examined in the corresponding 
brain regions assessed for neuronal activation in the previous c-fos and Egr-1 studies 
(Chapters 3 and 4 respectively). Additionally, the effect of chronic antidepressant 
treatment on 5-HT1A receptor mRNA expression was assessed. This was included to 
determine whether chronic Org 34167 administration had similar, or differential effect 
on 5-HT1A mRNA compared with other antidepressants, as no data concerning its effect 
on 5-HT were known. 5-HT1A receptor function is known to be modulated by 
antidepressant administration with chronic fluoxetine, desensitising 5-HT1A receptor 
function in the dorsal raph6 (Hensler et al., 2003). In contrast Hervas et al., (2001) 
demonstrated that chronic fluoxetine (3 mg/kg/2wk) administration had no significant 
affect on 5-HT1A receptor mRNA or protein expression in the dorsal raph6 or 
hippocampus. Similar findings have been reported following chronic imipramine 
treatment (5 mg/kg/8wk) in the dorsal raph6 (Burnet et al., 1994). Therefore, if Org 
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34167 is acting via a novel mechanism it may differentially regulate 5-HTIA mRNA 
expression to that of current antidepressants. 
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5.2 Materials and Methods 
5.2.1 Animals and experimental procedure 
Study A- Vehicle, fluoxetine and mirtazapine 
Male Sprague-Dawley rats (Harlan Olac, U. K. ) weighing 230 - 250 g were housed in 
groups of 6 on a 12 h light/dark cycle (lights on at 06: 00 h) at 22 ±2 °C and given free 
access to tap water and food. Rats were allowed to habituate to the conditions for 7 
days prior to the start of the experiment. 
Rats received administration of fluoxetine (5 mg/kg) or mirtazapine (2 mg/kg) dissolved 
in a5% mulgofen, 0.9 % NaCl solution, or an equal volume of vehicle (5 % mulgofen 
dissolved in 0.9 % NaCl) at a dose of 1 ml/kg i. p. once daily for 21 consecutive days 
(between 09: 00 - 10: 00 h). One day after the last injection the rats were sacrificed in a 
C02-chamber with a flow-rate of 6 1/min then decapitated using a guillotine. The 
treatment was performed by the Pharmacology Support Unit (PSU) at Organon 
Laboratories. 
Study B- Vehicle and Org 34167 treatment 
Male Sprague-Dawley rats (Harlan Olac, U. K. ) weighing 210 - 240 g were housed in 
groups of 6 on a 12 h light/dark cycle (lights on at 06: 00 h) at 22 ±2 °C and given free 
access to tap water and food. Rats were allowed to habituate to the conditions for 7 
days prior to the start of the experiment. 
Rats received an i. p. dose of Org 34167 (0.5 mg/kg) or an equal 1 mg/kg injection of 
vehicle (5 % mulgofen dissolved in 0.9 % NaCl) once daily, between 09: 00 - 10: 00 h, 
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for 28 consecutive days. One day after the last injection the rats were sacrificed in a 
C02-chamber with a flow-rate of 6 1/min then decapitated using a guillotine. The 
experiment was performed by the Pharmacology Support Unit (PSU) at Organon 
Laboratories. 
Study C- Vehicle and lithium chloride treatment 
Male Sprague-Dawley rats (Harlan Olac, U. K. ) weighing 210 - 240 g were housed in 
groups of 6 on a 12 h light/dark cycle (lights on at 06: 00 h) at 22 ±2 °C and given free 
access to tap water and food. Rats were allowed to habituate to the conditions for 7 
days prior to the start of the experiment rats received either vehicle (0.9 % NaCl 
solution) or LiCI (75 mg/kg/day) via Alzet osmotic minipumps planted subcutaneously, 
under halothane anaesthesia, for 28 days at a rate of 1 µl/h. At the end of the infusion 
the rats were sacrificed by halothane overdose and then cervical and the brains 
immediately removed and frozen in isopentane cooled on dry-ice to -32 °C and stored in 
a -80 °C freezer until required. This study was performed by Dr Caroline Stewart at the 
Department of Psychiatry, Dundee University. 
5.2.2 Cryostat sectioning 
The brains were removed from -80 °C freezer and allowed to thaw to -18 t2 °C inside 
a Bright OTF cryostat for 30 min before mounting on to a Bright orientating specimen 
holder with Cryo-M-Bed (Bright Ltd., U. K. ). Once solidly mounted, the chuck was 
attached to the microtome, with the blade aligned at an angle of 15 ° and set to collect 
sections of 20 pm. Sections were thaw-mounted on to Superfrost Plus electro-statically 
charged nuclease-free slides (VWR, formerly BDH, UK) and 4 series of 12 superfrost 
slides (BDH) with 3 sections on each slide were collected. 
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Table 5.1 Approximate bregma co-ordinates sectioned following chronic treatment and brain 
regions analysed. 
Schematics taken from Paxinos & Watson (1986). 
tlrepma J20 rtýa 
öý\; 
The cryostat sectioning was performed by Fiona Adams and Joyce van de Leemput 
(both of Organon Laboratories Ltd). For Study C only 4.7 to 4 mm and -2.5 to -3.2 mm 
relative to bregma series of slides were available for in situ hybridisation. 
5.2.3 In situ hydridisation study 
In situ hybridisation was performed as described in Section 2.2.1.3 using probes 
complementary to the HCN1 -3 and 5-HTIA transcripts (see Appendix B for probe 
details). The probes were validated as described in Section 2.2.1.4 (see Appendix C for 
autoradiograms) and analysis of the resultant autoradiograms performed as described in 
Section 2.2.1.5. 
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5.2.4 Statistical analyses 
The raw data from each brain region recorded in Study A were analysed using a One- 
way analysis of variance with Dunnett's post-hoc test. Due to the presence of only two 
treatment groups in Studies B and C, each set of raw data was analysed using an 
unpaired t-test. In all cases statistical significance was assigned when P<0.05 and 
performed using Graphpad Prism v3.02 (Graphpad Software Inc). In order to tabulate 
and graph the different studies together the raw data from each study was converted to 
% vehicle. 
5.2.5 Histological staining 
Haematoxylin and eosin staining was performed as described in Section 2.2.3.5 on 
sections, which HCN 1 in situ hybridisation had been performed. 
5.2.6 Drugs and chemicals 
Org 34167, fluoxetine and mirtazapine were synthesised by Organon Laboratories Ltd. 
See Section 2.2.1.9 for other drugs and chemicals used. 
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5.3 Results 
5.3.1 In situ hybridisation following chronic drug treatment 
In situ hybridisation utilising probes complementary to the HCN1 -3 and 5-HTIA 
transcripts following chronic drug treatment revealed differential expression levels for 
each of the different mRNAs analysed. Vehicle-treated rats were observed to display 
low expression levels of HCN3 (Monteggia et al., 2000; Moosmang et al., 1999) and 5- 
HTIA mRNA (Hervas et al., 2001), as previously described, while HCN1 and 2 mRNA 
levels were high. 
4.7 to 4 mm relative to bregma 
Chronic Org 34167 administration (0.5 mg/kg/28d) upregulated 5-HT1A mRNA in the 
secondary motor cortex, compared with vehicle (P < 0.05; Figure 5.1). No further 
significant alterations of 5-HT1A mRNA were observed at these bregma co-ordinates. 
Fluoxetine and mirtazapine treatments (5 and 2 mg/kg/21d, respectively) significantly 
downregulated HCNI mRNA in all areas of the frontal cortex and the anterior olfactory 
nucleus (P < 0.001; Figure 5.1). Org 34167 and LiCI treatment did not significantly 
affect HCN I mRNA at any region analysed. Similarly no significant effect of LiCI or 
Org 34167 administration on HCN2 mRNA was observed in any region. However, 
fluoxetine and mirtazapine downregulated mRNA expression in all cortical areas 
(P < 0.05; Figure 5.1). Chronic fluoxetine and mirtazapine administration upregulated 
HCN 3 mRNA expression in the anterior olfactory nucleus (P < 0.05) but no further 
significant differences were observed (Figure 5.1). 
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Figure 5.1 Effect of chronic antidepressant drug treatment on 5-HT1A and HCN1-3 mRNA 




Data represent mean ± s. e. mean of three sections per animal (n = 6) were optical density readings have 
been converted to nCi/g of tissue. These values have then been converted to represent % vehicle mRNA 
expression to enable the different studies to be put into one graph. Treatment groups represented; 
fluoxetine (5 mg/kg, 21-day  ), mirtazapine (2 mg/kg, 21-day Q), LiCI (75 mg/kg, 28-day ), Org 34167 
(0.5 mg/kg, 28-day ). One-way ANOVA with Dunnett's post-hoc test was performed for vehicle, 
fluoxetine and mirtazapine study. t-test was performed for vehicle and LiCI study, and for vehicle and 
Org 34167 study. *P<0.05, *** P<0.001. All statistical analyses were performed using the raw data 
and against the appropriate vehicle control. Abb: M2 ctx, secondary motor cortex, PrL ctx, prelimbic 
cortex, VM Orb, ventromedial orbital cortex, Ant. Olfact nuc, anterior olfactory nucleus (Paxinos and 
Watson, 1982). 
2.2 to 1.5 mm relative to bregma 
In this more caudal region of the rat brain, chronic mirtazapine administration 
significantly upregulated 5-HTIA in the dorsolateral and ventrolateral striatum 
(P < 0.001) and in the nucleus accumbens shell region (P < 0.05; Figure 5.3). There 
were no significant alterations at any other brain region analysed or following fluoxetine 
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or Org 34167 administration on 5-HT1A or HCN1 mRNA expression (Figure 5.3). 
Chronic Org 34167-treatment significantly downregulated HCN2 and HCN3 mRNA 
expression in the nucleus accumbens core (P < 0.01) and HCN2 expression in the 
nucleus accumbens shell, insular cortex (P < 0.001) and septum (P < 0.01). Fluoxetine 
or mirtazapine administration did not significantly alter HCN2 or HCN3 mRNA 
expression in any brain region analysed. 
Figure 5.2 Representative autoradiograms of HCN1 -3 mRNA expression in the frontal cortex 
following chronic fluoxetine or mirtazapine administration 
Vehicle Fluoxetine Mirtazapine 
HCN1 mRNA ISH 
HCN2 mRNA ISH 
HCN3 mRNA ISH 
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-2.5 to -3.2 mm relative to bregma 
In situ hybridisation demonstrated that lithium chloride administration did not 
significantly affect HCNI -3 or 5-HTIA mRNA expression levels (Table 5.2), similar 
to the results obtained in the frontal cortex (Figures 5.1 & 5.2). Fluoxetine or 
mirtazapine administration increased 5-HTIA in the primary somatosensory cortex, and 
in the thalamus the latter case only (P < 0.05; Table 5.2). Org 34167 did not alter 5- 
HT, A mRNA in any brain region analysed and fluoxetine-treatment did not significantly 
affect any of the HCN isoform mRNAs examined (Table 5.2). Chronic mirtazapine 
administration was observed to elevate HCN1 mRNA expression in the thalamus 
compared with vehicle (P < 0.05), and HCN2 expression in the posterior insular cortex 
(P < 0.05). No other significant alterations following mirtazapine treatment were 
observed for any HCN isoform (Table 5.2). Chronic administration of the novel 
antidepressant, Org 34167, downregulated HCN1 mRNA levels in the secondary 
somatosensory cortex and HCN2 mRNA in the primary somatosensory cortex 
(P < 0.05; Table 5.2). Org 34167-treatment was demonstrated to upregulate 
hippocampal levels of HCN2 and HCN3 mRNA expression, in the CA2 region and 
dentate gyrus respectively (P < 0.05; Table 5.2). 
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Figure 5.3 Effect of chronic treatment on 5-HTIA and HCN1-3 mRNA expression (2.2 to 1.5 mm 
relative to bregma) 
Data represent mean ± s. e. mean of three sections per animal (n = 6) were optical density readings have 
been converted to nCi/g of tissue. These values have then been converted to represent % vehicle mRNA 
expression to enable the different studies to be put into one graph. Treatment groups represented; 
fluoxetine (5 mg/kg, 21-day  ), mirtazapine (2 mg/kg, 21-day o), Org 34167 (0.5 mg/kg, 28-day ). 
One-way ANOVA with Dunnett's post-hoc test was performed for vehicle, fluoxetine and mirtazapine 
study. t-test was performed for the vehicle and Org 34167 study. ** P<0.01, *** P<0.001. All 
statistical analyses were performed on the raw data and against the appropriate vehicle control. Abb: 
Cing ctx, cingulate cortex, Ins ctx, Insular cortex, Pir ctx, piriform cortex, DM Str, dorsomedial striatum, 
VL Str, ventrolateral striatum, VM Str, ventromedial striatum, AcbC, nucleus accumbens core region, 
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-4.8 to -5.6 mm relative to bregma 
In the most caudal brain regions analysed neither, chronic fluoxetine or Org 34167, 
significantly affected HCNI -3 mRNA expression (Table 5.3). Chronic mirtazapine 
administration significantly downregulated HCN2 mRNA levels in the CA2 field of the 
hippocampus (P < 0.05) and increased HCN3 mRNA expression in the ventral 
tegmental area (P < 0.05; Table 5.3). No further significant alterations in HCN I-3 or 
5-HTIA mRNA levels were observed following mirtazapine treatment. Chronic Org 
34167 administration significantly increased 5-HTIA mRNA expression in the 
retrosplenial cortex by 27 % (P < 0.01; Table 5.3), and the only other alteration in 
5-HTIA mRNA levels was in an increase in the dentate gyrus following fluoxetine- 
treatment (P < 0.05). 
Figure 5.4 Representative pseudocolour representations of HCN 2 in situ hybridisation 
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5.4 Discussion 
The aim of the current study was to determine whether chronic antidepressant treatment 
altered HCN channel mRNA expression in a number of brain regions. Chronic 
fluoxetine, mirtazapine or Org 34167 differentially regulated HCN isoform mRNA 
expression compared with vehicle, whereas lithium administration had no significant 
affects. 
Chronic administrations of fluoxetine, or mirtazapine, were observed to downregulate 
HCN 1 and HCN2 mRNA in all regions of the frontal cortex analysed (Figures 5.1 & 
5.2). As discussed in Chapters 3 and 4, the frontal cortex has been implicated in 
depression, particularly the orbital cortex (Drevets, 2000; Tekin et al., 2002). Acute 
fluoxetine has been demonstrated to be inactive in electrophysiological studies 
involving Chinese Hamster Ovary cells overexpressing HCN 1 (Mason, Personal 
communication) but there are a number of possible reasons to explain the current 
findings. The main factors believed to modulate ion channel gene expression include, 
repetitive activity, depolarisation, protein kinase activation or elevation of intracellular 
Ca2+ (Kang et al., 1997; Roden et al., 1994). HCN channels are positively modulated 
by PKA and cAMP, which fluoxetine has been demonstrated to increase (Edgar et al., 
1999). Moreover, it has been shown that 5-HT receptor activation alters the properties 
of HCN 2 channels; 5-HT4- and 5-HT7-receptor agonists shift the V1/2 to more 
depolarised potentials, whereas 5-HTIA-receptor activation shifts gating to more 
hyperpolarised membrane potentials. This could explain the downregulation of HCN 2 
mRNA observed following chronic fluoxetine or mirtazapine administration, as both 
drugs increase in 5-HT release (de Boer, 1996; Hervas et al., 2001), which could then 
lead to an overactivation of HCN channels. 
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The fact that HCN1 channels are poorly modulated by cAMP (Table 1.4), is suggestive 
of a different mechanism behind the downregulation in mRNA expression. It is 
possible that if chronic fluoxetine or mirtazapine administration alter the properties of 
HCN2 isoforms to increase cell firing, there is a concurrent increase in HCN 1 channel 
opening, which display faster kinetics than HCN2 channels. Another possibility is that 
heteromeric HCN 1 and HCN2 channels are present in the frontal cortex, as has been 
demonstrated in cells expressing both isoforms (Ulens et al., 2001a). If heteromeric 
channels were the case, it would may expected that alteration of either isoform would be 
reflected in the other. 
This regulation of HCN channel isoform expression in the frontal cortex by fluoxetine 
and mirtazapine may represent a therapeutic action, which is exploited by the direct 
blocker Org 34167. The fact that Org 34167 does not alter HCN channel expression in 
the frontal cortex, suggests that fluoxetine and mirtazapine modulate the channel via an 
indirect action in the frontal cortex. Additionally, the fact that fluoxetine or mirtazapine 
administration did not alter 5-HTIA or HCN3 mRNA expression in these regions implies 
that the downregulation of HCN1 and HCN2 is a specific effect. This may have 
implications regarding the delayed onset of action of these current antidepressants. It is 
believed that adaptive changes underlie the delay in antidepressant action and this 
modulation of HCN isoforms following chronic treatment may represent one such 
adaptive response to chronic drug treatment. If this were the case it may be that by 
directly targeting HCN channels with drugs such as Org 34167 that a faster onset of 
clinical benefit may be achieved. If part of the antidepressant profile of fluoxetine and 
mirtazapine is to chronically downregulate HCN expression, Org 34167, by directly 
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blocking the channel would negate the requirement of chronic downregulation of the 
channel by acting there immediately. 
Org 34167-treated rats display an upregulation of 5-HT1A expression in the secondary 
and retrosplenial cortices (Figure 5.1 and Table 5.3), as was demonstrated for c-fos and 
Egr-1 mRNA. Activation of postsynaptic 5-HTIA receptors is associated with head- 
weaving (Hoyer et al., 2002), as is the retrosplenial cortex, which has been implicated 
as the region responsible for MK-801 associated head-weaving (Wozniak et al., 1996). 
Taken as a whole, this is suggestive that Org 34167 indirectly activates 5-HT1A- 
receptors which results in head-weaving behaviour. 
Org 34167 treatment resulted in a downregulation of HCN2 mRNA expression in the 
anterior insular and piriform cortices and the nucleus accumbens core and shell regions, 
as well as HCN3 in the accumbens core (Figure 5.3). The anterior insular cortex and 
nucleus accumbens are important regions in emotion, and as previously discussed 
display altered metabolism in patients with depression (Drevets, 2000). It is possible 
therefore, that Org 34167 is acting in these two brain regions to normalise brain activity 
via HCN channel modulation. The finding that the antagonist Org 34167 downregulates 
the expression of HCN2 mRNA, is similar to the administration of a2-adrenoceptor 
antagonists, which are known to downregulate a2-adrenoceptor expression (Heal, 1990). 
Furthermore, the striatum is predominantly comprised of HCN2 mRNA, which may 
imply that Org 34167 treatment reduces the number of functional channels in the 
accumbens. This could be delineated by measuring protein expression with an 
antibody. 
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Org 34167 treatment significantly downregulated HCN1 and HCN2 mRNA expression 
in the secondary and primary somatosensory cortices, respectively, compared with 
vehicle (Table 5.2). The somatosensory cortex projects to the striatum and is involved 
in the control and sequencing of movements, including grooming, head and forelimb 
co-ordination (Hoover et al., 2003). Ih channels are of highest density in apical 
dendrites in layer V pyramidal cells (Berger et at., 2001; Santoro et al., 1997). 
Therefore, modulation of HCN isoform expression in these regions may partially 
explain the tremorogenic side-effects observed following Org 34167 administration 
(Blackburn-Munro et at., Personal communication). Interestingly, fluoxetine and 
mirtazapine were demonstrated to elevate 5-HT1A receptor mRNA expression in the 
primary somatosensory cortex (Table 5.2), which may be a compensatory adaptation to 
chronic desensitisation of the receptors. Le Poul et at., (2000) previously demonstrated 
that chronic fluoxetine treatment (8 mg/kg/21d, i. p. ) did not affect 5-HT1A mRNA 
expression in the forebrain. However, this finding was performed on total RNA extract, 
whereas the present study used Densitometric analysis of individual brain regions. 
Hippocampal HCN mRNA was differentially regulated by mirtazapine and Org 34167 
treatment. The former downregulated HCN2 mRNA in the caudal CA2 region, and Org 
34167 upregulating HCN2 expression in the rostral CA2 field and HCN3 levels in the 
dentate gyrus (Tables 5.2 and 5.3). The differential regulation of hippocampal HCN 
expression is interesting, as Ih activation has been associated with hippocampal long 
term potentiation (Chevaleyre et al., 2002; Mellor et al., 2002). Additionally, 
Brewester et al., (2002) demonstrated that kainate-induced seizures in immature rats 
resulted in elevated HCN2 expression in all hippocampal fields and decreased HCN1 
mRNA in the CAl field in the adults. This is similar to the HCN2 mRNA increase 
observed following Org 34167 administration, which produces tremors in adult rats at 
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the same dose as used in the present study (0.5 mg/kg). Increased HCN2 mRNA 
expression, if translated to active channels would lead to enhanced depolarisation in the 
hippocampus, which would in turn cause LTP (Chevaleyre et al., 2002; Mellor et al., 
2002). No treatment significantly altered 5-HT1A receptor mRNA expression in the 
hippocampus, as has been shown previously following fluoxetine administration (3 
mg/kg, i. p., 14d; Hervas et al., 2001). 
Chronic mirtazapine administration was demonstrated to increase both 5-HT1A-receptor 
and HCN1 mRNA expression in the thalamus (Table 5.2), which is an important brain 
region in the control of sleep organisation. Ih channels in the thalamus are believed to 
play a crucial role in sleep via modulation of spindle wave duration and frequency in the 
thalamus (McCormick et al., 1997). Therefore, it is possible that mirtazapine, by 
increasing the expression of HCN1 mRNA alters the properties of these oscillations, 
which then has a rebound effect on sleep organisation. 
In conclusion, chronic treatment with a variety of antidepressants differentially 
modulates HCN mRNA expression in the rat brain. Fluoxetine and particularly 
mirtazapine were observed to alter HCN channel expression in a number of brain areas, 
including the frontal cortex. This has potential implications in their mechanisms of 
action due to the role that Ih channels play in neuronal activity and organisation of 
neuronal networks and may represent an adaptive change underlying antidepressant 
action. Org 34167 treatment also altered HCN isoform expression, in the anterior 
insular cortex and nucleus accumbens, two regions implicated in depression, and may 
represent a basis for it's antidepressant profile. Additionally, if the adaptive changes 
observed following fluoxetine and mirtazapine are required for clinical benefit, directly 
targeting Ih channels with Org 34167 may provide a faster onset of action. 
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The fact that the mechanism of action of currently prescribed antidepressants are 
modulation of the monoamine system has lead to increasing difficulty to find new drugs 
to attain approval. This has increased interest and research into potential 
antidepressants with novel mechanisms of action in a bid to improve efficacy and onset 
of clinical benefit. The focus of this thesis has been on one such novel antidepressant; 
Org 34167, which is presently entering Phase II clinical trials. Prior to entering clinical 
trials, the compound was subject to a battery of assays, which demonstrated that the 
compound displayed high affinity for Ih channels (Ruigt, Personal communication). 
However, a lack of selective pharmacological tools to study the behavioural effects of Ih 
channels in vivo has hindered further insight into the channels potential role in 
depression. It is unknown whether blockade of Ih channels is responsible for the 
antidepressant-like effect of Org 34167 in pre-clinical animal models. In order to 
address this, a number of different approaches have been performed in the course of this 
thesis to examine Org 34167 and a number of clinically used antidepressants. 
Antisense oligonucleotides have been employed to inhibit numerous specific proteins to 
improve the understanding of their function and were used in the current studies in an 
attempt to elucidate the mechanism of action of Org 34167. It was unknown, which, if 
any, HCN isoform is responsible for the antidepressant-like effect of Org 34167, with 
electrophysiological studies revealing that the compound inhibits HCN1,2 and 4 
homomeric channels with similar affinity (Mason, Personal communication). The 
HCN2 isoform was initially targeted due to both its widespread distribution and high 
expression throughout the rat CNS (Monteggia et al., 2000). Despite designing 
numerous antisense sequences complementary to regions along the length of the HCN2 
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transcript and altering the backbone chemistry of the oligonucleotides no successful 
sequence was demonstrated. However, with the radioligand [3H]-Org 34167 proving 
unsuitable for autoradiography and no available HCN2 antibody at the time of 
experiments only mRNA expression was quantified. Although antisense technology is 
an extremely powerful tool, it has been proved more difficult than expected to design 
efficient sequences. There are numerous reasons for this, the main one of which is the 
believed inaccessibility of the oligonucleotide to the folded RNA molecule. Indeed, it is 
estimated that only 1 in 10 antisense sequences cause downregulation of the target 
protein (Smith et al., 2000). Additional problems with toxicity, which the introduction 
of phosphorothioate oligonucleotides causes, also hindered design of a successful 
sequence (see Chapter 2 discussion). 
The recent discovery of the phenomenon of RNA interference (RNAi) may provide a 
possible alternative to antisense oligonucleotide infusion. RNAi is a process, which 
achieves gene silencing via complementary double-stranded RNA (dsRNA) sequences 
of 21 - 23 nt termed short-interfering RNAs (siRNA; Fire et al., (1998); Tabara et al., 
(1999)). One strand of siRNA then forms an RNA-induced silencing protein complex 
(RISC) which then cleaves the complementary mRNA (Elbashir et al., 2001; Martinez 
et al., 2002). It may be that when Zamecnik & Stephenson (1978) used phosphodiester 
oligonucleotides that they had accidentally stumbled across an artificial RNAi process. 
In a recent study, Bertrand et al., (2002) demonstrated that after 5 and 20 h incubations 
siRNA was more efficient than its complementary antisense sequence. Therefore, it is 
possible that a siRNA to the HCN2 antisense sequences used in the present studies 
would produce an effective downregulation of the HCN2 isoform. However, the major 
limiting factor with siRNA at present is their use in vivo which is the final step to 
overcome before their widespread employment. 
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A method, which has gained increasing prominence in gaining insight into the 
mechanism of drug effects is immediate early gene (EEG) neuronal activity mapping. 
Examination of the EEG profiles of numerous psycho-active drugs, suggest that related 
classes of drug evoke a similar expression pattern (See Chapters 3&4 Discussion). 
Therefore, in addition to determining which brain regions a compound acutely affects, it 
appears that it may represent a pre-clinical method for characterising novel compounds 
before they undergo expensive behavioural screening. In an attempt to characterise the 
novel antidepressant, Org 34167, a range of antidepressant classes were subjected to 
EEG mapping throughout the rat CNS. Previous studies using fluoxetine, imipramine 
and LiCI only focussed on a small number of brain regions, such as the amygdala, 
striatum and hippocampus (Beck, 1995; Duncan et al., 1996; Lamprecht et al., 1995), 
which necessitated their inclusion in the present trial. Additionally, EEG mapping 
studies are sensitive to environmental factors and show circadian oscillations (Hess et 
al., 1995; Ziolkowska et al., 2002) therefore employing all the drugs in the same 
laboratory and within a tight timeframe maximises experimental control. As discussed 
in Chapters 3 and 4, all the compounds differed in their IEG profile but there were a 
number of common findings in brain regions implicated in depression. All drugs 
similarly affected c-fos expression in the central amygdala, which had previously been 
demonstrated for fluoxetine, imipramine (c-fos; Beck, (1995); Duncan et al., (1996) and 
LiCI (Egr-1; Lamprecht et al., 1995). Furthermore, in two more regions associated with 
depression, the septum and anterior insular cortex, all drugs had a similar effect on c-fos 
expression (Table 3.3). However, in the corresponding Egr-1 study only the central 
amygdala was demonstrated as a site of common manipulation by acute drug treatment 
and in general, substantially fewer brain regions showed altered expression compared 
with vehicle (see Table 4.8). This is with the exception of Org 34167, which 
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significantly increased Egr-1 in the majority of cortical regions examined (Table 4.8). 
Interestingly, this was also witnessed in the corresponding c-fos study, with fluoxetine 
being the only other drug to show cortical c fos induction, but in fewer regions (Table 
3.9). The strong cortical induction of IEGs by Org 34167 is interesting, as throughout 
the cortex, HCN1 and 2 expression is high (Lorincz et al., 2002; Monteggia et al., 2000; 
Moosmang et al., 1999), which is suggestive of the presence of a high density of 
channels. Indeed, the majority of sub-cortical regions in which an induction of IEG 
expression was observed also possess high levels of HCN 1 and 2 expression, with the 
exception of the striatum where HCN 2 is the dominant isoform (Monteggia et al., 
2000; Moosmang et al., 1999). This is suggestive, given the in vitro data (Ruigt, 
Personal communication), that HCN 1 and 2 isoforms play a prominent role in the 
mechanism underlying this induction. Clearly more experiments are required to 
substantiate this hypothesis, and a similar experiment could be performed using HCN 
knockout mice. 
The widespread activation of IEG expression caused by Org 34167 (0.5 mg/kg) implies 
that this dose evokes a widespread activation of these genes. A previous study 
examining two doses of LiCl demonstrated that, while c-Fos was only significantly 
induced in the amygdala with a low dose (20 mg/kg), a much more widespread 
induction was observed with a higher dose (100 mg/kg; Hamamura et al., (2000)). It 
would be interesting to discern whether Org 34167 displays a similar dose relationship. 
However, the dose used in the present study was that established to display 
antidepressant-like properties in the DRL 72 and ACSO animal model paradigms and 
lower doses may not retain the antidepressant profile (Ruigt, Personal communication). 
Analysis of previous c-fos neuronal mapping studies reveals that this strong cortical 
induction is akin to psychostimulant drugs, such as amphetamine, cocaine, MK-801 and 
PCP (See Section 3.4). Despite fewer studies involving Egr-1, similar cortical 
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activation has been demonstrated with psycho-stimulants (Saffen et al., 1988). 
Therefore, despite the novel antidepressant Org 34167 displaying characteristics of 
current clinically used antidepressants (in the central amygdala, anterior insular cortex 
and septum) it also shares a similar profile to that of psychostimulants. The similarity 
of the EEG profile to that of psychostimulants is interesting, especially as the dose used 
is active in the rat intracranial self-stimulation paradigm (Ruigt, Personal 
communication). Obviously if this were to translate into human studies it warrants 
further investigation. A number of pre-clinical behavioural tests could be performed to 
establish the validity of this hypothesis. However, this psychostimulant profile may 
account for Org 34167's antidepressant-like properties as NMDA antagonists also 
display antidepressant properties (Berman et al., 2000; Trullas et al., 1990). 
The current studies demonstrate that Org 34167 acutely activates brain regions 
associated with antidepressant drug administration and implicates the HCN channel in 
depression. Chronic treatment (21-day) with Org 34167, fluoxetine or mirtazapine, but 
not LiCl altered HCN isoform mRNA expression in a number of brain regions (see 
Chapter 5). If these alterations in HCN mRNA expression were mirrored in protein 
levels, it would indicate a potentially important mechanism of action of current 
antidepressants and also provide further evidence of these channels roles in depression. 
Fluoxetine has been demonstrated to be less selective for 5-HT reuptake inhibition than 
first thought, displaying affinity for 5-HT reuptake transporter and delayed rectifier 
K(v) potassium currents (Choi et al., 1999; Yeung et al., 1999). It also alters mRNA or 
protein expression of µ-opioid, D2, D3, CRF and glucocorticoid receptors (Ainsworth et 
al., 1998a; De Gandarias et al., 1999; Dziedzicka-Wasylewska et al., 1997b; Torres et 
al., 1998). Alteration in HCN channel density and/or isoforms would lead to large 
changes in both gating and subsequent transmitter release. With evidence suggesting 
that HCN channels are directly coupled to presynaptic vesicular machinery (Beaumont 
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el at., 2000), modulation of HCN channels may alter neurotransmitter release, which 
may be an important component of antidepressant drug action. The fact that in Phase I 
clinical trials Org 34167 prolonged REM sleep in healthy volunteers (vanBerkel, 
Personal communication) and the importance of Ih channels in thalamic sleep-wake 
organisation (McCormick et al., 1997) indicates another potential link between the 
channels and depression. 
The observations described in this thesis have helped to characterise the novel 
antidepressant Org 34167 and have provided a link between Ih (HCN) channels and 
depression. There is also insight into current antidepressants, revealing which brain 
regions they acutely target and evidence supporting a link between current 
antidepressants and HCN channel expression following chronic treatment. These 
observations strengthen the rational for targeting Ih channels to treat depression. 
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Appendix A- Buffers used 
10 mM Phosphate Buffered Saline Solution pH 7.4 
1. Dissolve 2.76 g di-sodium hydrogen orthophosphate in 100 ml dH2O (Solution 
A). 
2. In a separate container, dissolve 0.83 g sodium di-hydrogen orthophosphate in 
30 ml dH2O (Solution B). 
3. Add 80.8 ml Solution A and 19.0 ml Solution B to 1900 ml dH2O to make a final 
volume of 2 L. 
4. Finally, add 18 g NaCl to the final solution. 
4% Para formaldehyde 
1. Add 24 g paraformaldehyde and 5.4 g NaCl in 600 ml DEPC-treated H20- 
2. Heat to approximately 80 °C to dissolve the paraformaldehyde. 
3. When dissolved add 36 ml NaOH to clear solution. 
Paraformaldehyde can be stored for 2 weeks at 4 °C 
Gelatin subbing solution 
1. Add 7.5 g gelatin and 0.9 g chromic potassium sulphate in 1.5 L dH2O. 
2. Stir and heat solution (do not allow to boil) for 2h to dissolve. 
Acetic anhydride solution 
1. Dissolve 11.15 g triethanolamine and 5.4 g NaCl in 600 ml DEPC-treated H20. 
2. Add 1.5 ml acetic anhydride and stir solution. 





1. Add 20 ml concentrated hydrochloric acid (HCl) to IL methanol 
20x standard sodium citrate solution 
I. Dissolve 439.3 g NaCl in 2.5 L DEPC-treated H2O to give a final concentration 
of 3M. 
2. Add 220.5 g trisodium citrate to create a final concentration of 0.3 M. 
3. Adjust pH to 7 with NaOH. 
'Maximalist' hybridisation solution 
1. Into a sterile screw capped 50 ml tube add 25 ml formamide and 5g dextran 
sulphate. 
2. Shake well to speed up dissolving process. 
3. Add 10 ml 20x SSC, 5 ml Denhardt's solution, 1 ml 10 mg / ml Salmon testes 
DNA, 0.5 ml 10 mg / ml Poly-A and 1 ml 1M DTT. 
4. To dissolve stir and heat (do not allow to boil). 
5. Once dissolved make up to a final volume of 50 ml with DEPC-treated H20. 
Maximalist hybridisation buffer is stable for 6 months stored at 4°C. 
0.2 and 0.4 % glacial acetic acid in ethanol 
1. Add I ml glacial acetic acid to 400 ml 100 % ethanol (0.2 % glacial acetic acid 
in ethanol). 
2. In a separate container add 1.6 ml glacial acetic acid to 400 ml 100 % ethanol 
(0.4 % glacial acetic acid). 
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0.25 % Cresyl Violet 
1. Add 4.8 ml glacial acetic acid to 400 ml deionised H20. 
2. In a separate container dissolve 2.7 g sodium acetate in 100 ml deionised H20. 
3. Add the solutions together and stir to produce 200 mM acetate buffer. 
4. Finally add Ig cresyl violet to 400 ml 200 mM acetate buffer and stir 
continuously for 7 days. 
3M sodium acetate, pH 5.5 
1. Dissolve 2.46 g sodium acetate in 10 ml DEPC-treated H20- 
2.2. Adjust to a final pH of 5.5 with concentrated HCI. 
0.1 M acetate buffer, pH 6.0 
I. Dissolve 0.82 g sodium acetate in 100 ml dH2O then adjust to pH 6.0 by adding 
glacial acetic acid. 
Acetylcholinesterase incubating medium 
1. Firstly, prepare 0.1 M acetate buffer, pH 6,0.1 M sodium citrate and 0.03 M 
cupric sulphate solutions (all in dH2O) 
2. To make 20 ml add 0.01 g acetylthiocholine iodide to 13 ml 0.1 M acetate 
buffer 
3. Mix well then add 1 ml 0.1 M sodium citrate, 2 ml 0.03 M cupric sulphate, 4 ml 
dH2O and 12 mg ethopropazine (inhibitor of butylcholinesterase). 
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Appendix C- In situ probe validation 
5-HT1A probe validation 
Figure C. 1: In situ autoradiograms for 5-HTIA probe validation. 
AB C 
A= Standard protocol, B= RNase A pre-treated tissue and C= excess unlabelled probe 
ß-actin probe validation 
Figure C. 2: In situ autoradiograms for ß-actin probe validation. 
BC 
A= Standard protocol, B= RNasc A pre-treated tissue and C= excess unlabelled probe 
c-fos probe validation 









Egr-1 probe validation 
Figure C. 4: In situ autoradiograms for Egr-1 probe. 
A __ý w. ý B 
C 
A= Standard protocol, B= RNase A pretreated tissue and C= excess unlabelled probe 
HCN1 probe validation 
Figure C. 5: In situ autoradiograms for HCNI probe validation. 
A BC 
A= Standard protocol, B= RNase A pretreated tissue and C= excess unlabelled probe 
HCN2 probe validation 
Figure C. 6: In situ autoradiograms for HCN2 probe validation. 
C 
A= Standard protocolControl, B= RNasc A pretreated tissue and C= excess unlabelled probe 
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HCN3 probe validation 




A= Control, B= RNasc A pretreated tissue and C= excess unlabelled probe 
246 
Appendices 
Appendix D- Raw data for figures and tables represented as % 
vehicle 
Tables D. 1 Raw data of chronic antidepressant studies A-C (4.7 to 4 mm relative to bregma) 
5-HT1 A mRNA Vehicle Lithium 
expression Average sem Average sem 
M2 Ctx 57.13 12.33 57.73 3.95 
Prelimbic ctx 62.98 11.38 61.17 4.61 
VM orbital ctx 68.39 9.74 73.18 2.48 
Ant. Olfact nuc 33.40 11.68 44.74 1.86 
HCN1 mRNA Vehicle Lithium 
expression Average sem Average sem 
M2 Ctx 16.61 0.65 16.87 1.33 
Prelimbic ctx 20.99 1.21 21.15 1.77 
VM orbital ctx 19.94 1.89 22.26 1.97 
Ant. Olfact nuc 39.40 1.45 39.81 1.89 
HCN2 mRNA Vehicle Lithium 
expression Average sem Average sem 
M2 Ctx 127.33 2.94 122.16 2.40 
Prelimbic ctx 140.10 5.79 132.79 4.63 
VM orbital ctx 157.87 2.48 154.95 3.11 
Ant. Olfact nuc 164.89 7.73 150.77 3.34 
HCN3 mRNA Vehicle Lithium 
expression Average sem Average sent 
M2 Ctx 63.46 8.35 62.11 12.25 
Prelimbic ctx 103.45 11.07 101.78 23.19 
VM orbital ctx 100.11 10.48 103.48 21.46 
Ant. Olfact nuc 150.23 8.45 157.36 9.98 
5-HT1A mRNA Vehicle Fluoxetine Mirtazapine 
expression Avera e sem Average sem Average se 
M2 Ctx 33.49 2.34 34.05 1.00 32.24 2.06 
Prelimbic ctx 61.36 4.08 64.32 2.55 62.19 3.17 
VM orbital ctx 55.30 4.16 64.94 3.49 57.12 2.25 
Ant. Olfact nuc 58.62 5.78 73.08 5.80 73.18 3.94 
HCN1 mRNA Vehicle Fluoxetine Mirtazapine 
expression Average sem Average sem Average sem 
M2 Ctx 36.93 0.72 19.55 1.31 16.77 0.68 
Prelimbic ctx 43.96 1.21 24.59 1.19 22.09 0.99 
VM orbital ctx 48.48 0.84 27.27 1.71 23.89 0.60 
Ant. Olfact nuc 41.33 2.52 22.56 1.51 19.86 0.60 
HCN2 mRNA Vehicle Fluoxetine Mirtazapine 
expression Average sem Average sem Average sem 
M2 Ctx 209.11 7.61 169.81 1.55 169.30 5.07 
Prelimbic ctx 278.12 10.11 
225.25 3.73 225.46 6.86 
VM orbital ctx 232.94 10.15 187.33 4.12 187.18 7.68 











M2 Ctx 57.20 6.27 62.20 4.32 62.72 3.09 
Prelimbic ctx 89.20 12.02 89.40 6.84 87.42 3.86 
VM orbital ctx 83.46 10.71 87.86 6.50 85.81 3.53 
Ant. Olfact nuc 100.82 7.57 121.14 4.86 125.21 2.93 
5-HT1A mRNA Vehicle Org 34167 
expression Average sem Average sem 
M2 Ctx 56.43 2.17 64.46 2.63 
Prelimbic ctx 81.90 4.85 82.79 1.95 
VM orbital ctx 78.11 3.73 82.16 2.97 
Ant. Olfact nuc 38.26 4.97 35.06 2.24 
HCN1 mRNA Vehicle Org 34167 
expression Average sem Average sem 
M2 Ctx 24.34 2.87 24.68 1.08 
Prelimbic ctx 32.47 3.33 33.18 2.67 
VM orbital ctx 32.54 4.09 31.90 2.61 
Ant. Olfact nuc 39.12 3.17 38.90 1.73 
HCN2 mRNA Vehicle Org 34167 
expression Average sem Avera e sem 
M2 Ctx 154.91 4.05 152.53 6.87 
Prelimbic ctx 165.00 5.88 162.01 2.52 
VM orbital ctx 176.17 3.92 175.28 3.96 
Ant. Olfact nuc 173.96 2.44 175.40 5.37 
HCN3 mRNA Vehicle Org 34167 
expression Average sem Average sem 
M2 Ctx 52.43 7.11 38.65 4.61 
Prelimbic ctx 81.27 7.69 75.42 10.40 
VM orbital ctx 82.27 10.92 67.40 8.89 
Ant. Olfact nuc 120.86 4.15 120.60 8.29 
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Tables I). 2 Raw data of chronic antidepressant studies A-C (2.2 to 1.5 mm relative to bregma) 






Cing ctx 58.10 2.61 51.92 2.07 
Ins ctx 34.07 1.20 33.13 1.78 
Pir ctx 55.20 2.39 50.62 1.03 
Septum 91.37 2.88 94.25 2.98 
DM str 13.70 2.20 16.51 1.27 
DL str 14.20 2.58 16.31 0.73 
VL Str 10.55 1.94 15.18 1.48 
VM str 11.56 1.82 15.21 1.23 
AcbC 11.20 1.43 14.80 1.53 




Average SD n sem 
Org34167 
Average SD n sem 
Cing ctx 30.76 4.11 6.00 1.68 29.88 6.24 6.00 2.55 
Ins ctx 26.19 5.26 6.00 2.15 21.40 3.02 6.00 1.23 
Pir ctx 45.32 9.33 6.00 3.81 37.90 6.14 6.00 2.51 
Septum 41.24 8.94 6.00 3.65 38.15 9.19 6.00 3.75 
DM str 6.05 0.90 6.00 0.37 6.70 1.48 6.00 0.60 
DL str 5.76 1.08 6.00 0.44 6.96 1.25 6.00 0.51 
VL Str 5.27 0.88 6.00 0.36 6.33 0.82 6.00 0.34 
VM str 5.59 0.68 6.00 0.28 6.41 1.65 6.00 0.67 
AcbC 6.37 0.39 6.00 0.16 7.09 1.46 6.00 0.60 
AcbSh 7.27 2.21 6.00 0.90 6.37 1.18 6.00 0.48 
HCN2 mRNA Vehicle Org34167 
expression Average sem Average sem 
Cing ctx 228.68 9.66 225.12 6.23 
Ins ctx 155.93 6.46 121.86 3.46 
Pir ctx 308.16 15.71 250.25 6.82 
Septum 184.75 6.55 172.05 5.90 
DM str 156.52 5.88 148.11 4.70 
DL str 195.31 7.65 190.20 4.58 
VL Str 162.56 8.86 150.45 4.58 
VM str 125.89 6.00 110.74 4.78 
AcbC 131.85 5.44 107.52 5.09 
AcbSh 144.33 4.28 108.03 4.52 
HCN3 mRNA Vehicle Org34167 
expression Average sem Average sem 
Cing ctx 27.62 1.07 28.20 2.13 
Ins ctx 26.08 1.03 23.09 1.72 
Pir ctx 24.56 1.51 31.97 4.08 
Septum 16.85 1.47 28.61 6.15 
DM str 12.46 0.67 10.29 1.14 
DL str 10.88 0.73 10.21 0.60 
VL Str 9.93 1.16 9.40 0.87 
VM str 11.39 0.50 9.92 1.41 
AcbC 12.49 0.52 9.55 0.69 











Cing ctx 37.65 1.78 42.04 1.62 42.71 1.86 
Ins ctx 58.65 2.20 63.10 4.67 65.81 3.46 
DM str 52.50 2.63 48.72 0.79 49.82 1.79 
DL str 98.76 5.52 98.33 3.08 105.24 5.17 
VL Str 17.74 5.79 10.37 1.26 19.63 1.75 
VM str 12.29 1.38 11.81 0.33 18.02 1.48 
AcbC 8.73 1.30 11.30 1.36 16.95 1.13 
AcbSh 9.25 1.64 8.78 1.25 13.37 1.43 
Septum 11.00 3.03 7.58 1.14 13.85 1.31 
Pir ctx 8.76 1 . 









Cing ctx 20.58 2.14 20.95 1.48 21.79 0.82 
Ins ctx 16.84 1.64 18.06 1.56 18.78 0.76 
DM str 3.54 0.20 3.34 0.25 3.55 0.12 
DL str 3.22 0.23 3.39 0.33 3.66 0.15 
VL Str 3.16 0.18 3.15 0.32 3.37 0.19 
VM str 3.38 0.19 3.70 0.39 3.66 0.18 
AcbC 3.41 0.28 3.68 0.41 3.55 0.24 
AcbSh 4.65 1.10 4.00 0.46 4.12 0.15 
Septum 19.20 1.72 20.12 1.34 20.93 0.74 









Cmg ctx 251.14 2.14 274.78 10.84 259.69 6.67 
Ins ctx 174.87 15.85 163.54 9.65 157.88 6.58 
Pir ctx 255.46 9.09 268.18 12.30 279.50 10.97 
Septum 203.14 4.81 201.02 7.37 186.61 6.86 
DM str 149.42 5.30 161.01 6.26 151.32 6.22 
DL str 189.72 5.14 201.54 7.37 195.47 7.05 
VL Str 174.54 6.57 176.90 9.79 168.39 8.17 
VM str 126.58 4.43 133.98 4.79 125.97 5.50 
AcbC 122.36 4.84 127.48 5.73 121.57 5.91 









Cing ctx 48.24 2.09 47.75 2.07 49.42 1.42 
Ins ctx 35.19 3.96 31.96 1.54 30.85 1.69 
Pir ctx 116.19 5.98 112.60 4.40 122.40 6.33 
Septum 90.04 5.68 94.04 3.33 99.71 4.59 
DM str 73.48 4.07 68.67 3.69 84.00 5.59 
DL str 66.26 2.32 68.15 4.33 73.10 3.85 
VL str 72.09 3.50 69.71 4.21 78.14 4.25 
VM str 79.87 4.85 77.44 3.43 83.38 3.91 
AcbC 76.25 5.18 78.16 4.81 82.23 2.87 
AcbSh 74.50 3.02 79.09 2.89 82.48 4.49 
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Tables D. 3 Raw data of chronic antidepressant studies A-C (-2.5 to -3.2 mm relative to bregma) 
5-HT1A mRNA Vehicle Lithium 
expression Average sem Avera e sem 
RSGb 4.17 1.02 3.74 0.78 
S1 ctx 6.70 0.87 6.93 0.89 
S2 ctx 5.26 0.61 5.49 0.55 
Ins ctx 5.38 0.59 6.62 0.82 
Pir ctx 9.95 1.09 9.75 0.57 
CA1 18.60 1.14 18.37 0.99 
CA2 18.36 2.09 18.88 1.08 
CA3 27.10 1.42 30.87 1.39 
Dg 53.26 3.28 55.87 2.58 
Thal 2.71 0.25 3.12 0.36 
CeA 2.09 0.34 2.49 0.37 
HCN1 mRNA Vehicle Lithium 
expression Average sem Average sem 
RSGb 58.98 6.10 67.14 3.92 
S1 40.18 4.06 33.10 3.38 
S2 ctx 46.38 4.86 37.48 3.39 
Ins ctx 38.72 1.44 35.04 1.69 
Pir ctx 45.40 7.49 40.21 3.88 
MeA 79.53 2.34 65.12 4.36 
CA1 71.82 5.46 70.87 3.24 
CA2 53.95 2.96 56.78 2.33 
CA3 41.48 6.04 46.98 3.41 
Dg 23.12 8.77 18.43 1.65 
Thalamus 48.20 4.55 48.74 3.60 
HCN2 mRNA Vehicle Lithium 
expression Average sem Average sem 
RSGb 67.37 4.89 58.24 2.67 
S1 35.98 2.26 34.10 1.11 
S2 ctx 41.61 3.01 37.09 1.47 
Ins ctx 35.11 3.51 35.35 2.23 
Pir ctx 26.63 1.21 28.90 1.89 
MeA 36.88 2.06 37.19 2.07 
CA1 38.28 2.38 38.73 2.74 
CA2 57.85 3.81 52.54 2.57 
CA3 39.73 2.56 41.49 2.66 
Dg 71.24 6.01 64.41 3.77 
Thalamus 28.90 3.14 32.34 1.80 
HCN3 mRNA Vehicle Lithium 
expression Average sem Average sem 
RSGb 29.73 3.13 28.20 3.04 
S1 ctx 27.26 2.30 25.34 2.96 
S2 ctx 28.23 2.36 23.84 2.89 
Ins ctx 35.19 2.57 27.16 3.05 
Pir ctx 33.30 3.06 27.20 2.54 
CA1 26.28 1.97 23.13 1.71 
CA2 35.45 2.94 31.44 3.36 
CA3 39.33 3.65 34.37 4.33 
Dg 37.12 2.30 33.64 3.48 
Thalamus 30.34 2.14 25.74 1.79 
CeA nd nd nd nd 
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5-HT1 A mRNA Vehicle Org 34167 
expression Average gem Average sem 
RSGb 25.87 1.01 28.13 1.14 
S1 ctx 37.49 1.18 39.63 0.76 
S2 ctx 41.35 1.31 39.46 1.82 
Ins ctx 39.57 0.94 41.87 1.51 
Pir ctx 60.98 5.85 57.93 3.58 
CA1 91.95 6.84 106.05 4.76 
CA2 92.64 7.59 113.15 8.41 
CA3 127.31 12.29 148.30 3.26 
Dg 251.01 14.01 245.66 16.23 
Thal 21.29 0.89 21.06 0.54 
MeA 151.11 17.65 179.47 10.94 
HCN1 mRNA Vehicle Org 34167 
expression Average sem Average sem 
RSGb 282.93 9.87 256.03 8.09 
S1 ctx 162.81 9.06 142.71 3.40 
S2 ctx 188.50 7.88 164.95 6.71 
Ins ctx 176.16 10.47 157.00 3.60 
Pir ctx 208.82 10.10 186.44 5.81 
CeA 213.08 8.63 197.26 6.27 
CA1 79.91 6.41 75.58 2.20 
CA2 77.05 9.24 73.58 5.66 
CA3 64.63 5.44 58.07 3.71 
Dg 37.73 3.08 38.49 2.19 
Thalamus 8.71 1.15 9.62 1.36 
HCN2 mRNA Vehicle Org 34167 
expression Average sem Average sern 
RSGb 240.78 7.05 221.13 7.96 
S1 144.22 4.97 127.86 3.50 
S2 ctx 183.97 9.67 178.56 3.84 
Ins ctx 136.25 6.70 128.58 4.01 
Pir ctx 125.01 7.27 114.04 3.28 
MeA 197.73 12.45 213.94 10.22 
CA1 217.36 7.43 219.07 2.65 
CA2 293.14 15.23 330.74 5.11 
CA3 314.07 11.74 340.04 12.71 
Dg 209.91 5.21 223.06 5.71 
Thalamus 308.77 15.07 336.20 15.60 
HCN3 mRNA Vehicle Org 34167 
expression Average Sem Average sem 
RSGb 22.75 1.86 23.09 1.21 
S1 ctx 19.52 0.79 17.90 1.02 
S2 ctx 19.75 1.52 18.83 1.40 
Ins ctx 21.73 1.21 21.34 2.13 
Pir ctx 22.68 2.85 21.77 1.36 
CA1 17.23 0.99 20.30 1.25 
CA2 22.69 0.74 27.10 2.24 
CA3 21.67 0.88 25.14 1.71 
Den Gyrus 22.34 0.76 27.26 1.43 
Thalamus 21.02 1.46 25.53 1.99 
CeA nd nd nd nd 
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5-HT1A mRNA Vehicle Fluoxetine Mirtazapine 
expression Average sem Average sem Average sem 
RSGb 25.26 1.77 26.29 2.19 25.38 1.86 
S1 ctx 37.36 2.32 44.96 0.67 46.27 2.76 
S2 ctx 42.08 1.94 47.46 2.22 50.95 2.92 
Ins ctx 39.63 3.12 41.57 1.93 46.64 2.56 
Pir ctx 72.19 3.87 67.09 1.57 73.51 2.83 
CA1 101.67 7.76 105.83 8.85 108.92 3.71 
CA2 63.42 7.24 74.10 6.99 69.14 4.69 
CA3 142.95 9.68 131.15 4.30 146.98 7.07 
Dg 233.74 14.84 223.95 6.29 248.23 5.01 
Thal 18.71 0.65 22.15 0.77 24.33 2.31 
MeA 141.07 4.19 119.93 5.53 118.66 9.31 
HCN1 mRNA Vehicle Fluoxetine Mirtazapine 
expression Average sem Average sem Average sem 
RSGb 40.97 4.40 36.64 1.29 43.57 3.60 
S1 ctx 28.88 2.21 25.75 1.14 30.60 2.13 
S2 ctx 29.83 2.31 26.37 0.80 31.38 1.78 
Ins ctx 26.36 1.50 25.94 0.93 30.29 2.02 
Pir ctx 29.93 2.66 28.17 1.38 31.21 2.43 
CeA 31.28 3.19 29.79 0.81 35.99 3.04 
CA1 67.11 6.81 63.17 2.81 70.19 5.37 
CA2 59.74 5.12 63.46 4.62 66.63 5.08 
CA3 50.70 3.15 48.17 1.57 50.38 2.72 
Den Gyrus 41.22 3.61 38.44 2.68 43.13 3.95 
Thalamus 7.35 1.00 8.60 0.68 10.36 0.54 
HCN2 mRNA Vehicle Fluoxetine Mirtazapine 
expression Average sem Average sem Average sem 
RSGb 328.95 9.40 308.39 12.11 327.54 12.91 
S1 ctx 230.98 6.55 217.82 5.47 234.81 7.15 
S2 ctx 222.52 8.37 225.96 10.82 220.27 6.37 
Ins ctx 183.53 5.67 183.02 6.56 205.52 3.52 
Pir ctx 158.26 7.06 157.64 7.02 165.44 8.54 
MeA 254.68 21.44 256.93 21.20 229.86 6.97 
CA1 310.80 15.70 283.83 15.40 303.45 23.71 
CA2 356.25 11.39 384.82 13.13 375.50 14.29 
CA3 356.24 8.08 371.50 13.93 378.57 14.54 
Den Gyrus 217.79 4.04 227.28 5.11 231.73 8.77 
Tha'a-us 35181 7.04 366.70 11.86 371.58 7.60 
HCN3 mRNA Vehicle Fluoxetine Mirtazapine 
expression Average sem Avera e sem Average sem 
RSGb 71.24 4.25 78.99 9.22 94.24 9.03 
S1 ctx 51.76 3.35 67.60 9.62 75.03 8.62 
S2 ctx 70.66 8.53 75.99 9.66 95.47 11.33 
Ins ctx 77.16 7.58 83.93 7.99 95.22 10.30 
Pir ctx 70.22 4.53 85.32 12.10 87.63 7.22 
CeAmygdala #DIV/O! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
CA1 63.46 3.26 68.73 7.90 68.36 6.15 
CA2 77.48 3.94 82.42 7.54 85.09 3.54 
CA3 78.35 3.22 83.93 7.11 79.43 5.66 
Den Gyrus 85.22 3.38 92.92 7.18 94.96 5.89 
Thalamus 72.35 5.04 77.46 5.10 81.77 5.58 
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Tables D. 4 Raw data of chronic antidepressant studies A-C (-4.7 to -5.5 mm relative to bregma) 
5-HT1 A rnRNA Vehicle Org 34167 
expression Average sem Avera e sem 
RSGb 3.01 0.17 3.83 0.17 
V2 ctx 4.13 0.14 4.30 0.11 
Au ctx 4.11 0.18 4.34 0.18 
Prh ctx 4.23 0.17 4.43 0.17 
PAG 4.41 0.37 4.18 0.17 
Gen 2.46 0.14 2.42 0.18 
VTA 3.66 0.43 4.25 0.53 
PMCo 6.60 0.21 6.38 0.34 
CA1 21.22 0.30 21.48 0.95 
CA2 20.59 2.16 20.74 1.26 
CA3 34.69 1.60 30.19 1.46 
D 56.92 2.77 51.73 1.42 
HCN1 mRNA Vehicle Org 34167 
expression Average sem Average sem 
RSGb 37.26 1.34 37.79 3.02 
V2 26.09 1.14 26.77 2.50 
Au ctx 28.43 2.28 29.13 2.70 
Prh ctx 23.95 2.13 23.96 2.29 
PAG 11.05 1.19 10.58 1.02 
Gen 4.69 0.45 4.71 0.30 
VTA 8.83 0.44 9.25 0.96 
PMCo 24.79 2.74 24.93 2.78 
CA 1 399.57 17.25 370.15 13.56 
CA2 354.37 15.22 324.48 10.53 
CA3 227.12 11.09 220.90 6.28 
D 198.26 7.13 193.62 2.86 
HCN2 mRNA Vehicle Org 34167 
expression Average sem Avera e sem 
RSGb 308.91 5.85 322.59 8.90 
V2 ctx 236.93 3.34 246.01 10.41 
Au ctx 235.27 6.87 248.45 10.58 
Prh ctx 150.53 2.65 157.14 6.05 
PAG 244.49 7.06 240.42 18.81 
Gen 359.97 11.86 415.66 27.87 
VTA 209.35 3.97 208.81 7.74 
PMCo 163.31 6.72 184.59 12.00 
CA1 166.63 4.05 163.54 1.71 
CA2 241.76 6.06 242.67 5.65 
CA3 233.36 7.43 229.14 2.57 
D 146.88 4.39 149.89 2.32 
HCN3 mRNA Vehicle Org 34167 
expression Average sem Average sem 
RSGb 28.82 1.21 31.39 3.45 
V2 ctx 25.67 1.02 26.15 2.60 
Au ctx 25.82 1.54 28.33 2.97 
Prh ctx 25.18 1.41 27.62 2.75 
PAG 29.50 1.94 35.84 3.95 
Gen 22.28 1.46 23.39 2.26 
VTA 29.73 2.36 33.37 2.97 
PMCo 22.27 1.18 25.17 2.43 
CA 1 20.08 0.97 22.32 2.57 
CA2 30.21 1.87 37.01 4.27 
CA3 34.76 2.44 42.19 4.90 
Dg 29.21 1.74 33.03 3.45 
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5-HT1A mRNA Vehicle Fluoxetine Mirtazapine 
expression Average sem Average sem Average gem 
RSGb 6,37 0.53 5.97 0.14 6.19 0.31 
V2 ctx 7.82 0.54 8.22 0.16 8.05 0.27 
Au ctx 8.58 0.42 7.83 0.28 7.89 0.27 
Prh ctx 8.54 0.67 7.64 0.18 8.20 0.11 
PAG 8.12 0.44 6.94 0.29 7.35 0.21 
Gen 5.51 0.39 5.20 0.21 5.31 0.20 
VTA 7.24 0.82 5.56 0.54 6.12 1.00 
PMCo 9.55 0.40 9.95 0.44 9.76 0.47 
CA1 29.10 0.59 29.91 0.82 28.86 0.61 
CA2 30.43 1.30 34.75 3.72 35.52 2.53 
CA3 44.47 0.70 47.42 1.46 44.64 1.31 
D 64.27 1 95 69.01 0.49 67,65 0.78 
HCN1 mRNA Vehicle Fluoxetine Mirtazapine 
expression Average sem Average sem Average sem 
RSGb 174 98 7.88 184.36 4.69 160.60 6.56 
V2 ctx 119.87 5.65 124.70 2.44 107.29 5.61 
Au ctx 139.95 5.64 140.28 3.92 125.21 6.56 
PrH ctx 118.76 4.68 124.46 3.89 103.06 7.32 
PAG 40.89 2.16 42.04 3.71 34.65 3.76 
Gen 19.76 2.57 14.88 1.90 12.91 2.41 
VTA 38.95 1.17 34.27 3.66 32.37 3.29 
PMCo 122.93 12.32 103.28 5.93 101.05 8.60 
CA 1 398.44 19.41 398.10 22.95 401.54 17.76 
CA2 426.78 32.59 455.74 24.27 450.46 33.85 
CA3 333.10 17.40 326.30 21.29 322.64 18.20 
Dg 221.56 6.11 225.95 10.16 216.95 7.79 
HCN2 mRNA Vehicle Fluoxetine Mirtazapine 
expression Average sem Average sem Average sem 
RSGb 279,49 5.24 281.01 10.07 279.36 4.16 
V2 ctx 219.31 7.01 222.60 7.52 220.12 1.45 
Au ctx 237.73 3.95 250.25 10.20 238.74 4.59 
PrH ctx 169.79 5.06 178.61 6.97 159.96 4.38 
PAG 251.19 4.74 245.89 9.81 248.14 7.08 
Gen 419.10 13.77 446.86 19.55 454.57 7.51 
VTA 249.20 8.04 264.10 9.01 241.74 6.44 
PMCo 138.28 4.65 138.97 4.37 145.11 3.66 
CA1 240.51 4.81 240.12 7.32 230.55 4.09 
CA2 328.76 15.20 313.93 6.90 283.69 B. 01 
CA3 354.47 7.96 345.19 9.07 327.10 5.44 
D 21513 2.64 222.96 611 210.49 1.95 
HCN3 mRNA Vehicle Fluoxetine Mirtazapine 
expression Average sem Average sem Average sem 
RSGb 27.20 2.06 27.52 1.75 30.41 0.93 
V2 ctx 24.03 1.62 24.89 1.32 27.73 1.98 
Au ctx 25.12 1.52 25.71 1.20 28.81 1.37 
Prh ctx 25.65 1.43 27.19 1.08 29.75 1.56 
PAG 34.12 2.15 32.32 1.52 35.95 1.62 
Gen 23.02 1.06 24.26 1.06 27.22 1.34 
VTA 31.56 1.70 34.00 1.63 38.36 1.15 
PMCo 24.58 1.02 24.04 1.13 28.29 1.54 
CA 1 20.96 1.13 21.25 0.94 24.10 1.04 
CA2 31.19 1.79 30.89 1.95 35.15 2.02 
CA3 35.88 2.11 35.92 1.35 41.07 1.78 
D 28.53 1.80 29.68 1.19 32.73 1.18 
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